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Chapter One: Introduction
Background and Significance
Parkinson’s disease (PD) is one of the fastest growing neurodegenerative disorders in the world
and a leading cause of disability. [1] The number of patients with PD was 6.9 million in 2015 and is
expected to rise to 14.2 million by 2040. [2] PD is characterized by the classical motor features of
parkinsonism with early prominent death of dopaminergic neurons in the substantia nigra (SN). [3]
The current diagnostic criteria for clinical PD from the International Parkinson and Movement
Disorder Society (MDS) [4] include consideration of ancillary diagnostic tests such as PET imaging
which can be used to assess the density of presynaptic dopaminergic terminals within the striatum as
a surrogate of SN neurodegeneration. [3] The strength of dopaminergic imaging as a diagnostic
biomarker is that it could help differentiate Parkinson’s disease from other movement disorders
without presynaptic dopaminergic terminal deficiency. [5] However, PET imaging is not widely
available, it is expensive, and it uses radioisotopes.
Though still under debate, it is generally believed that neuronal loss and lack of dopamine
content in the SN lead to movement disorders in these patients. [6, 7] The loss of neuromelanin in
particular has been thought to lead to an increase in iron content in the SN which has been
implicated in a number of PD studies. [8-10] In fact, the SN seems to be the only brain structure
through which a meaningful relationship with neuronal loss has been consistently found in the
literature. [11] Since the onset of PD is generally later and brain iron levels tend to increase as a
function of age in deep gray matter (DGM) structures even under normal conditions, [12-14] it is
imperative to account for these age–dependent changes as well. [15]
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Another alternative qualitative approach that does not measure NM throughout the whole SN but
is nonetheless sensitive to the NM in the nigrosome-1 (N1) territory has also been claimed to be a
possible means to distinguish between PD subjects and healthy controls (HC) [16-18]. The absence
of the N1 sign is a potential marker to the loss of NM as well as an increase in local iron content.
[19] However, this approach does not actually measure NM or iron content quantitatively. With that
said, the sensitivity and specificity of NM, iron or the N1 may not be sufficient to qualify as
diagnostic biomarkers by themselves. [20-22]
On the other hand, however, a clinically reliable, non-invasive biomarker to diagnose PD is still
absent. Since MRI is non-invasive, widely available and relatively inexpensive, many researchers
have used it to investigate the pathophysiological changes of PD. The most promising biomarker
candidates are iron content as seen with susceptibility weighted imaging (SWI) and as measured
with R2*, and quantitative susceptibility mapping (QSM) [11] and neuromelanin (NM) content (as
measured with NM-MRI) [17]. The literature generally supports the concept that iron content is
expected to increase in the pars compacta aspect of the SN at a higher extent in PD patients while
NM is expected to decrease [21, 22].
As for the iron deposition, Liu et al. investigated a cohort of 174 healthy adults using QSM with
the purpose of assessing the effects of normal aging on the iron levels in seven DGM structures. [12]
In addition to their evaluation of mean susceptibility from the entire 3D region covered by each
nucleus as a function of age (also known as the global analysis) in the basal ganglia and midbrain,
they introduced a new age- and structure-dependent high iron susceptibility-age baseline (also
known as the regional analysis). In this technique, age-dependent susceptibility values are chosen
from the upper 95% prediction intervals derived from the corresponding global analyses of the
normal population. The threshold-dependent high iron (RII) content voxels are then estimated by
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having a susceptibility value higher than that specific threshold for a given structure at a given age.
[12] The regional analysis appeared to be more robust and sensitive to age-related changes compared
against the global analysis. Furthermore, by applying the same methodology, Ghassaban et al.
established the global and regional susceptibility-age baselines for the dentate nucleus of the
cerebellum as the eighth main DGM structure using 81 healthy adults with a similar age range. [11]
Therefore, it is hypothesized that this regional analysis may also be more sensitive in picking up
subtler MRI-dependent changes in PD patients as well as possible correlations of these parameters
with disease severity.
The NM content also appears to be linked to dopaminergic functions in healthy controls (HCs);
positive correlation between dopamine D2 receptor binding and NM accumulation has been
observed [23]. In PD patients, however, the loss of NM has been correlated with the loss of
dopaminergic neurons in both PET [24] and single photon emission computed tomography (SPECT)
studies [25]. It has been shown that the rate of dopaminergic neuronal loss in the SN pars compacta
(SNpc) is accelerated for PD patients and 60-80% of neurons may be lost before the manifestation of
motor symptoms [26]. The hyperintense signal in the SN associated with in vivo NM-MRI has been
shown to correlate with that seen in postmortem measurements [27, 28]. Further, it has been shown
that the MRI representation of NM matches that seen in PET and that the intensity of the NM signal
in MRI correlates with the dopamine release capacity [24]. High field imaging with tyrosine
hydroxylase, a critical indicator of NM production, has also shown a similar spatial match between
NM and hydroxylase [27].
In the last few years, NM-MRI has been used in an attempt to diagnose idiopathic PD (IPD) [8,
29-31] and differentiate it from essential tremor (ET) [32, 33], progressive supra-nuclear palsy
(PSP) [34], and multiple system atrophy (MSA) [35] with some success by quantifying the
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depigmentation of NM loss. This has been accomplished using magnetization transfer contrast
(MTC), [8], NM volume [29, 30], width of the SNpc in the central territory [33, 36] as well as lateral
loss of NM volume [31]. It is encouraging that there is a consistent finding that NM volume is
significantly reduced in PD patients compared to HCs [10, 29, 34, 37-42]. It is believed that
dopaminergic neuronal death in the midbrain is followed by cellular depigmentation leaving behind
iron that is then phagocytized and becomes visible in MRI [43]. For this reason, many studies have
used iron as measured with R2* or QSM as a means to differentiate PD patients from HCs. [11]
A few prior studies have combined NM and iron measures, but these usually require two
different sequences as well as co-registration and interpolation of the data when different resolutions
are used [21, 22, 30, 44, 45] and in some cases the use of a NM mask from a template data set. [9]
However, the sensitivity and specificity of these individual measures (NM or iron in the SN) may
not be good enough for them to qualify as diagnostic biomarkers by themselves [20-22]. Therefore,
it is hypothesized that a single MT pulse augmented GRE multi-echo sequence be used that would
provide quantitative NM and iron measures simultaneously through which the overlap of NM and
SN iron-containing regions is introduced as an additional measure which, in combination with the
NM itself, could provide a stronger biomarker to help diagnose and assess the progression of the
disease.
Additionally, as another form of potential neuronal loss, idiopathic rapid eye movement (REM)
sleep behavior disorder RBD (iRBD) is recognized as the prodromal stage of α-synucleinopathies,
particularly PD, with iRBD representing a unique opportunity for potential disease-modifying
interventions. [46-48] Similar to PD, previous studies have shown cognitive dysfunction [49, 50] and
subtle motor impairment in iRBD patients [51, 52] as well which might be useful in predicting early
conversion and the specific type of α-synucleinopathy. With that being said, we hypothesize that
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abnormal levels of iron deposition and N1 loss could potentially be correlated with cognitive
dysfunction and motor impairment reported in iRBD patients. However, whether global or RII iron
accumulation in the cerebral nuclei correlates with cognitive and motor impairment in iRBD patients
remains uninvestigated.
Based on the abovementioned background, the following chapters of this dissertation are
arranged as the following. Chapter two will discuss the basic concepts of MRI gradient echo
magnitude and phase data along with QSM reconstruction and the use of MT pulse for the MTC
images. The role of MRI iron quantification and NM visualization in PD pathology will be discussed
in detail in chapter three. The next three chapters will build the main body of the dissertation in a
retrospective order in terms of PD progression. That is, in chapter four MRI iron quantification will
be used to differentiate PD from healthy controls. This will then be followed by chapter five in
which a single MT-enabled GRE sequence will be used to quantify iron, evaluate the N1 sign and
analyze NM volumetrics simultaneously specifically in PD patients going through the early stages of
the disease compared against healthy controls. In chapter six, we take one more step back and
evaluate the same criteria in RBD patients to assess the role of brain iron deposition and
neuromelanin loss as well as their relationships with cognitive and motor functions as precursor and
early biomarkers for PD. Finally, the conclusions and future directions derived from the results of
these studies will be discussed in chapter seven.

Project Aims
Based on the discussions in the previous section of this chapter, the following summarizes the
project specific aims and their corresponding hypotheses:
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Specific Aim 1: To assess the global and regional iron deposition in major deep gray matter
nuclei of PD patients and healthy controls using QSM and R2* mapping and their correlations with
disease severity.
Hypothesis 1a: Substantia nigra will be the only structure consistently showing elevated iron
content in PD patients compared to that of healthy controls with the regional analysis being more
sensitive in differentiating the two cohorts.
Hypothesis 1b: Patients with more severe clinical scores will tend to develop abnormally
elevated iron content in their substantia nigra.
Specific Aim 2: To evaluate the diagnostic accuracy of imaging midbrain NM, N1 and iron
simultaneously using a single 3D multi-echo MT augmented GRE sequence in early PD patients and
healthy controls.
Hypothesis 2a: The volumetric measurements associated with NM and iron-containing SN will
decrease while iron content will increase in the midbrains of PD patients compared to those of ageand sex-matched healthy controls.
Hypothesis 2b: The combination of volumetric measurements including NM and iron-containing
SN with the N1 sign and susceptibility-based iron quantification in the SN will provide the highest
diagnostic accuracy in early PD.
Specific Aim 3: To investigate volumetrics as well as global and regional high iron content in
major deep gray matter nuclei and the N1 loss in the SN of idiopathic RBD patients and their
potential correlations with cognitive and motor functions.
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Hypothesis 3a: Even though not as highly predominant as in PD, some of the RBD patients will
show N1 loss as well as higher iron content in the SN.
Hypothesis 3b: Iron and volumetric analyses will reveal correlations with cognitive and motor
scores in some of the deep gray matter nuclei
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Chapter Two: Basics of MR Gradient Echo, Phase and Magnetic Susceptibility
In this chapter, a review of the basics of magnitude and phase information acquired through a
GRE signal is given, followed by the current MRI techniques used to quantify iron deposition as
well as visualizing neuromelanin content in the brain.

MR Signal Acquisition
⃑ ), for a right handed
From the basic physics of a spin (½) particle in an external magnetic field (𝐵
system, the spin precesses around the magnetic field at the Larmor frequency, 𝜔, as given by [53]:
⃑
𝜔
⃑ = −𝛾. 𝐵

(2.1)

where γ is the gyromagnetic ratio of the particle1 and 𝜔
⃑ is the angular frequency. Since the water
content makes up a major proportion of the human body components, the proton (present in the 1H
hydrogen nucleus with the spin value of +1/2) is the most important source of nuclear interactions of
human tissue when exposed to an external magnetic field.

Ideal Signal Formation
In an “isochromat” of spins (i.e., where a microscopic group of many spins are exposed to an
approximately constant magnetic field), the sum of magnetic vectors, known as the net
⃑⃑ ) can be calculated through the Bloch equation [54]:
magnetization (𝑀
⃑⃑
𝑑𝑀
⃑⃑ × 𝐵0 𝑧̂
= 𝛾𝑀
𝑑𝑡

1

γ is unique for each magnetized particle. For proton, the gyromagnetic ratio is 2.68×10 8 rad/s/T.

(2.2)
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where 𝐵0 is the external magnetic field applied along 𝑧, also known as the longitudinal direction.
After separating the parallel and perpendicular (transverse) components of the magnetization,
equation (2.2) yields:
⃑⃑⃑⃑⃑𝑧
𝑑𝑀
=0
𝑑𝑡

(2.3)

⃑⃑⃑⃑⃑⃑⏊
𝑑𝑀
⃑⃑⃑⃑⃑⃑⏊ × 𝐵0 𝑧̂
= 𝛾𝑀
𝑑𝑡

(2.4)

Based on equation (2.4), the time-varying ⃑⃑⃑⃑⃑⃑
𝑀⏊ (or ⃑⃑⃑⃑⃑⃑⃑
𝑀𝑥𝑦 ) only occurs when the net magnetization
has a transverse component, which does not happen under normal conditions. In order to detect the
signal originated from the magnetization process, at a given external magnetic field 𝐵0, a
radiofrequency (RF) pulse “on resonance” with the proton Larmor frequency is applied to the whole
spin isochromat, tipping it away from the longitudinal direction and towards the transverse x-y
plane. Depending on the degree to which the magnetization is tipped (i.e., “flip angle”) the
magnitude of ⃑⃑⃑⃑⃑⃑⃑
𝑀𝑥𝑦 is defined. Physically, ⃑⃑⃑⃑⃑⃑⃑
𝑀𝑥𝑦 rotates around B0, inducing a varying flux in a
“receive coil” which then creates an electromotive force (EMF) under Faraday’s law. The origin of
the potentially detectable MR signal is this electrical current created from the EMF, which is then
converted to the image format [54]. However, it should be noted that the discussion above holds only
under ideal conditions in which there is neither an interaction among the spins nor between the spins
and the surrounding “lattice”.

MR Signal Affected by Relaxation Times
Under realistic circumstances, spins interact with each other as well as the lattice. Practically,
when our body is put into the magnetic field the spins begin to return to an equilibrium
magnetization that takes usually many seconds. At this point, an RF pulse can be applied to create a
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transverse magnetization orientation. If the spins are rotated 90o, then the longitudinal magnetization
𝑀𝑧 will start to recover toward its equilibrium value along the z axis. The time constant representing
this regrowth is called the “spin-lattice relaxation time”, also known as T1 [54]. Each tissue has its
own T1 which is usually determined by experiment. By taking the T1 effect into consideration, and
after applying an RF pulse, equation (2.3) becomes:
𝑑𝑀𝑧
1
=
(𝑀 − 𝑀𝑧 )
𝑑𝑡
𝑇1 0

(2.5)

yielding the following time dependence:
𝑀𝑧 (𝑡) = 𝑀𝑧 (0)𝑒 −𝑡/𝑇1 + 𝑀0 (1 − 𝑒 −𝑡/𝑇1 )

(2.6)

The story is quite different for the transverse magnetization. Once there is a transverse
component, subtle variations present in the local magnetic field cause the spins to dephase from
each other leading to a reduction in 𝑀𝑥𝑦 . The characteristic time during which the transverse
magnetization decreases back to its equilibrium level (i.e., 𝑀𝑥𝑦 = 0) is called the “spin-spin
relaxation time”, also known as T2 [54] (See Figure 2.1).

11

Figure 2.1 Illustration of the T2 effect on a set of spins. The upper row shows a spin isochromat after being
exposed to a 90º RF excitation which is tipped along the y direction and then dephases due to spin-spin
interactions. The lower row shows the same effect in the form of the net transverse magnetization. If the T1
⃑⃑ at the bottom right would be shorter.2
effect was also accounted for, the vector ⃑𝑴

After taking the T2 effect into account, equation (2.4) becomes:
⃑⃑⃑⃑⃑⃑⏊
𝑑𝑀
1
⃑⃑⃑⃑⃑⃑⏊ × 𝐵0 𝑧̂ −
⃑⃑⃑⃑⃑⃑
= 𝛾𝑀
𝑀
𝑑𝑡
𝑇2 ⏊

(2.7)

which after solving leads to:
⃑⃑⃑⃑⃑⃑⏊ (𝑡) = 𝑀
⃑⃑⃑⃑⃑⃑⏊ (0)𝑒 −𝑡/𝑇2
𝑀

(2.8)

The time-course representation of equations (2.6) and (2.8) along with the simultaneous combined
effect of both T1 growth and T2 decay are shown in Figure 2.2.

2

Image taken from 54.
Haacke, E.M., Magnetic resonance imaging : physical principles and sequence
design. 1999, New York: Wiley. xxvii, 914 p.
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Figure 2.2 Regrowth of the longitudinal magnetization (a) and decay of the transverse magnetization (b)
after applying the RF pulse showing the effects of T1 and T2 relaxation times, respectively. The combined
⃑⃑⃑ (𝒕) in (c). [54]
effect is visualized as a typical trajectory of the tip of the magnetization 𝑴

The plot in (b) in the figure above shows the profile of the signal in the rotating frame.3 The
actual signal profile, called Free Induction Decay (FID), oscillates with an angular Larmor frequency
of ω0 in the laboratory frame. In other words, the actual detected signal in the laboratory frame is
defined as:
𝑡

𝑆(𝑡) = 𝑆0 𝑒 −𝑇2 sin (𝜔0 𝑡)

(2.9)

In addition to the mutual spin-spin interactions which lead to the intrinsic T2 decay, there is
another source of dephasing which initially stems from external magnetic field (B0) global
inhomogeneities, known as T2′ . As a result, the combined time constant associated with the decay of
the transverse magnetization, known as T2*, is defined as:
1
1
1
=
+ ′
∗
𝑇2
𝑇2 𝑇2

(2.10)

Defining the relaxation rates to be the inverse of the relaxations times, this expression becomes:
𝑅2∗ = 𝑅2 + 𝑅2′

(2.11)

Therefore, after accounting for the local field heterogeneities, equation (2.9) becomes:

3

This type of reference frame rotates at the Larmor frequency, making the analyses easier for the observer.
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𝑡

(2.12)

𝑆(𝑡) = 𝑆0 𝑒 −𝑇2∗ sin (𝜔0 𝑡)

Gradient echo imaging, to be discussed next, is sensitive to T2* effects while spin echo imaging
(which uses an additional 180º RF pulse) is only sensitive to T2 since it rephases the spins and
removes the dephasing effects. It should be noted that in the following sections the signal behavior
will be considered in the rotating frame in which the oscillating term is eliminated.

Gradient Echo Imaging
With respect to recent technological developments, magnetic field uniformity has reached
reasonably minimum levels, making global B0 heterogeneities less problematic and the use of timeconsuming SE sequences less common in the clinical setting. Consequently, the 180o pulse can be
eliminated and replaced by the usual gradient echo (GRE) rephasing used to create an echo which is
subsequently sampled, and Fourier transformed to create an image. Today GRE imaging is
commonly used in many clinical applications across all manufacturers. [53]

GRE Sequence and Signal Acquisition
In order to differentiate one spin isochromat from another, the object to be imaged is frequency
encoded by applying a magnetic field that is different at each location. This can be accomplished by
linearly varying the field across the object using, ideally, a constant gradient field. A onedimensional example is shown in Figure 2.3. In this implementation, the transverse magnetization is
first purposely dephased and then rephased to create an echo at 𝑡 = 𝑡4 −

𝑡4 −𝑡3
2

(𝑡 ′ = 0). It is

important to note that this echo time only refocuses the dephasing effects stemming from applying
fields and not those originating from intrinsic spin dephasing at the molecular level [54].
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Figure 2.3 A typical 1D GRE experiment. The cylinders consist of arbitrary spin isochromats located at
different locations along the z axis. The dephasing part (a) uses a negative gradient -G and the rephrasing part
(b) uses a positive gradient +G with the same amplitude.4

For 2D and 3D GRE data acquisition, the concept illustrated in Figure 2.3 should be repeated
every TR (i.e., repetition time) and as many times as the number of phase encoding steps. A typical
2D GRE sequence diagram is shown in Figure 2.4. In 3D experiments, on the other hand, there is
another gradient table added to the slice select direction (Gz,ss).
After allowing the magnetization to reach equilibrium5, Mze is found to be:
𝑇𝑅

𝑀𝑧𝑒 = 𝑀0

1 − 𝑒 −𝑇1
1 − 𝑐𝑜𝑠𝜃. 𝑒

−

𝑇𝑅
𝑇1

(2.13)

where θ is the flip angle and Mze is the equilibrium longitudinal magnetization.

4
Image taken from 54.
Haacke, E.M., Magnetic resonance imaging : physical principles and sequence
design. 1999, New York: Wiley. xxvii, 914 p..
5
The number of RF pulses prior to the acquisition can vary from only a few pulses in higher FAs to hundreds of
pulses in lower FAs.
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Figure 2.4 A typical 2D GRE experiment where there is a gradient table along the phase encoding (y in this
example) direction. The time difference between the gradient steps ΔGPE is TR. Analog to Digital Convertor
(ADC) is on when the echo time TE occurs during the sampling time along the readout direction (x in this
example). [54]

By combining equations (2.8) and
(2.13), the transverse magnetization at the echo time is given by:
𝑇𝑅

𝑆𝑖𝑔𝑛𝑎𝑙 ∝ 𝑀𝑥𝑦 = 𝑀0

1 − 𝑒 − 𝑇1
1 − 𝑐𝑜𝑠𝜃. 𝑒

−

𝑇𝐸

− ∗
𝑇2
𝑇𝑅 𝑠𝑖𝑛𝜃. 𝑒

(2.14)

𝑇1

Equation (2.14) is known as the Ernst equation and accounts for the major intrinsic and extrinsic MR
tissue properties. This equation tells us that by manipulating the MR parameters, such as flip angle,
TE and TR, different contrast mechanisms can be created. For example, at lower flip angles and very
short TE, the image is spin-density weighted, while at higher flip angles and short TR relative to T1,
the image will be more T1-weighted. A T2* weighted image can be obtained by acquiring the data
with longer echo times and lower flip angles (to remove the T1 effect).
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Complex MR Signal
From a signal processing perspective, the final image will have both magnitude and phase
components. That is, the MR signal acquired by a GRE sequence is complex in nature with the
magnitude extracted from equation (2.14) and, for a right handed system, the phase defined as [54]:
𝜙(𝑟, 𝑡) = Δ𝜔. 𝑡 = −𝛾. Δ𝐵(𝑟). 𝑡

(2.15)

where Δ𝐵(𝑟) is the field variation experienced by a spin isochromat due to the global and local
sources of magnetic field inhomogeneities and chemical shift. Therefore, the complex form of the
MR signal can be represented as:
𝑆(𝑟, 𝑡) = |𝑆(𝑟, 𝑡)|𝑒 𝑖𝜙(𝑟,𝑡)

(2.16)

which after accounting for equation (2.14) at the echo time can be written as:
𝑆(𝜃, 𝑇𝐸, 𝑇𝑅) = 𝑆𝑥𝑦 (𝜃, 𝑇𝐸, 𝑇𝑅). 𝑒 −𝑖𝛾Δ𝐵.𝑇𝐸

(2.17)

Fourier Transform and K-Space
In order to get an image, the signal picked up by the coil has to be transformed into an image.
The time dependent signal is given by a sum over the spin densities, 𝜌(𝑟), weighted by the phase
induced by the applied gradients:

𝑠(𝑡) = ∭ 𝑑3 𝑟. 𝜌(𝑟). 𝑒 𝑖𝜙(𝑟,𝑡) = ∭ 𝑑𝑥𝑑𝑦𝑑𝑧. 𝜌(𝑥, 𝑦, 𝑧). 𝑒 𝑖𝜙𝐺(𝑥,𝑦,𝑧,𝑡)

(2.18)

where the phase 𝜙𝐺 (𝑥, 𝑦, 𝑧, 𝑡) is the sum of the accumulated phase in three different directions:
𝜙𝐺 (𝑟, 𝑡) = −𝛾Δ𝐵(𝑟)𝑡 = −𝛾. 𝐺(𝑟, 𝑡)𝑟. 𝑡

The total phase imparted to the spins is given by:

(2.19)
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𝜙𝐺 (𝑥, 𝑦, 𝑧, 𝑡) = −𝛾. 𝐺(𝑟, 𝑡)𝑟. 𝑡
𝑡

(2.20)
𝑡

= −𝛾 (∫ 𝑑𝑡 ′ 𝐺𝑥 (𝑡 ′ )𝑥 + ∫ 𝑑𝑡 ′ 𝐺𝑦 (𝑡 ′ )𝑦
0

0

𝑡

+ ∫ 𝑑𝑡 ′ 𝐺𝑧 (𝑡 ′ )𝑧) 𝑡
0

Therefore, if we define the following “k-space variables” as:

𝑘𝑥 (𝑡) =

𝛾 𝑡 ′
∫ 𝑑𝑡 𝐺𝑥 (𝑡 ′ )𝑥
2𝜋 0

(2.21)

𝑘𝑦 (𝑡) =

𝛾 𝑡 ′
∫ 𝑑𝑡 𝐺𝑦 (𝑡 ′ )𝑦
2𝜋 0

(2.22)

𝑘𝑧 (𝑡) =

𝛾 𝑡 ′
∫ 𝑑𝑡 𝐺𝑧 (𝑡 ′ )𝑧
2𝜋 0

(2.23)

equation (2.18) can be rewritten as:

𝑠(𝑘𝑥 , 𝑘𝑦 , 𝑘𝑧 ) = ∭ 𝑑𝑥𝑑𝑦𝑑𝑧. 𝜌(𝑥, 𝑦, 𝑧). 𝑒 −2𝜋𝑖(𝑘𝑥 𝑥+𝑘𝑦 𝑦+𝑘𝑧𝑧)

(2.24)

Equation (2.24) is technically the Fourier transform of the effective spin density. When written as a
function of the spatial frequencies, this signal or data is referred to as k-space data.
Figure 2.5 shows how k-space is filled following every step illustrated in Figure 2.4. Assuming
that the starting point is kx=ky=0, after applying each RF pulse at the corresponding constant phase
encoding gradient (GPE) the readout gradient moves the k-space point from –kR,max to +kR,max which
then creates a line of k-space. After the phase encoding gradient increases by one step (ΔGPE) the
same process happens again but this time the simultaneous change of kx and ky sweeps over one line
higher in k-space. This process continues until the desired k-space is filled with complex sampled
points. By applying the inverse Fourier transform, original magnitude and phase information are
then extracted in the spatial domain. That reconstructed signal is then represented by equation (2.17).
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Figure 2.5 A schematic of a 2D k-space filling trajectory corresponding to Figure 2.4. Due to the
simultaneous changes of readout and phase encoding gradients as a function of time, k-space filling follows a
diagonal trajectory when ΔGPE occurs.

Susceptibility Weighted Imaging
Susceptibility Weighted Imaging (SWI) uses a special type of GRE sequence. In order to
minimize the phase-dependent artifacts due to blood flow effects, SWI is usually fully flowcompensated in all directions. [54] The logic behind incorporating flow compensation is the fact that
we are interested in measuring the phase caused by local field variations, not other unrelated factors.
As in all 3D GRE sequences, complex data are acquired yielding magnitude and phase images.
However, in order to reconstruct the final susceptibility-weighted image, further steps are applied to
the original phase image to remove phase wraps and low spatial frequency components. From this
processed image, a mask is created which is then multiplied into the original magnitude image to
enhance the visualization of local susceptibility changes. The post-processing pipeline of SWI image
reconstruction is not the main scope of this dissertation. Nevertheless, the use of the original SWI
phase image, which plays a key role in QSM, will be discussed in the following sections.
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Magnetic Susceptibility
Magnetic susceptibility (χ) is an intrinsic property of a tissue which manifests its tendency
towards being magnetized when exposed to an external magnetic field. Magnetic properties of a
typical substance can be characterized by three different categories; paramagnetism with positive
susceptibility (χ > 0) whose magnetic moments align parallel to the external field, diamagnetism
with negative susceptibility (χ < 0) whose magnetic moments align anti-parallel to the main field,
and ferromagnetism with very high positive susceptibility (χ ≫ 1). Iron and calcium are two
common paramagnetic and diamagnetic substances, respectively, present abundantly in the human
body. However, to date, ferromagnetism has not been reported in living tissues in significant
amounts. [53]
A homogeneous external constant magnetic field can be defined as:
⃑⃑⃑⃑
⃑
𝐵0 = 𝜇0 𝐻

(2.25)

⃑ is the vector form of the magnetic field intensity (Ampere/meter) and 𝜇0 is the absolute
where 𝐻
permeability of free space (4π × 10-7 Tm/A). When an external static field (B0) interacts with an
⃑⃑ ) inside the object creating a new total field given by:
object, it induces a magnetization vector (𝑀
⃑ = 𝜇0 (𝐻
⃑ +𝑀
⃑⃑ )
𝐵

(2.26)

Practically, the induced magnetization (or permanent in case of ferromagnetism) is related to the
magnetic field intensity through the magnetic susceptibility:
⃑⃑ = 𝜒𝐻
⃑
𝑀

(2.27)

Therefore, using equation (2.27), equation (2.26) can be rewritten as:
1+𝜒
⃑ = 𝜇0 (
⃑⃑
𝐵
)𝑀
𝜒

(2.28)

20

Assuming that χ ≪ 1, then equation (2.28) can be simplified to:
⃑ =
𝐵

𝜇0
⃑⃑
𝑀
𝜒

(2.29)

⃑⃑ =
𝑀

1
⃑
𝜒𝐵
𝜇0

(2.30)

or

Equations (2.29) and (2.30) show the relationship between the induced magnetization and
perturbed magnetic field inside the exposed object. A magnetic source will produce fields outside
itself that depend on the object’s geometry and orientation. For example, in the human body, venous
blood vessels (which can be modeled as cylinders) and microbleeds (which can be modeled as
spheres) will create magnetic fields outside themselves. [53] It should be noted, however, that the
susceptibility values reported in the equations above are the absolute values in vacuum. In the case
of veins and microbleeds, the measured values will represent the relative susceptibility (Δχ)
compared to the tissue in which they are embedded. Since the brain is mostly water it is
predominantly diamagnetic relative to air.

Phase Signal and Susceptibility Mapping
Phase Image Processing
Based on equation (2.15), the phase value at echo time TE can be rewritten as:
𝜙(𝑟) = −𝛾. Δ𝐵(𝑟). 𝑇𝐸

(2.31)

Basically, there are two different sources of field variation: first, macroscopic or global sources
such as geometric orientation of the structures (e.g. air-tissue and air-bone interface) and external
field inhomogeneities. Second, microscopic or local sources of variation which are in the form of
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chemical shift and internal susceptibility sources (such as iron in the form of ferritin). Overall, the
total field change is made up of all these contributions:
Δ𝐵𝑇𝑜𝑡𝑎𝑙 = Δ𝐵𝐸𝑥𝑡𝑒𝑟𝑛𝑎𝑙 𝐹𝑖𝑒𝑙𝑑 + Δ𝐵𝐶ℎ𝑒𝑚𝑖𝑐𝑎𝑙 𝑆ℎ𝑖𝑓𝑡

(2.32)

+ Δ𝐵𝐺𝑙𝑜𝑏𝑎𝑙 𝐺𝑒𝑜𝑚𝑒𝑡𝑟𝑦 + Δ𝐵𝑆𝑢𝑠𝑐𝑒𝑝𝑡𝑖𝑏𝑖𝑙𝑖𝑡𝑦

The chemical shift term, Δ𝐵𝐶ℎ𝑒𝑚𝑖𝑐𝑎𝑙 𝑆ℎ𝑖𝑓𝑡 , is a point like effect, while the local susceptibility sources,
Δ𝐵𝑆𝑢𝑠𝑐𝑒𝑝𝑡𝑖𝑏𝑖𝑙𝑖𝑡𝑦 , depend on their shape and orientation.6 Due to the fact that the local susceptibility
sources are the target of interest, the confounding external sources need to be removed.
One of the problematic issues present in the original phase images is “phase aliasing”. This
phenomenon occurs because the phase is limited to [-π π) range. As a result, each value equal to or
higher than π wraps back to –π and, accordingly, any phase value lower than -π wraps back to less
than π. The actual phase value can be calculated as:
𝜙 𝑇𝑟𝑢𝑒 (𝑟) = 𝜙𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 (𝑟) + 2𝜋. 𝑛(𝑟)

(2.33)

where 𝑛(𝑟) is the number of times the pixel-wise phase value has been aliased. Since background
field variations have comparatively low spatial frequency, applying a high-pass spatial filter (HPF) is
a reliable and robust method to minimize these background field effects inside the brain (although
not as effective at the edges of the brain). [55]
In a typical homodyne high-pass filter, a Hanning window is located at the center of the k-space
and depending on the filter size, only collects low spatial frequency information. As shown in
equation (2.34) and Figure 2.6, a complex division of the original reconstructed image (𝜌̂) by the
truncated filtered image will then output a homodyne high-pass filtered phase image. [56]

6

In this dissertation, since the focus is on the brain tissue, the local field variation is mostly dominated by the
susceptibility distribution.
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𝑎𝑟𝑔(𝜌̂𝐻𝑖𝑔ℎ𝑃𝑎𝑠𝑠 ) = 𝑎𝑟𝑔 (

𝜌̂
𝜌̂𝐿𝑜𝑤𝑃𝑎𝑠𝑠

)

(2.34)

Figure 2.6 General pipeline of a homodyne high-pass filter.

One of the most important advantages of high-pass filtering is its high execution speed and the
fact that it does not require any phase unwrapping steps, making it a suitable choice in both research
and clinical settings. However, using a bigger HPF window size (e.g., 128 × 128) also removes
useful intermediate spatial information in intermediate sized structures underestimating the
contribution of the signal itself. For this reason, other background field removal techniques such as
variable high-pass filtering (vHPF) [57] and Sophisticated Harmonic Artifact Reduction for Phase
data (SHARP) [58] have been suggested for susceptibility quantification purposes.

Quantitative Susceptibility Mapping
Assuming that the external static field is along the z-axis, for a right-handed system equation
(2.31) can be rewritten as:
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𝜙(𝑟) = −𝛾. Δ𝐵𝑧 (𝑟). 𝑇𝐸

(2.35)

where Δ𝐵𝑧 (𝑟) can be derived via [57]:

Δ𝐵𝑧 (𝑟) =

𝜇0
3𝑀𝑧 (𝑟⃑⃑⃑′ )(𝑧 − 𝑧 ′ )2
𝑀𝑧 (𝑟⃑⃑⃑′ )
∭ 𝑑3 𝑟 ′ [
−
3]
5
4𝜋
𝑟′|
|𝑟 − ⃑⃑⃑
𝑟′|
|𝑟 − ⃑⃑⃑

(2.36)

This expression can be reformulated into a convolution:
Δ𝐵𝑧 (𝑟) = 𝜇0 𝑀𝑧 (𝑟) ∗ 𝐺(𝑟)

(2.37)

where 𝐺(𝑟) is called the Green’s function and is given by:

𝐺(𝑟) =

1 3𝑐𝑜𝑠 2 𝜃 − 1
4𝜋
𝑟3

(2.38)

Here, θ is the angle between the position vector 𝑟 and the external field direction 𝑧. By incorporating
equations (2.29) and (2.37) we can modify equation (2.37) to:
Δ𝐵𝑧 (𝑟) = 𝐵0 𝜒(𝑟) ∗ 𝐺(𝑟)

(2.39)

If the susceptibility distribution is known, then equation (2.39) can be used to predict the local
changes in magnetic field. This is known as the “forward modeling process”.
Practically, it is the phase information that is available and so an inverse process must be used to
determine 𝜒(𝑟). This can be accomplished by taking the Fourier transform of equation (2.39)
yielding:
Δ𝐵𝑧 (𝑘⃑ ) = 𝐵0 . {𝜒(𝑘⃑ ) . 𝐺(𝑘⃑ )}

(2.40)

and hence:

𝜒(𝑘⃑ ) =

Δ𝐵𝑧 (𝑘⃑ ). 𝐺 −1 (𝑘⃑)
𝐵0

The Fourier transform of the Green’s function is given by [57]:

(2.41)
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1 𝑘𝑧2
𝐺(𝑘⃑ ) = {3 − 𝑘 2 ,
0

𝑘≠0

(2.42)

𝑘=0

where 𝑘 2 = 𝑘𝑥2 + 𝑘𝑦2 + 𝑘𝑧2 .
Finally, using the available phase information as a representation of the local field changes, the
susceptibility distribution in the image domain can be found from:

𝜒(𝑟) = −

𝐹𝑇 −1 (𝜙(𝑘⃑ ). 𝐺 −1 (𝑘⃑ ))

(2.43)

𝛾. 𝐵0 . 𝑇𝐸

A schematic diagram of this quantitative susceptibility mapping (QSM) process is shown in
Figure 2.7. It should be noted that brain masks are not a necessary part of the algorithm but using
them improves the susceptibility map by removing streaking artifacts that can be caused by sharp
edged parts of the brain if they are not removed.

Figure 2.7 Schematic diagram of general QSM post-processing algorithm. Involvement of the phase
unwrapping step depends on the background removal method. Brain extraction step is not mandatory but
enhances reconstruction speed and accuracy.7

7

Image taken from 56.
Liu, S., Technical Improvements in Quantitative Susceptibility Mapping, in
School of Biomedical Engineering. 2014, McMaster University. with permission.
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⃑ ) has zeroes along a conical shape in kOn the other hand, as seen in equation (2.44), 𝐺 −1 (𝑘
space points rendering the inverse problem ill-posed. A variety of methods have been used to try and
overcome these limitations, but most of them have some type of remnant streaking artifacts that
corrupt the susceptibility map [59].
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Chapter Three: Iron and Neuromelanin as Seen with MRI
Neuromelanin in the Brain8
Neuromelanin Physiology
Neuromelanin (NM), the neuronal version of melanin, is a dark pigment found in the brain that is
naturally produced through oxidation of amino acids followed by a polymerization process. NM is
believed to in be present in large quantities in catecholaminergic cells of the substantia nigra (SN)
pars compacta of the midbrain and locus coeruleus (LC), giving a dark color to these structures. [25]
Even one hundred years ago, it was believed that the NM pigment loss in the substantia nigra was
associated with PD. [60] This loss has been shown to originate from the dopaminergic neurons in the
SN and the noradrenergic neurons of the LC. [61]
Unlike melanin that uses a group of special cells, known as melanocytes (which is almost not
present in the SN), NM takes advantage of a different synthetic process, that is, the conversion of
norepinephrine. Some types of catecholamines in the cytosol and especially dopamine through
oxidative processes are responsible for its dark color as well as NM being an electron-dense
pigment. [62] Playing a very important role in both behavioral and physical functions, dopamine is a
neurotransmitter (i.e., one of the chemicals responsible for transmitting signals between the nerve
cells of the brain) very few of which are produced by the organelles in the brain. Dopaminergic cell
groups are collections of neurons in the central nervous system that synthesize dopamine. [26] The
NM pigmentation of these organelles appears to be acting as a protector for these neurons under
healthy conditions as excessive amounts of dopamine content in the cytosol may induce cell damage

Some of the content from this chapter is now published in the following journal paper: Ghassaban, K., et al.,
Quantifying iron content in magnetic resonance imaging. Neuroimage, 2019. 187: p. 77-92.
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(through reactive types of oxygen) ultimately leading to neuronal death. [63] Sulzer et al. further
addresses the synthetic process of NM and defines it as an insoluble pigment stemming from
dopamine derived quinones that are present in autophagic lysosomes along with lipid bodies and
other soluble proteins. [64] The melanic component of the NM chemical structure is bound to crossβ-sheet peptides making them a major part of the lipid bodies found within the organelles containing
NM. [43] While playing a neuroprotective role through removing unnecessary cytosolic dopamine in
the midbrain, NM tends to bind high levels of metals and particularly iron forming a paramagnetic
NM-iron complex which is crucial for MR signal detection [43] which will be discussed in the
following sub-sections.

Neuromelanin Interactions with Iron
As discussed previously, metal ions (e.g., iron, copper and zinc) can be chelated by the NM
pigment. In addition to making the NM structure a candidate for MR detection, these metals can
contribute to the catecholamine oxidation in the NM synthesis process during the early stages while
remaining bound to NM-containing auto-lysosomal organelles. [65] Iron has been seen to be
substantially the most abundant metal present in pigmented dopaminergic neurons in the SN. [66] In
other words, research shows that under healthy conditions the iron concentration in the SN can vary
significantly from 0.1 μg/mg to 6 μg/mg in SN tissue and NM-pigmented intraneuronal content [67]
while this value could be as high as 11 μg/mg in an isolated NM pigment. [68] With that being said,
these iron measurements suggest that the intraneuronal NM content is not fully saturated and is
capable of chelating more iron. It should be noted that this is not necessarily the case for LC. That is,
as opposed to SN, the iron concentration of NM pigment isolated from LC is approximately 16% of
that measured from NM isolated from SN, most likely due to the fact that the NM content in the LC
tends to bind more copper rather than iron to help with norepinephrine synthesis. [67]
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Generally speaking, iron complexes in the human body are mostly in the form of Fe2+ (ferrous)
or Fe3+ (ferric) that are chelated by smaller size molecules such as ATP and especially proteins
including ferritin, hemoglobin and transferrin. [62, 69] Iron is believed to be a key cofactor in
dopamine synthesis in the SN while, as mentioned earlier, copper appears to play the same role in
the norepinephrine system in the LC. [43] A more in-depth discussion regarding different forms of
iron is given below.
Even though reactive ferric iron content can be seen in non-NM pigmented neurons in a healthy
SN, this type of iron deposition is undetectable in pigmented neurons of the SN, most likely due to
the efficient sequestration of NM. On the other hand, although the SN is a host to significant
amounts of reactive iron content, these iron depositions are almost undetectable in the LC due to the
lower levels of total iron content; the synthetic process of NM binding to reactive iron is believed to
block the redox activity for the iron to avoid neurotoxicity. [67] However, it is of vital importance to
know that even though the presence of NM-containing organelles may be a neuroprotective process,
once neuronal death occurs the iron previously bound to NM could turn into extracellular iron and
potentially cause toxicity through activating microglia which may then lead to tissue inflammation.
[70] In the following sections a more detailed review of different forms of iron and how to visualize
and quantify its MR-detectible content will be given.

Neuromelanin-Sensitive MRI
Over the past decade, the ultimate goal of NM-sensitive MRI (NM-MRI) research has been
predominantly focused on improving the signal from protons associated with NM while increasing
the contrast between NM against the surrounding background tissue. Among some of the early
studies in this area, Sasaki et al. were the first group to have successfully implemented an in vivo
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visualization of the NM content in the SN and LC using MRI. [71] In this early work, they utilized a
T1-weighted multi-slice acquisition taking advantage of relatively short duration turbo/fast spin echo
(TSE/FSE) sequence and concluded that NM-dependent MR signal is significantly more visible on
the 3T magnet compared to that of 1.5T. Unsurprisingly, they also noted T1 shortening effects due to
the presence of metal elements (i.e., mostly iron in SN and copper in LC) associated with the MR
signal coming from NM-containing voxels. [71] Since the advent of NM-MRI over a decade ago, a
few other T1W TSE-based studies have investigated the NM content in the SN and LC of healthy
subjects as well as neurodegenerative conditions where NM depigmentation may occur, especially in
PD. [37, 39, 42, 71, 72]
On the other hand, a phenomenon known as magnetization transfer (MT) has caught a lot of
attention among researchers aiming for suppression of tissues with high macromolecular content and
hence an improved contrast of gray matter to white matter. MT is currently thought to be the primary
source of NM-MRI contrast derived from applying MT preparation pulses prior to the actual
imaging sequence. [73] By definition, MT is usually referred to a process by which the
macromolecules and the water molecules they interact with inside the “bound pool” exchange
magnetization with the protons that belong to the “free pool”. A magnetization transfer contrast
(MTC) can then be created through applying specially designed MT RF pulses prior to the imaging
pulse sequence. Nevertheless, in order to avoid frequency interference with the subsequent pulses
used for actual free pool spin excitation, the MT pulses are usually followed by spoiling gradients.
Upon applying the MT pulse, the bound pool gets excited which then leads to pre-saturation of the
MR signal detected from macromolecule-containing tissue. [74] It should be noted, however, that
depending on the degree to which these pools are coupled some of the spin isochromats may become
partially saturated (i.e., direct saturation) as well through the transfer of energy applied to the bound
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water pool over to the free water pool. In other words, when using routine RF pulses to image a
given tissue, minor signal reduction may occur due to a secondary MT effect in the free water pool
and that is something that should be taken into consideration when interpreting the MR signal. [75]
The frequency at which the MT pulse is applied can be challenging. A study done by Ramani et
al. investigated the MT spectrum through which images were acquired at multiple RF offsets shifted
from the free water center frequency (i.e., Larmor frequency) and fitted a model to measure MT
exchange levels, bound to free pool ratio as well as transverse and longitudinal relaxation
measurements associated with each pool. [76] At lower frequency offsets (ranging from a few
hundred to a few thousand hertz shifted from the Larmor frequency) the MT pulse will partially
saturate the free pool protons as well which means that the final observed signal is attenuated due to
a combination of both MT and direct saturation effects. Even though off-resonance MT pulses are
commonly used for NM-MRI applications, special binomial or multinomial on-resonance pulses
inducing similar MT effects (only in the bound pool since the applied MT pulse in this case has the
same frequency as the free pool) can also be used depending on the commercial manufacturer and
RF coil hardware design.
As mentioned earlier, paramagnetic substances such as iron and copper are known to cause
shortening of relaxation times; this is true in both free protons and protons restricted by
macromolecules which consequently results in reduced MT effects in samples in which
paramagnetic ions are present. With that said, one can argue that the presence of iron affects the MT
spectrum. While the main iron protein in the SN is known to be ferritin which usually shows
relatively low paramagnetic characteristics, the dominant iron storage in pigmented dopaminergic
neurons of the SN is the NM-iron complex which are highly paramagnetic. The reason for this
difference is that the chelating groups in the NM-iron complex are chemical compounds (catechols)
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carrying a stable free radical while the chelating groups in ferritin protein are mainly amino acids.
Additionally, the NM-iron complex also hosts aliphatic chain compounds that are believed to further
impact the MT-induced energy exchange between macromolecules and free water protons that are
absent in ferritin. [77]
When using NM-MRI the SN pars compacta (SNpc) shows the highest signal intensity compared
to the surrounding tissue due to higher levels of NM pigmented dopaminergic neurons compared to
that of the SN pars reticulata (SNpr) which is rich in iron but has less NM-iron complex. [73]
Needless to say, due to lack of NM content, other iron-rich deep gray matter structures such as
globus pallidus, putamen and caudate nucleus do not show as high signal intensity on NM-MRI
images. On the other hand, it has been confirmed that T1 and T2 shortening effects are both
significantly higher in melanin-iron complexes compared to those of iron-free melanin or iron by
itself. [78] The chemical structure of NM-iron complex causes far more dominant T1 shortening
effect compared to that of T2 which further improves the contrast between SNpc and the
surrounding gray matter tissue. Therefore, one can conclude that the NM-MRI contrast seen in SNpc
is due to a combination of T1 and MT effects put together. [78]

Quantifying Cerebral Iron Content using MRI
Iron has long been known for playing a key role in a variety of brain physiologic interactions
such as brain metabolism, neuronal maturation, dopamine production, myelin generation, electron
and oxygen transport [79, 80] making it the most important transition metal present in the human
brain. Additionally, brain iron levels have been seen to correlate with normal aging which could also
explain some of the pathophysiological effects in Alzheimer’s Disease (AD) [81], PD [82], and
Multiple Sclerosis (MS). [83] According to the literature, iron deficiency is also a sign of some other
disorders such as Attention Deficit Hyperactivity Disorder (ADHD) [84] and neurodegeneration in
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general. [85] On the other hand, living organisms in the human body apply different methods to keep
the iron homeostasis level and prevent iron overload or deficiency [86].

Different Forms of Iron
Basically, there are two general categories of iron forms present in the human body; almost 70%
of that is in the form of heme-iron (i.e., hemoglobin which is responsible for oxygen transport) while
30% is in the form of non-heme iron (e.g., deposited in the organs, structures, proteins etc.). [13, 87]
As the name of “transitional metal” suggests, iron is mostly in the form of Ferric (Fe3+) or Ferrous
(Fe2+) with ferric being comparatively more stable leading to its higher proportion in the human
body.
Iron is usually stored in an ubiquitous soluble protein, ferritin, which is naturally produced by
living organisms in the body. The major function of ferritin is to make excess iron accumulate in its
subunits thereby keeping the iron homeostasis level from changing. Ferritin is a fairy large spherical
molecule which consists of 24 sub-units and can store up to 4500 atoms of iron in its central hollow
part. (see Figure 3.1 below).

Figure 3.1 Ferritin protein. The hollow section (mineral core) of the molecule can store up to 4500 iron atoms.
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Hemosiderin is another form of iron storage protein; unlike ferritin, hemosiderin is an insoluble
molecule which is known to be a fairly immediate product of the ferritin denaturation process. This
protein can be found in white blood cells and has been seen to be present in comparatively large
proportions in diseased brains associated with cerebral hemorrhages. [88] Stroke [89] and Traumatic
Brain Injury (TBI) [90] often show the presence of hemosiderin associated with cerebral
hemorrhage.
The last type of the normal non-heme iron proteins is called transferrin. As the name suggests,
the major role of this molecule is to deliver iron and iron-related products to different parts of the
body. Specifically in the brain, its responsibility is to deliver iron to the brain through the blood
brain barrier (BBB). [87, 91] However, since transferrin binds only two iron atoms, the effect of iron
on this molecule is not enough to cause considerable magnetic field variation which makes it
practically undetectable via MR methods.
From a distribution standpoint, different types of non-heme iron have been shown to be
heterogeneously distributed in different parts of the brain. [87] Histochemical research has reported
both iron atoms (mostly Fe3+) and ferritin molecules to be almost equally distributed in gray matter
and white matter, while transferrin showed more notable presence in the white matter. [92]
However, in deep gray matter structures, ferritin appears to be the dominant type of iron and shows
spatially and temporally variable levels with the highest average values being in the Globus Pallidus
and the highest age-dependency rate in the Putamen. Moreover, as reported by a well-known study
by Hallgren and Sourander, the highest concentration of non-heme iron content in the cortical
regions was found in the motor cortex followed by occipital cortex and sensory cortex. [13]
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Iron in the Aging Brain
Iron deposition in the brain as a function of normal aging has been investigated for a long time.
Back in the 1950s, from a cadaver brain study, Hallgren and Sourander showed that the brain iron
levels change in different parts of the brain as a function of age generally with very low values in
infants, followed by an almost exponential increase in the first two decades and leveling off or a
linear trend afterwards. [13] These findings have been validated in other studies using in vivo MR
techniques in which the same conclusions have been drawn [93-95]. For instance, deep gray matter
nuclei showed different exponential and linear trends of iron deposition as a function of age; in a
study done by Li et al., some structures such as the putamen, dentate nucleus, and caudate nucleus
have been reported to show an almost linear iron-age increasing behavior across the lifespan, while
other nuclei such as the globus pallidus, red nucleus, and substantia nigra revealed an exponential
growth pattern with higher increase rate in the first two decades followed by an almost constant
levels of iron in subsequent decades. [94] However, by using a novel method called regional high
iron content analysis, there are also some new subtle susceptibility-age trends revealed that were not
investigated in previous studies. [12] Generally speaking, basal ganglia, midbrain and cerebellum
nuclei tend to have higher levels of iron concentration in the elderly, while the thalamic regions and
cortical white matter are believed to have more iron storage in younger people. [96] Although iron
presence is believed to be mostly dominated by deep gray matter nuclei, a whole-brain study has
shown that in addition to these regions, frontal lobes also tend to build up excessive iron content as a
function of age. [97]
Several MRI techniques are available for quantifying in vivo iron content, including various
methods based on mapping T2, T2*, T2′, phase and magnetic susceptibility of the tissue. [54, 98, 99]
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The optimal technique for a given clinical application is dependent on the amount or concentration
of iron.

Determining T2, T2* and T2′
As discussed earlier in this chapter, the transverse relaxation time, T2, can be determined using
data collected with a multi-echo, spin echo sequence or multiple single-echo spin echo sequences,
[100] by modeling the signal at different echo times (TEs) as:
𝑆(𝑇𝐸) = 𝜌0 𝑒 −𝑇𝐸/𝑇2

(3.1)

where 𝜌0 is the effective spin density. Similarly, T2* can be determined using data collected with a
multi-echo gradient echo sequence, using the same exponential decay model except that T2 is
replaced with T2* in the equation above. However, when multiple types of tissues with different T2
or T2* values are present in the same pixel, more complex models such as a bi-exponential model
may be required. T2′ is derived via

1
𝑇2∗

=

1
𝑇2

+

1
𝑇2′

(or R2* = R2 + R2′) and can be obtained by

calculating the difference between R2* and R2. This can be done by either estimating T2 and T2*
using two separate sequences or by using sequences such as gradient echo sampling of the free
induction decay and echo (GESFIDE) or gradient echo sampling of a spin echo (GESSE) to obtain
T2 and T2′ simultaneously. [101, 102]
However, to do a good job in estimating T2, T2* and T2′, the gradient echo sequence must be
run with a high enough resolution, low enough echo time and high enough bandwidth (BW) to
minimize dephasing and geometric distortion. [103] Estimating T2′ can be done through the
GESFIDE sequence along with T2, T2* and SWI. Once R2′ is measured, the local susceptibility due
to sources such as iron, calcium or blood can be found if the volume fraction of that substance is
known via:
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𝑅2′ = κλ𝛾Δ𝜒𝐵0

(3.2)

where κ is 0.42, λ is the volume fraction, 𝛾 is the gyromagnetic ratio, and Δ𝜒 is the change in local
susceptibility.[101] If the source of susceptibility change is capillary blood, then the hematocrit and
the level of deoxyhemoglobin would be required to estimate the blood’s susceptibility.

Determining phase
The phase contains key information about the field variations inside the tissue, that is the
changes that occur from a perfectly homogeneous field caused either by an imperfect field or by
changes in tissue susceptibility. [57, 102] The phase from a gradient-echo sequence can be written
as:
𝜙(𝑇𝐸) = 𝛾Δ𝐵 ∙ 𝑇𝐸 + 𝜙0

(3.3)

for a left-handed system, where Δ𝐵 is the field variation and the offset 𝜙0 is related to coilsensitivity and tissue conductivity. [54] At a given echo time, the more the iron concentration, the
higher the local field variation and the more rapidly the phase accumulates. In theory, iron
concentration can be quantified using local phase information. [104] Practically, when imaging the
human body, the field variation Δ𝐵 can be considered as a combination of the global field variation
induced by the air-tissue interfaces and the local field variations induced by tissue susceptibility
changes. Usually, the background field components should be removed before the phase images can
be used for iron quantification. This is done by using various background field removal algorithms,
[105-107] including high-pass filtering, [108] methods based on the spherical mean value properties
of harmonic functions, [58] as well as solving the background field removal as a Laplacian boundary
value problem. [109] The advantages and disadvantages are discussed in detail in a few recently
published review papers on SWI and quantitative susceptibility mapping (QSM). [57, 98, 102, 110]
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It has been shown that the phase shifts correlate with the iron content measured using X-ray
fluorescence (XRF). [111] This technique has been used in several studies to quantify cerebral iron
content in normal controls and in patients affected by neurodegenerative diseases such as PD and
MS. [104, 112, 113] However, it is also known that phase can be affected by the orientation of the
structures and by imaging parameters such as the main field strength and echo time. [102]
Fundamentally, since phase is induced by the changes of magnetic susceptibility, it would be better
to quantify the source directly, as introduced in the next section.

Determining susceptibility
As previously discussed, quantifying 𝜒(𝑟) is an ill-posed problem. This problem can be solved
by using the straight-forward thresholded k-space division algorithm, [59, 114] or by using more
sophisticated algorithms in which the geometries of interest extracted from magnitude, phase and an
initial reconstruction of susceptibility maps are utilized as constraints. [115-120] One advantage of
using susceptibility for iron quantification, instead of using phase directly, is that susceptibility is not
dependent on imaging parameters such as main field strength and echo time. [57] Moreover, unlike
phase, which is geometry and orientation dependent, the susceptibility of structures with iron
overload (e.g., deep grey matter structures) is generally not dependent on the orientation of the
object. [102, 121] Nonetheless, the susceptibility of the white matter can be orientation dependent
due to structural and magnetic susceptibility anisotropy. [118, 122, 123] Finally, and clinically very
important, QSM provides information via the sign of the susceptibility as to whether a given
structure is paramagnetic (containing more iron) or diamagnetic (containing calcium).
The relationship between susceptibility and iron content has been investigated in several studies,
based on ferritin phantoms and/or postmortem studies where the iron content can be verified using
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XRF and inductively coupled plasma mass spectrometry (ICPMS). [124, 125] Linear relationships
between susceptibility and iron content have been shown in earlier studies, with slopes varying from
0.6 to 1.3 ppb/(µgFe per g wet tissue). [125] A recent paper suggests that 1ppb in susceptibility is
roughly equivalent to a value closer to 1 µgFe per g wet tissue. [12] The variation in the slopes is
partly due to the differences in the QSM reconstruction algorithm. [125] QSM based iron
quantification has been quite successful especially for the basal ganglia, midbrain and dentate
nucleus (DN) structures. [12, 94, 126] However, when interpreting the measured susceptibility
values in white matter, the contribution of myelin content and susceptibility anisotropy should be
considered. [127-130] A summary of the linear correlations of R2* and QSM with cerebral iron
concentration is provided in Table 3.1. One key point to be aware of is that the coefficient relating
susceptibility to iron content will depend on the QSM method and choice of threshold.
It has been shown that R2* is more sensitive to the changes of cerebral iron content than R2, and
QSM has even superior sensitivity than R2*. [124, 131, 132] Compared with R2*, QSM shows
better reproducibility due to its independence of main field strength and imaging parameters.
Although slightly different due to reconstruction algorithms, the reproducibility of QSM can be
reflected by the consistent slopes in the relationships between susceptibility and iron concentration
found in different studies conducted at different field strength, whereas the slopes found in studies
using R2* showed a clear dependence on the main field strength, as shown in Table 3.1. This makes
QSM a better choice in longitudinal studies or studies comparing results obtained from other
imaging sites using different data acquisition protocols. [133] Nonetheless, studies involving the
differentiation or separation of the effects of cerebral iron and myelin content may benefit from a
combination of R2* mapping and QSM [134, 135] Because iron content is paramagnetic and myelin
is diamagnetic, while both can increase the R2*. [134, 136, 137] Using R2* mapping and QSM
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together, the investigation of the properties of tissue and the underlying pathological mechanisms
become possible. The advantages of the joint use of R2* and QSM has been demonstrated in several
recent studies focusing on MS lesions. [138-140] However, care should be taken when interpreting
the R2* and QSM results in the white matter, since both R2* and susceptibility may be dependent on
fiber orientation. [127, 141-144]
Furthermore, as seen in Table 3.1, there is a clear and strong linear correlation between both
QSM and R2* with direct measurements of iron concentration in the brain, validated by several in
vivo and in vitro studies over the past decade. [12, 58, 114, 124-126, 136, 145-159] This implies
that, with R2* (being careful to use the conversion factor at a given field strength) and susceptibility
mapping techniques, abnormal iron levels in the brain structures of neurodegenerative diseases such
as MS and PD can be associated with elevated levels of iron concentration in different regions of a
diseased brain.

Other Techniques
In addition to the T2, T2*, T2ʹ and susceptibility mapping based methods introduced above,
there are some other techniques which can also be used to measure iron, including T1 mapping, field
dependent R2 increase (FDRI), [160] magnetic field correlation (MFC), [161] as well as direct
saturation based method such as water-saturation shift-referencing (WASSR). [162] These methods,
although less frequently used due to technical challenges, may provide unique information about
tissue properties and can be used as reference methods. For example, compared to T2* mapping, T1
mapping is less susceptible to the field inhomogeneity, and hence, it has the potential to improve
both the accuracy and reproducibility of in vivo iron quantification although it is much less sensitive
to iron than T2*. [163-165] Ge et al. demonstrated the quantification of iron content in grey matter
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in multiple sclerosis patients using MFC. [166] Pfefferbaum et al. compared FDRI with SWI phase
imaging for cerebral iron quantification and showed that FDRI has higher specificity to non-heme
iron than SWI. [96]
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Table 3.1 Review of studies investigating the linear correlation of R2* and QSM with iron
concentration in different brain structures.

Studya

Yao et al. [145]

Ning et al. [146]

Sample
Size

9 HC

56
Infants

Iron

Field

Linear

Quantification

Strength

Regression

Method

(Tesla)

Parameters

R2*

1.5 T

R2*

1.5 T

Linear
Correlation

Brain Structures

Equation

Included

A×[Fe]+B d

PCC = 0.79, P

A = 0.06, B =

< 0.01

1.08

PCC = 0.75
(CN)
PCC = 0.66
(PUT)
PCC = 0.67
(GP)
P < 0.001

NA

A = 0.06 ±
Uddin et al. [147]

17 HC

R2*

1.5 T

PCC = 0.85, P

0.003

< 0.0001

B = 12.81 ±
0.42

Martin et al. [148]

13 HC

R2*

3T

Péran et al. [149]

30 HC

R2*

3T

Yao et al. [145]

9 HC

R2*

3T

b

Langkammer et
al. [124]

b

Langkammer et
al. [136]

Yan et al. [150]

Sedlacik et al.
[151]

Barbosa et al.
[126]

Uddin et al. [147]

7 DS

6 DS

24 HC

66 HC

30 HC

17 HC

R2*

R2*

R2*

R2*

R2*

R2*

3T

3T

3T

3T

3T

4.7 T

PCC = 0.91, P
= 0.01

NA

CN, PUT, GP

CN, PUT, GP

CN, PUT, GP,
RN, SN, THA,
FWM, CGM
CN, PUT, GP,
RN, SN, FWM

PCC = 0.96, P

A = 0.14, B =

< 0.001

11.31

PCC = 0.87, P

A = 0.12, B =

< 0.01

1.41

PCC = 0.95, P

A = 0.27, B =

< 0.001

14.3

PCC = 0.37, P

A = 0.12, B =

FC, FWM, OC,

< 0.01

22.38

OWM

PCC = 0.98, P
< 0.001

PCC = 0.94, P
= NA

CN, PUT, GP

CN, PUT, GP
CN, PUT, GP,
THA, FWM,
TWM, OWM

CN, PUT, GP,
NA

RN, SN, THA,
FWM

A = 0.11 ±
0.006, B =

CN, PUT, GP

10.69 ± 0.80
CN, PUT, GP,

PCC = 0.79, P

A = 0.13, B =

= NA

20.0

PCC = 0.95, P

A = 0.196 ±

CN, PUT, GP,

< 0.0001

0.005, B =

RN, SN, THA,

THA, RN, SN,
GM
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16.87 ± 0.71

Yao et al. [145]
Shmueli et al.
[114]

Bilgic et al. [152]

Persson et al.
[153]

Liu et al. [12]

Schweser et al.
[58]

b

Langkammer et
al. [155]
c

Zheng et al.
[125]

Lim et al. [154]

Chai et al. [156]

He et al. [157]

Xia et al. [158]

Barbosa et al.
[126]
Shmueli et al.
[114]

9 HC

R2*

7T

1 HC

R2*

7T

23 HC

183 HC

174 HC

5 HC

13 DS

1 MS

5 HC

45 HC

35 HC

31 HC

30 HC

1 HC

QSM

QSM

QSM

QSM

QSM

QSM

QSM

QSM

QSM

QSM

QSM

QSM

1.5 T

1.5 T

1.5 T

3T

3T

3T

3T

3T

3T

3T

3T

7T

PCC = 0.92, P

A = 0.32, B =

< 0.0001

1.98

PCC = 0.83, P
= 0.042
PCC = 0.88, P
= 0.02

NA

NA

< 0.001

-24.50

PCC = 0.86, P
< 0.001

PCC = 0.87, P
< 0.001

PCC = 0.87, P
= NA

0.03, B = -

THA, RN, SN,

B = NA

DN, FWM

A = 0.97 ±

CN, PUT, GP,

0.03, B = -

THA, FWM,

37.0 ± 2.0

TWM, OWM

A = 0.80 ±

CN, PUT, GP

0.01, B =

(Left

10.8 ± 2.9

Hemisphere)

A = 0.55, B =

= 0.037

- 18.80

NA

CN, PUT, GP
CN, PUT, GP,
THA, RN, SN,
DN, FWM
CN, PUT, GP,
RN, SN
CN, PUT, GP,

NA

THA, RN, SN,
DN, FWM

PCC = 0.83, P

A = 0.65, B =

= NA

-13.8

< 0.01

GP, PUT, THA

CN, PUT, GP,

PCC = 0.90, P

PCC = 0.92, P

DN

e

-44.15

= 0.01

THA, RN, SN,

A = 1.3 ± 0.2

= NA

PCC = 0.84, P

CN, PUT, GP,

48.51 ± 4.09

A = 0.73, B =

= 0.007

THA, RN, SN,

A = 0.89 ±

PCC = 0.99, P

PCC = 0.90, P

PUT, RN, SN

DN, FWM
A = 0.95. B =

< 0.01

CN, PUT, GP

CN, PUT, GP,

PCC = 0.97, P

PCC = 0.98, P

FWM, CGM

NA

CN, PUT, GP,
THA, RN, SN.
GM
PUT, RN, SN
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Wharton et al.
[159]

5 HC

QSM

7T

PCC = 0.96, P

A = 0.75 ±

= NA

0.1, B = NA

CN, PUT, GP,
RN, SN, THA,
FC

HC: healthy controls, PCC: Pearson Correlation Coefficient (R), DS: Deceased Subjects, PD: Parkinson’s Disease, MC: Myelin
Corrected, CN: Caudate Nucleus, PUT: Putamen, GP: Globus Pallidus, SN: Substantia Nigra, RN: Red Nucleus, THA:
Thalamus, GM: Gray Matter, WM: White Matter, FWM: Frontal White Matter, TWM: Temporal White Matter, OWM: Occipital
White Matter, FC: Frontal Cortex, OC: Occipital Cortex, CGM: Cortical Grey Matter, MS: Multiple Sclerosis
a The in vivo iron concentration was estimated based on the study by Hallgren and Sourander (1958), unless otherwise stated.
b The iron concentration in this study was determined using Inductively Coupled Plasma Mass Spectroscopy (ICPMS).
c The iron concentration in this study was determined using X-Ray Fluorescence (XRF).
d For the relationship between R2* and iron, the unit of the slope (A) is s-1 per µg Fe / g wet tissue, and the unit of the intercept
(B) is s-1. For the relationship between susceptibility and iron, the unit of the slope (A) is ppb per µg Fe / g wet tissue, and the
unit of the intercept (B) is ppb.
e In this study, the slope was obtained by correcting the contribution of myelin content with magnetization transfer saturation
map.
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The Role of MRI in Parkinson’s Disease
As pointed out in the previous chapters, with the current technology the clinical diagnosis of PD
can only occur when 30-40% of the dopaminergic neurons have already been lost in the midbrain,
particularly in the SN which introduces a significant challenge to PD therapeutics since such
treatments are ideally required to be started before most of the dopaminergic neurons are dead. To
date, no useful clinical test has been established to detect PD prior to the onset of motor symptoms.
However, it is worth mentioning that it is common for PD patients to often show early symptoms
that may develop to become PD-related later on. Loss of smell, anxiety, depression, restless leg
syndrome and especially REM sleep behavior disorder are among the more common ones, even
though they may also be associated with many other disorders. Specifically, it has been reported that
a high percentage of RBD patients may develop synucleinopathies with more aggressive progression
over a few years to a few decades. Nevertheless, it should also be noted that not all patients who
develop PD have a history of RBD. [47]
Some studies suggest that the damage to the axons of dopaminergic neurons may occur prior to
cell death, with SPECT and PET based imaging for dopamine-dependent labels such as dopamine
transporter (DAT) supporting such findings. [167] However, these modalities are usually very
expensive and require radiation exposure which have made researchers look for less costly and safer
in vivo alternatives, particularly MRI, with the ultimate goal of detecting PD before the onset of the
disease.

Quantifying Abnormal Iron in Parkinson’s Disease
As discussed earlier, QSM has recently played a major role in research and clinical studies
investigating iron deposition in deep grey matter structures of both healthy and diseased conditions.
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[57] One of the most common forms of neurodegeneration is PD which is known to be associated
with elevated iron content in deep gray matter and the brain regions responsible for motor function.
[6, 7] Although other advanced post-processing MR techniques such as phase, R2 and R2* maps
have been utilized to quantify iron content, QSM has proven to be a more promising and reliable
method in terms of sensitivity and specificity. [57, 126, 168-170] Iron deposition has been found to
be heterogeneously distributed in the brains of PD patients. [113, 171] However, the most prominent
deficit is the degeneration of dopaminergic interactions in the SN which leads to high levels of nonheme iron in this midbrain structure. [172, 173] Cross-sectional and longitudinal research studies
have quantitatively investigated this abnormality by monitoring the patients’ iron-rich brain
structures, particularly in the SN. In this dissertation, we only focus on R2* and QSM techniques
which are the most widely used iron quantification methods in PD.
Using R2* maps, several studies have found abnormally elevated R2* rates, putatively indicative
of higher iron deposition, across different subcortical brain regions in PD patients either in
comparison with healthy control groups or after a specific period of time when monitored
longitudinally. In the form of a cross-sectional study, Gorell et al. demonstrated higher R2* values in
the SN of a non-demented PD group compared to a healthy cohort. [173] Rossi et al. showed
increased levels of R2* not only in the SN, but also in the globus pallidus compared to a normal
group. [174] In another article, however, Hopes et al. claimed that nigrostriatal structures including
the SN, caudate nucleus and putamen had significantly greater R2* values in untreated PD patients
compared to a healthy cohort. [175] Esterhammer et al. demonstrated a significant increase of R2* in
the putamen and globus pallidus only in the early stages of PD with the SN maintained significant in
both early and advanced stages. [176] On the other hand, two longitudinal R2* studies by Ulla et al.
and Wieler et al. have both reported an increase in the R2* rate of SN over a 3-year time period
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indicating that the iron content in the PD patients progresses over time. [177, 178] Ulla et al. also
reported a significant progression of iron deposition in the caudal putamen.[177]
Over the past decade, QSM has been used to investigate iron related pathology and progression
of PD. Similar to R2*, QSM has also shown higher levels of iron accumulation in the brains of PD
patients, particularly in the SN. [126, 168-170] Guan et al. showed that susceptibility values are
directly correlated with the disease stage and claimed that substantia nigra pars compacta (SNpc) is
characterized by significantly higher iron content only in the early stages, whereas in more advanced
stages of PD other structures such as substantia nigra pars reticulate (SNpr), red nucleus and globus
pallidus also tend to develop high levels of iron deposition. [179] Elevated iron content in the SNpc
was also reported in a 7T high resolution QSM study done by Lotfipour et al. in which significantly
higher magnetic susceptibility values were seen for this substructure in the PD patients compared to
the control group. [180] In Azuma et al.’s work, QSM was found to be a useful technique for
quantitatively assessing lateral asymmetries in the SN of PD patients where the hemisphere
differences were more prominent compared to those of the healthy controls. [181] Another study by
Guan et al. showed that depending on the type of PD, the structures characterized by high iron
accumulation vary; they claimed that iron accumulation in the nigral regions is the dominant effect
in PD regardless of the disease type, whereas excessive iron deposition in the DN and red nucleus
was seen only in patients with tremor symptoms. [182] Similarly, in a study done by He et al. the
DN was shown to be the structure of choice that could be a potential biomarker to differentiate
tremor-dominant PD from other types due to the increased magnetic susceptibility values only in this
cerebellar structure. [183] Conversely, Acosta-Cabronero et al. reported that although magnetic
susceptibility is expectedly higher in the dorsal SN, iron content in the DN decreases in idiopathic
PD compared to healthy controls. [15]
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To date, the high iron content of the SN appears to serve as the only reliable biomarker to
characterize PD as has been consistently reported in the literature. [6, 15, 126, 157, 168-170, 173181, 184, 185] Moreover, in a few studies where both R2* and QSM techniques were used to
quantify iron content in PD patients, QSM showed superior sensitivity and accuracy in terms of
diagnostic performance as well as detecting significant differences between PD and healthy groups
making it the preferred iron quantification technique and a reliable imaging biomarker for PD. [126,
168-170] This could be due in part to the fact that increased water content can confound increases in
iron content making R2* less sensitive. On the other hand, increased water content does not affect
the susceptibility from the local iron content making QSM potentially more valuable in the
assessment and quantification of iron content.
Under normal conditions, non-heme iron levels also change in the aging brain. Assessing
quantified iron content against normal aging across brain structures dates back to the 1950s when
Hallgren and Sourander investigated iron concentration in cadaver brains. [13] Over the past few
decades, several research groups have tried to quantify normal brain iron content versus age with in
vivo MR post-processing techniques. By using QSM, Li et al. introduced baselines of magnetic
susceptibility changes as a function of age over the lifespan in cortical and subcortical brain regions.
[94] In addition to validating their normal susceptibility-age baselines through a 3D ROI-based
algorithm (known as the global analysis) for different deep gray matter nuclei, Liu et al. developed a
new algorithm by which the local high iron content can be detected depending on the structure of
interest and the age of the subject. [12] In this algorithm, the upper 95% prediction interval from the
susceptibility-age global analysis of each nucleus is used to define an age-dependent threshold. Any
voxel within the associated 3D ROI with a susceptibility value higher than that threshold would be
considered as a high iron content (RII) voxel. The mean RII susceptibilities as a function of age for
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different deep gray matter structures then establish new normal baselines, known as the regional
analysis, which is claimed to have higher sensitivity, reliability and robustness for monitoring agedependent changes in iron content compared to the global analysis. [12]
Table 3.2 reviews the studies investigating the brain iron content in cohorts of PD patients
compared to healthy controls using R2* and QSM techniques. As seen in the table, the SN is the
only deep gray matter nucleus which is consistently showing significantly elevated iron deposition in
PD patients compared to healthy controls across all the reported studies. [126, 157, 168-170, 174182, 184-188] Furthermore, in a few studies this significance expands to substructures of the SN,
particularly the SNpc. [126, 169, 174, 177-182, 187] By taking the mean of the increased rates in the
SN and SNpc in the studies which provided statistical information, the average increased rates were
10.3±8.5% and 13.6±4.0% in the R2* values of the SN and SNpc, respectively, in the PD patients
compared to the healthy controls. However, these changes are reflected in considerably higher rates
when QSM techniques were used. Specifically, the average increase rates were 28.2±14.6% and
35.2±2.7% for the SN and SNpc, respectively. These increased rates in R2* and QSM reflects the
increase in iron concentration. However, these may be an under-estimation of the actual changes of
the iron content in the SN, since the voxels with low levels of iron content were included in those
studies and because all PD patients were included not just those showing high iron content in the SN.
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Table 3.2 Recent studies on R2* and QSM comparing different brain structures in PD patients
and healthy controls.
Study
Péran et al.
[184]
Du et al.
[185]

Rossi et al.
[174]

b

c

Ulla et al.
[177]

Ulla et al.
[177]

Wieler et al.
[178]
Murakami et
al. [168]
Esterhammer
et al. [176]
He et al.
[157]
Barbosa et
al. [126]
Du et al.
[169]

Hopes et al.
[175]

Sample
Size (N)

Iron
Quantification
Method

Field
Strength

R2*

3T

R2*

3T

22 HC
30 PD
16 HC

Brain
Structures
Assessed
CN, GP,
PUT, THA,
RN, SN

Brain Structures
with Significant
Differences

(Mean ± SD
in HC, Mean
± SD in PD)a

SN

NA

SN

SN

NA

16 PD
21 HC
R2*

3T

SN, GP

Medial SNpc,
Lateral SNpc

34 PD

26 HC (8
M, 18 F)
R2*

1.5 T

GP, PUT, SN,
GM, WM

SNpc, SNpr

ΔR2*

1.5 T

GP, PUT, SN,
GM, WM

SNpc, SNpr, PUT

NA

R2*

3T

GP, PUT,
RN, SN

SNpc

NA

R2*

3T

CN, GP,
PUT, THA,
RN, SN

SN

R2*

1.5 T

CN, GP,
PUT, THA,
SN, CC

SN

R2*

3T

CN, GP,
PUT, RN, SN

SN

R2*

3T

CN, GP,
PUT, THA,
RN, SN

SNpc

R2*

3T

SN

SNpc

R2*

3T

CN, GP,
PUT, SN

L-SN, R-SN

27 PD (13
M, 14 F)

18 HC
14 PD
13 HC
19 ES-PD
21 HC
21 PD
38 HC
82 PD
35 HC
44 ES-PD
30 HC
20 PD
47 HC
47 PD

20 HC
15 LS-PD

Medial SNpc:
(43 ± 7, 51 ±
10)
Lateral SNpc:
(42 ± 6 , 50 ±
10)
SNpc-M:
(20.2 ± 0.41 ,
22.7 ± 0.48)
SNpc-F:
(20.9 ± 0.39 ,
22.5 ± 0.61)
SNpr-M:
(25.3 ± 1.10 ,
28.7 ± 0.95)
SNpr-F: (25.1
± 0.4 , 25.5 ±
0.50)

SN: (29.0 ±
2.0 , 30.1 ±
1.5)
SN: (20.58
[17.4–23.9] ,
21.25 [15.8–
29.4]) d
SN: (34.9 ±
4.41 , 38.9 ±
5.91)
SNpc: (47.7 ±
8.4 , 52.8 ±
11.7)
SNpc: (32.8 ±
5.0, 37.8 ±
4.3)
L-SN: (37.7
[36–39] , 50.2
[45–52]) d
R-SN: (36.8
[35–39] , 47.8
[45–52]) d
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28 HC
Ji et al. [186]

R2*

3T

R2*

3T

R2*

3T

R2*

3T

QSM

54 PD

Langkammer
et al. [170]
Guan et al.
[179]
Guan et al.
[182]
Lotfipour et
al. [180]
Murakami et
al. [168]

He et al.
[157]

Barbosa et
al. [126]

Du et al.
[169]
AcostaCabronero et
al. [187]

e

Azuma et
al. [181]

Langkammer
et al. [170]

58 HC
66 PD
40 HC
45 ES-PD
15 LS-PD
40 HC
27 TD-PD
27 AR-PD
11 HC
6 TD-PD
3 PIGD
21 HC

CN, GP,
PUT, THA,
RN, SN

L-SN, R-SN, LRN, R-RN

CN, GP,
PUT, THA,
RN, SN
CN, GP ,
PUT, THA,
RN,SN, DN
CN, GP ,
PUT, THA,
RN,SN, DN

SNpc

NA

SNpc

NA

7T

SN

SNpc

NA

QSM

3T

CN, GP,
PUT, THA,
RN, SN

SN

QSM

3T

CN, GP,
PUT, RN, SN

SN, RN

QSM

3T

CN, GP,
PUT, THA,
RN, SN

SN, SNpc

QSM

3T

SN

SNpc

3T

Whole-brain
pattern, SN

SN, vSN, dSN,
LOC, PPC,
RMPC, MTC, DN,
HIP

21 PD
35 HC
44 ES-PD

30 HC
20 PD

SN

47 HC
47 PD
50 HC
QSM
25 PD

25 HC
QSM

3T

CN, GP,
PUT, RN, SN

SN, mSN, pSN

QSM

3T

CN, GP,
PUT, THA,
RN, SN

SN, RN, GP, THA

24 PD

58 HC
66 PD

L-SN: (34.2 ±
0.85 , 37.0 ±
0.74)
R-SN: (34.6 ±
0.97, 37.3 ±
0.69)
L-RN: (29.7
± 0.61 , 31.7
± 0.64)
R-RN: (29.3
± 0.68 , 31.7
± 0.54)
SN: (37.6 ±
5.8 , 41.1 ±
8.7)

SN: (199.0 ±
14.0 , 224.0 ±
14.0)
SN: (83.7 ±
15.6 , 100.0 ±
18.3)
RN: (81.0 ±
14.5 , 93.0 ±
18.9)
SN: (114.7 ±
32.5 , 150.9 ±
41.5)
SNpc: (140.1
± 38.5 , 186.7
± 53.2)
SNpc: (108.0
± 33.0 , 148.0
± 44.0)
NA
SN: (104.7 ±
31.0, 158.0 ±
47.6)
mSN: (104.6
± 28.7, 166.6
± 53.2)
pSN: (66.5 ±
25.6, 120.8 ±
38.7)
SN: (90.0 ±
30.0, 114.0 ±
40.0)
RN: (89.0 ±
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30.0, 105.0 ±
40.0)
GP: (112.0 ±
30.0, 126.0 ±
30.0)
THA: (0.0 ±
10.0, 5.0 ±
10.0)
Guan et al.
[179]
Guan et al.
[179]
Guan et al.
[182]
Guan et al.
[182]
He et al.
[183]

40 HC
QSM

3T

QSM

3T

QSM

3T

QSM

3T

QSM

3T

45 ES-PD
40 HC
15 LS-PD
40 HC
27 TD-PD
40 HC
27 AR-PD
48 HC
19 TD-PD

CN, GP ,
PUT, THA,
RN,SN, DN
CN, GP ,
PUT, THA,
RN,SN, DN
CN, GP ,
PUT, THA,
RN,SN, DN
CN, GP ,
PUT, THA,
RN,SN, DN
DN

SNpc

NA

SNpc, SNpr, RN,
GP

NA

SNpc, RN, DN

NA

SNpc

NA

DN

DN: (63.0 ±
16.0 , 74.0 ±
18.0)

M: male, F: female, L: left, R: right, HC: healthy control, PD: Parkinson’s disease, SN: substantia nigra, TD-PD: tremor
dominant PD, AR-PD: akinetic-rigid dominant PD, PIGD: postural instability gait disorder, LS-PD: late stage PD, ES-PD: early
stage PD, SNpc: SN pars compacta, SNpr: SN pars reticulata, mSN: middle part of the SN , pSN: posterior part of the SN, vSN:
ventral SN, dSN: dorsal SN, PUT: putamen, DN: dentate nucleus, RN: red nucleus, THA: thalamus, GP: globus pallidus, GM:
gray matter, WM: white matter, HIP: hippocampus, LOC: lateral occipital cortex, PPC: posterior parietal cortex, MTC: middle
temporal cortex, RMPC: rostral middle prefrontal cortex. CC: corpus callosum
a Units of R2* and QSM are in s-1 and ppb, respectively.
b In this study, by combining male and female groups, an analysis of variance (ANOVA) showed a significant increase of R2*
in PD compared to HC group in both SNpr and SNpc.
c ΔR2* corresponds to the difference in the R2* value between the baseline and a follow up time-point after 3 years.
d In this study, R2* values are quoted as median [range].
e In this study, QSM values for the PD patients were quoted from the more affected hemibrain.
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Neuromelanin Loss in Parkinson’s Disease
A century after the first definition of PD, this movement disorder was seen to be somewhat
associated with NM pigmented neuronal loss in the midbrain area which was then found to belong to
dopaminergic neurons. [43] Fast forward to almost two decades ago, by measuring NM
concentration levels in the SN of normal subjects and PD patients, Zecca et al. claimed that NM
seems to be a good biomarker of the neuronal damage in the SNpc. [189]
Following the advent of early NM-MRI techniques, TSE-based MRI methods have been utilized
to examine NM changes in the SN and LC of PD patients. [37, 39, 42, 71, 72] In a validation study,
Kawaguchi et al. compared DAT-sensitive radioligand PET imaging with NM-MRI and suggested
that the accumulation of NM in the SN may be dependent upon actual dopamine concentration
maintained by DATs associated with nigral dopaminergic neurons. [190]
Early neuropathological findings confirm a close correlation between the number of NMcontaining dopaminergic neurons in the SNpc and the NM-MRI signal derived from the
corresponding regions. [28] As previously pointed out, the signal intensity derived from NM-MRI is
expected to decrease in PD patients due to NM loss. Figure 3.2 shows two examples, one from a HC
and the other from a PD patient, where an MT-prepared NM-MRI sequence was used to highlight
the NM content in the SNpc. As seen in this Figure, the CNR between the SNpc and cerebral
peduncle (as the reference region) is noticeably lower compared to that of the HC which according
to Sulzer et al. represents about 25% reduction in contrast. [43]
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Figure 3.2 A comparison between NM contrast in the SNpc of a HC (left) and a PD patient (right) derived from an MTC
sequence. The PD patient shows approximately 25% CNR reduction. Images courtesy of Sulzer et al. [43]

In order to compare different NM-sensitive sequences used for MRI in vivo evaluation of SN
degeneration in PD, one may argue that MTC is a better choice. In other words, TSE/FSE sequences
usually depend on incidental MT effects derived from multi-slice and mostly 2D interleaved image
acquisition to receive the NM signal. [73] This approach is not as effective as using an explicit MT
pulse to saturate the signal from macromolecules and generate an efficient NM-sensitive contrast.
Additionally, though also seen in MTC to a lesser extent, TSE/FSE MR sequences usually deposit
substantial amounts of energy in the brain tissue, to the point that specific absorption rate (SAR) on
the scanner may be an issue forcing the operator to either collect fewer slices, lengthen the TR and
total acquisition time or shorten the echo train. [191] Longer total scan times may turn into a serious
technical issue in PD patients, especially those going through late or terminal stages of the disease
with sever motor symptoms.
With respect to pre-symptomatic stages of PD, it has been shown that patients suffering from
RBD have also shown SNpc volume comparable to those from IPD patients [10, 192] which is in
agreement with potential reduction of dopamine loss in PD. Another study has also noted a loss of
MR hyperintensity in dorsolateral aspect of the SN in two-thirds of patients with RBD. [193] These
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pathophysiological changes in RBD as a relatively undiscovered disorder opens the door to more
extensive investigations to find MR-dependent in vivo biomarkers prior to arrival of PD-specific
symptoms.
In the next three chapters, a comprehensive analysis of abnormal NM and iron content in PD and
RBD patients will be discussed in much more detail in a backwards order starting from intermediate
stage of PD towards early stages and finally RBD as the pre-symptomatic prodromal phase of PD. In
Chapter Four abnormal levels of iron content in IPD patients will be discussed as a function of age
and also compared against an age-matched healthy population. In Chapter Five iron, NM and N1
will be evaluated using a single MT-prepared 3D GRE sequence strictly in early IPD patients and
their correlations with clinical scores. Finally, Chapter Six will specifically assess iron and N1
changes in RBD patients and age-matched HCs as well as their relationships with cognitive and
motor function scores.
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Chapter Four: Regional high iron in the substantia nigra differentiates Parkinson’s
disease patients from healthy controls
Introduction1
Parkinson’s disease (PD) is believed to be the second most common neurodegenerative disease
in developed countries. [194] Research has shown that the substantia nigra (SN) is one of the most
important structures playing a vital role in the pathophysiology of PD patients. [11] Neuronal loss
and lack of dopamine content in this midbrain nucleus generally lead to movement disorders in these
patients. [6, 7] The loss of neuromelanin in particular has been thought to lead to an increase in iron
content in the SN which has been implicated in a number of PD studies. [8-10] In fact, the SN seems
to be the only reliable brain structure through which a meaningful relationship with neuronal loss has
been found. [11] Since the onset of PD is generally late and brain iron levels tend to increase as a
function of age in deep gray matter (DGM) structures even under normal conditions, [12-14] it is
important to account for these age–dependent changes. [15]
A number of magnetic resonance imaging (MRI) techniques can be used to quantify iron content
in the human body. Conventionally, R2 and R2* relaxation rate mapping along with phase
information have been utilized to measure iron deposition in different regions of the human body in
vivo. [11] However, one of the most popular approaches today is the use of quantitative
susceptibility mapping (QSM); a post-processing technique that generates susceptibility maps using
phase information and, unlike other conventional quantification techniques, is independent of
imaging parameters such as geometry, echo time, spatial resolution, field strength and signal-to-

The content from this chapter is now published in the following journal paper: Ghassaban, K., et al., Regional High Iron
in the Substantia Nigra Differentiates Parkinson's Disease Patients From Healthy Controls. Front Aging Neurosci, 2019.
11: p. 106.
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noise ratio (SNR). [57] QSM also appears to have the greatest reliability and robustness compared to
other MR-based in vivo methods. [57, 169, 170] Specifically, in terms of consistency, QSM has been
shown to have high repeatability and less variability compared to R2*. [11]
Liu et al. investigated a cohort of 174 healthy adults using QSM with the purpose of assessing
the effects of normal aging on the iron levels in seven DGM structures. [12] In addition to their
evaluation of mean susceptibility from the entire 3D region covered by each nucleus as a function of
age (also known as the global analysis) in the basal ganglia and midbrain, they introduced a new
age- and structure-dependent high iron susceptibility-age baseline (also known as the regional
analysis). The regional analysis appeared to be more robust and sensitive to age-related changes
compared to the global analysis. [12] Furthermore, by applying the same methodology, Ghassaban et
al. established the global and regional susceptibility-age baselines for the dentate nucleus using 81
healthy adults. [11] Therefore, we hypothesized that this regional analysis may also be more
sensitive to changes in iron for PD patients.
In this study, using QSM and R2* techniques, we compare the iron content in the DGM
structures between a cohort of PD patients and a group of healthy controls (HC). Additionally, using
QSM maps we investigate the iron deposition rates of PD patients compared to the corresponding
global and regional normal baselines established by Liu et al. [12] and Ghassaban et al. [11]
Similarly, R2* maps are used to compare global measurements to those of the healthy population
established by Li et al. [94] Also, susceptibility measurements in terms of increased iron deposition
are compared to the clinical status of PD patients. Finally, the QSM data are compared directly to the
R2* across the different DGM nuclei using the HC data. This study could potentially pave the way
for developing future iron-based diagnostic studies and better understanding the etiology of PD.
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Methods
Data Collection
This study was approved by the local ethics committee at Ruijin Hospital and all subjects signed
consent forms. A total of 49 subjects were evaluated: 25 PD patients (61.8 ± 6.4 years old) and 24
HC subjects (63.4 ± 8.0 years old). All of the PD patients were recruited from local movement
disorder clinics. The inclusion criteria were: 1) a diagnosis of idiopathic PD, 2) Mini-Mental State
Exam (MMSE) score equal to or more than 24 and 3) Hoehn and Yahr (H&Y) scale of 1 through 3
as patients with higher scores had more severe symptoms and would have trouble staying still in the
magnet for the duration of the scans. The exclusion criteria were: 1) symptoms of secondary or
atypical parkinsonism or 2) a history of cerebrovascular disease, seizures, brain surgery, brain tumor,
moderate-to-severe head trauma or hydrocephalus or 3) treatment with antipsychotic drugs or with
any other drug possibly affecting clinical evaluation. Data were collected using a 16 echo, gradient
echo imaging sequence on a 3T GE Signa HDxt from an eight-channel receive-only head coil with
the following imaging parameters: TE1 = 2.69ms with ΔTE = 2.87ms, TR = 59.3ms, pixel
bandwidth = 488 Hz/pixel, flip angle = 12°, slice thickness = 1mm, matrix size = 256 × 256 and an
in-plane resolution of 0.86 × 0.86 mm2.
QSM Processing
The susceptibility maps were created using the first 8 echoes and were reconstructed for each
echo individually using SMART v2.0 (MRI Institute for Biomedical Research, Bingham Farms, MI,
USA) followed by a weighted average of the resultant QSM images based on their SNRs. Only 8
echoes were used because of severe frontal signal loss at echo times longer than roughly 20ms. The
reconstruction steps included the brain extraction tool (BET) to segment only the brain tissue using
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the fourth echo magnitude data, [195] quality guided 3D phase unwrapping algorithm (3DSRNCP)
for phase unwrapping, [196] sophisticated harmonic artifact reduction for phase data (SHARP) for
background field removal with a threshold of 0.05 and a deconvolution kernel of 6, [58] and a
truncated k-space division (TKD) approach (threshold = 0.1) referred to as susceptibility weighted
imaging and mapping (SWIM) for inverse filtering. [59] The DGM nuclei included in this study
were: the head of the caudate nucleus (CN), putamen (PUT), globus pallidus (GP), thalamus (THA),
pulvinar thalamus (PT), red nucleus (RN), substantia nigra (SN) and dentate nucleus (DN). Multislice 3D regions-of-interest (ROI) representing these structures were manually traced on QSM slices
using SPIN (Signal Processing in NMR, SpinTech, Inc., Bingham Farms, MI, USA) by the author
with more than 5 years of relevant experience. Original magnitude and phase images were used as
references to ensure accurate boundary drawings. An illustration of the 3D ROIs is given in Figure
4.1. Mean susceptibility values from the entire structures of both cohorts were then extracted and
plotted as a function of age, also known as the global analysis. Similar to Liu et al.’s work, agedependent susceptibility values were chosen as thresholds from the upper 95% prediction intervals
based on their global analysis of 174 controls from which regional high iron (RII) content voxels
were then estimated for a given structure at a given age for all the nuclei except the DN. [12] For the
DN, a similar process was performed on the global analysis established by Ghassaban et al.’s study
from 81 healthy adults. [11] Similarly, mean susceptibilities of the RII regions were calculated and
plotted as a function of age, also known as the regional analysis. The global and regional analyses of
both PD and HC cohorts were then superimposed on the corresponding plots introduced by Liu et al
and Ghassaban et al. [11, 12] Additionally, the average values were compared for both global and
RII susceptibilities between the PD and HC cohorts in both hemispheres and in all DGM nuclei.
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Figure 4.1. 3D regions of interest (ROIs) traced on susceptibility maps of a 65-year-old male. Structures include the
head of caudate nucleus (CN), globus pallidus (GP), putamen (PUT), thalamus (THA), pulvinar thalamus (PT), red
nucleus (RN), substantia nigra (SN) and dentate nucleus (DN). The numbers in the lower left corner represent the slice
numbers from 132 slices collected in this example.

R2* Processing
The R2* maps were also reconstructed using the first 8 echoes through a pixel-by-pixel fit to an
exponential curve. The exact same 3D ROIs traced on the QSM maps were also used on R2* maps.
Similar to QSM data analysis, mean R2* values were extracted from each structure and plotted as a
function of age (i.e., global analysis). These values were then superimposed and visually compared
to the corresponding R2*-age baselines established by Li et al for 6 DGM structures including the
CN, GP, PUT, RN, SN and DN. [94] For each structure the fitted exponential regression equation

60

and 95% confidence intervals provided by Li et al were used to predict the mean R2* values as a
function of age for the normal population. [94] Moreover, similar to the analysis done in QSM
processing, R2* values of both PD and HC cohorts were compared to each other in both
hemispheres for all DGM structures.
Correlation between Susceptibility and R2*
With both the QSM and R2* data available and in order to assess the relationship between these
two parameters in the DGM structures, a linear regression model was fitted to the mean R2* as a
function of mean susceptibility in all the nuclei. To avoid any sources of bias, only the healthy
cohort was included for this correlation, the results of which were compared to those of Li et al.’s
study. [94]
Statistical Analysis
All statistical analyses were carried out using Microsoft Excel 2013 (Microsoft Corporation,
Redmond, WA) with a two-tailed significance level of 0.05. Two-sample t-test analyses were
performed to compare the average global (for QSM and R2*) and regional (for QSM only) values of
PD and HC cohorts in both hemispheres. Furthermore, paired sample t-tests were performed to
compare susceptibility and R2* values between the left and right hemisphere of each DGM
structure. Additionally, a comparison between the mean susceptibility values of the SN and clinical
status of the PD patients was performed. The parameters to which SN global and regional
susceptibility values were compared included the unified Parkinson’s disease rating scale part III
(UPDRS-III) and H&Y scores as well as the disease duration. Finally, the same clinical status
parameters along with patients’ ages were used to compare a sub-group of PD patients with
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abnormal RII susceptibility values (i.e., higher than the corresponding upper 95% prediction interval
from the susceptibility-age baseline [12]) to another sub-group whose RII susceptibilities fall within
the normal ranges of the baseline.
Results
Figure 4.2 and Figure 4.3 show the QSM global and regional analyses for the right hemisphere of
both groups, respectively, superimposed on the corresponding previously established normal
populations. These susceptibility-age baselines were published by Ghassaban et al. (for the DN only)
[11] and Liu et al. (for the rest of the DGM structures). [12] The SN is the only structure showing
elevated susceptibility values in both global and regional analyses (see Figure 4.4).
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Figure 4.2. Right hemisphere global analyses of HC and PD cohorts superimposed on the susceptibility-age baselines
for different deep gray matter structures published by Ghassaban et al. [11] for the dentate nucleus and Liu et al. for the
other seven nuclei. [12] CN: caudate nucleus, GP: globus pallidus, PUT: putamen, THA: thalamus, PT: pulvinar
thalamus, RN: red nucleus, DN: dentate nucleus. Hollow circles: normal baselines, solid circles: HC data from this
study, triangles: PD data from this study, solid lines: linear regression models associated with the normal population,
dashed lines: 95% prediction intervals associated with the normal population.

63

Figure 4.3. Right hemisphere regional high iron (RII) analyses of HC and PD cohorts superimposed on the
susceptibility-age baselines for different deep gray matter structures published by Ghassaban et al. [11] for the dentate
nucleus and Liu et al. for the other seven nuclei. [12] CN: caudate nucleus, GP: globus pallidus, PUT: putamen, THA:
thalamus, PT: pulvinar thalamus, RN: red nucleus, DN: dentate nucleus. Hollow circles: normal baselines, solid circles:
HC data from this study, triangles: PD data from this study, solid lines: linear regression models associated with the
normal population, dashed lines: 95% prediction intervals associated with the normal population
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Figure 4.4. Substantia nigra global (entire structure) and regional (RII high iron) analyses of HC and PD cohorts
superimposed on the susceptibility-age baselines published by Liu et al. [12] Hollow circles: normal baselines, solid
circles: HC data from this study, triangles: PD data from this study, solid lines: linear regression models associated with
the normal population, dashed lines: 95% prediction intervals associated with the normal population.

The results of the two-sample and paired-sample t-tests comparing the susceptibility means of
HC and PD cohorts within and between the two hemispheres of different DGM structures are
summarized in Table 4.1. Only the SN showed significantly higher susceptibility values in PD
patients when compared with the HC cohort, with the regional analysis (PD: 221±18 ppb, HC:
200±14 ppb, p<0.001 for the right and PD: 223±17 ppb, HC: 210±15 ppb, p<0.001 for the left
hemisphere) revealing more prominent differences compared to those of the global analysis (PD:
140±27 ppb, HC: 116±30 ppb, p<0.01 for the right and PD: 144±26 ppb, HC: 122±28 ppb, p<0.01
for the left hemisphere). The SN was also the only structure showing significant differences between
the two hemispheres in both cohorts using both global and regional analyses. On the other hand, in
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addition to the SN, significant differences were seen between the hemispheres in both PD and HC
groups in the THA, RN and DN only using the regional analysis. Among all affected nuclei, the left
hemisphere showed significantly higher susceptibility values.
Table 4.1. Two-sample t-test statistics comparing susceptibility means of the global and regional
analyses between the two cohorts in both hemispheres.
Iron Analysis
Hemisphere
CN

GP

PUT

THA

PT

RN

SN

Global Analysis

RII Analysis

Right

Left

P-value

Right

Left

P-value

HC

54.6 ± 6.6

52.4 ± 7.6

0.27

99.1 ± 5.6

97.3 ± 6.1

0.32

PD
P-value
HC

59.3 ± 6.7
0.35
133.1 ± 10.1

54.7 ± 6.9
0.67
127.8 ± 7.8

0.16
NA
0.15

102.0 ± 7.8
0.56
231.8 ± 5.2

97.7 ± 8.6
0.95
231.1 ± 6.9

0.03
NA
0.82

PD
P-value
HC

133.7 ± 10.0
0.94
68.7 ± 6.4

127.6 ± 9.9
0.97
72.8 ± 7.0

0.11
NA
0.25

232.3 ± 7.2
0.92
150.5 ± 4.3

231.6 ± 7.9
0.92
144.9 ± 5.0

0.86
NA
0.08

PD
P-value
HC

75.8 ± 6.6
0.15
2.3 ± 2.8

73.6 ± 7.8
0.87
2.8 ± 2.9

0.32
NA
0.71

145.1 ± 4.8
0.19
30.2 ± 3.2

142.1 ± 6.1
0.10
36.5 ± 3.0

0.12
NA
<0.001

PD
P-value
HC

3.1 ± 3.7
0.24
45.3 ± 7.0

2.2 ± 3.7
0.66
45.6 ± 6.9

0.59
NA
0.90

33.3 ± 4.8
0.30
83.3 ± 3.7

36.8 ± 3.8
0.88
85.4 ± 2.8

<0.001
NA
0.10

PD
P-value
HC

51.8 ± 8.8
0.27
108.1 ± 13.0

47.7 ± 7.2
0.68
102.9 ± 12.9

0.12
NA
0.31

87.5 ± 5.5
0.22
173.2 ± 5.4

86.4 ± 4.7
0.74
177.5 ± 6.1

0.45
NA
0.03

PD
P-value
HC

112.8 ± 13.1
0.61
115.4 ± 11.6

112.2 ± 13.8
0.36
127.5 ± 10.8

0.85
NA
0.04

175.8 ± 6.8
0.55
200.1 ± 6.1

179.3 ± 6.8
0.69
210.3 ± 5.7

0.01
NA
<0.001

PD
P-value
HC

139.8 ± 10.4
<0.01
93.1 ± 9.7

147.5 ± 10.5
<0.01
95.3 ± 11.0

0.01
NA
0.41

220.7 ± 5.6
<0.001
147.6 ± 5.4

234.7 ± 5.9
<0.001
155.9 ± 6.2

<0.01
NA
<0.001

DN

PD
99.4 ± 10.2
102.1 ± 10.8
0.41
153.7 ± 7.2
159.1 ± 7.4
<0.01
P-value
0.38
0.39
NA
0.20
0.52
NA
Numbers are reported in Mean ± 95% confidence intervals. CN: caudate nucleus, GP: globus pallidus, PUT: putamen, THA: thalamus,
PT: pulvinar thalamus, RN: red nucleus, SN: substantia nigra, DN: dentate nucleus. P-values in bold show significant differences
between the means.

The relationship between mean global and regional susceptibility changes in the SN of PD
patients and clinical status parameters (i.e., disease duration and UPDRS-III) resulted in no
significant correlations (all p-values > 0.05). However, as shown in Table 4.2, dividing the PD
cohort in two sub-groups with normal and abnormal RII susceptibility values showed that there were
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significantly higher UPDRS-III scores in patients with elevated RII iron content (p < 0.05 in both
hemispheres).
Table 4.2. Comparison of clinical status between two sub-groups of the PD cohort with normal and
abnormal RII iron content in the substantia nigra.
Hemisphere
Group

Right
Abnormal
Iron (N=10)

Normal Iron
(N=14)

62.5 ± 8.6

Left
p-value

Abnormal Iron
(N=10)

Normal Iron
(N=14)

p-value

64.9 ± 7.8

0.51

63.9 ± 5.6

63.1 ± 9.7

0.80

Age (years)
Duration
(years)
UPDRS-III

4.7 ± 2.8

3.8 ± 3.3

0.49

5.1 ± 3.4

3.4 ± 2.9

0.29

30.4 ± 14.3

17.8 ± 9.6

0.03

28.6 ± 12.9

16.6 ± 9.7

0.03

H&Y

1.8 ± 0.6

1.4 ± 0.5

0.17

2.0 ± 0.75

1.5 ± 0.55

0.10

Normal and abnormal sub-groups are separated based on RII susceptibility values higher and lower than the baseline
upper 95% prediction intervals, respectively. P-values in bold show significant differences between the means.

The global measurements of R2* values superimposed on the corresponding age-dependent
baselines published by Li et al [94] resulted in no abnormal values with most of the means falling
within the 95% confidence intervals. The only exception was the SN of the PD patients with R2*
values slightly skewed upward but still most subjects were below the upper 95% confidence interval,
as shown in Figure 4.5. Also, the two-sample t-tests between PD and HC cohorts revealed significant
differences in the SN in both hemispheres (PD: 42±4 s-1, HC: 39±4 s-1, p=0.01 for the right and PD:
43±4 s-1, HC: 39±4 s-1, p=0.01 for the left hemisphere). The paired sample t-tests showed no
significant differences between the hemispheres for any of the structures in either cohort.
Figure 4.6 shows the linear regression model fitted to the R2* values as a function of the
corresponding QSM values for the HC group plotted for all the nuclei included in this study. The
Pearson correlation coefficient (PCC) value of 0.87 is indicative of a strong linear relationship
between these two parameters. Also, the linear slope of 0.123 s-1/ppb is very close to the slope of
0.126 s-1/ppb reported by Li et al. [94]
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Figure 4.5. Global analysis of the R2* measurements in the substantia nigra of PD patients and healthy adults
superimposed on the corresponding R2*-age exponential fits provided by Li et al. [94] Although most of the subjects fall
within the 95% confidence intervals, the PD patients showed higher R2* values compared to those of the HC. Solid
circles: HC data from this study, triangles: PD data from this study, solid lines: exponential regression models from the
normal population, [94] dashed lines: 95% confidence intervals associated with the fitted curves.

Figure 4.6. Mean R2* as a function of mean QSM in deep gray matter nuclei of the HC group fitted by a linear
regression model. The data points are the average means between the two hemispheres. Based on the estimated mean
values, the labels show the approximate locations around which each structure falls. The regression parameters are
shown on the plot. CN: caudate nucleus, GP: globus pallidus, PUT: putamen, THA: thalamus, PT: pulvinar thalamus,
RN: red nucleus, DN: dentate nucleus. Solid circles: HC data from this study, solid line: linear regression fit.

Discussion and Conclusions
To date, there is no clear answer to the contributing factors in the pathogenesis of Parkinson’s
disease. It is generally believed that the loss of neuromelanin content may initiate the process of
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increasing non-heme iron deposits in the midbrain which then leads to different forms of
parkinsonism. [8-10] On the other hand, there is also the hypothesis arguing that the depigmentation
of the nigrosome-1 content in the posterolateral part of the SN might lead to the subsequent increase
in iron deposition in this midbrain structure. [197]
In this chapter, we have shown that there is an increase in iron in the SN over and above the
normal increase due to age in PD patients. Although the average susceptibility value of the SN is
seen to increase in the PD cohort, especially in the thresholded regions characterized by high iron
content, we also note that there may, in fact, be two populations of PD patients, those that do not
change iron content and those that do. For the abnormally high iron content group, there was a
significantly higher UPDRS-III than the group showing normal iron content. Nevertheless, to draw a
stronger conclusion will require investigating a considerably larger sample size.
The global and regional analyses in the SN of PD patients has previously been evaluated in
Ghassaban et al. and Sethi et al. in which similar QSM reconstruction techniques were adopted using
different scanners and field strengths. [11, 198] The regional analysis being more sensitive to local
high iron content changes seen in the SN in this study is in accordance with their findings. This
validates the consistency and reliability of using gradient echo imaging and the use of the threshold
based QSM reconstruction for data from different MR manufacturers’ systems
The comparison between the two hemispheres revealed significantly higher iron deposition in the
left hemispheres of both PD and HC cohorts in the THA, RN, SN and DN in the regional (RII)
analysis and only in the SN for the global analysis. However, the largest effects in terms of absolute
shifts in susceptibility were seen in the SN where the differences were on the order of 20 ppb
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compared to all other cases where the differences are on the order of less than 8 ppb. This is
consistent with Liu et al.’s study where they showed that, except in the SN, small but significant
differences between the hemispheres of all DGM structures would vanish if other sources of error (in
their case excluding one slice from the top and/or bottom of the structures or changing the definition
of RII from upper 95% to 99% prediction interval of the global analysis) were taken into account
when measuring the susceptibility values. [12] However, simulation results for the SN show that
QSM has a systematic error of roughly 12 ppb in the SN due to streaking artifacts generated by the
QSM reconstruction. [57] Additionally, low spatial frequency undulations seen in QSM techniques
could also lead to asymmetry in the brain. [57] Therefore, by taking into consideration all these
sources of systematic error, the asymmetries seen in the SN may disappear as well. Another QSM
study in which lateral asymmetry was found in the SN of PD patients was done by Azuma et al.
where the mean susceptibility was seen to be significantly higher in the more affected hemisphere
compared to that of the less affected hemisphere although they had much larger errors compared to
our data due in part to the distribution of iron and the small sample size. [181] They also do not
account for the other sources of systematic error mentioned above which may again remove any
remaining small differences between left and right values of iron in the SN.
Evaluating R2* maps led to two major findings: first, in accordance with the literature, iron
content characterized by R2* values was seen to be higher in the SN of PD patients compared to the
healthy group. Second, even though these differences were statistically significant, considerably
lower p-values from QSM results (both between the two groups and between the hemispheres within
each group) showed higher sensitivity and reliability of susceptibility-based techniques to pick up
more subtle changes in brain iron. Additionally, the error analysis from both of these iron
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quantification techniques reveals that the variability of measurements associated with QSM is
considerably less compared to that of R2*, [199] especially in the high iron content (RII) region.
Despite the fact that R2* correlates well with QSM measures of iron content, R2* measurements
(especially from a limited number of echo times) is more prone to noise. One major advantage of
QSM is that it is in theory independent of echo time, but the SNR of the R2* maps depends critically
on the echo time. [57] Practically an echo time of roughly 20ms is enough to give excellent
susceptibility maps and in this case with 8 echoes excellent measurements of the DGM is possible.
Another key finding that validates previous results is the tightness (higher r2 values) of the iron
growth with age in the different DGM structures in the regional iron content measures. The fact that
regional changes are much tighter than global changes opens the door to a better separation of
patient types, specifically in terms of separating high iron content patients from normal iron content
patients. Averaging over all patients, especially in the global analysis, will reduce the shift in the
mean iron content and may be the reason that some of the previous studies failed to show increased
iron content in the SN. [200] RII iron content may provide a new means to evaluate the role of
regional changes in iron deposition. For example, it is believed that the loss of neuromelanin in the
nigrosome-1 territory of the SN pars compacta leaves behind MR-visible iron. [201] Localizing
where this high iron content occurs anatomically may help to answer this question.
Further, in this work, the ability to separate the high and normal RII iron content patients using
QSM data led to the finding that there are in fact group differences in UPDRS-III scores. Similarly,
by using R2*, Pesch et al. found a correlation between iron content and UPDRS-III scores in the SN
of 35 PD patients. [202] However, their R2* measurements were not corrected for age. Since R2*
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has been seen to increase as a function of normal aging, [94] it is imperative to take this factor into
account in iron quantification studies.
There are a number of limitations to this study. First, the number of samples is small and a much
larger population should be studied to best demonstrate the presence of two groups of PD patients.
Second, no clinical phenotypes were considered while analyzing imaging data. Third, ROI tracings
were done manually which might have induced some unwanted errors when demarcating different
DGM nuclei especially around the edges; this source of error, however, gets substantially reduced
when thresholded low susceptibility values are excluded in the regional analysis. Nonetheless, the
undesired errors associated with manual ROI tracing in the global analysis could be effectively
minimized by using atlas-based automated DGM segmentation techniques. [203] Finally, the fairly
low in-plane resolution used in the GRE sequence made it difficult to evaluate the sub-structures,
especially the SNpc whose abnormally high iron deposition is believed to be correlated with NM
degeneration in the midbrain. [8-10] Higher spatial resolution is recommended in future studies for
this purpose. In conclusion, the increase in iron in the SN in some PD patients is higher than the
normal range in HC as found in both regional and global analyses. Using regional high iron content
may provide a means to separate two populations of PD patients; one with and one without iron
increases in the SN. Separating the PD population into two groups may prove useful in
understanding the etiology of the disease as well as monitoring the disease progression.

72

Chapter Five: Imaging Iron and Neuromelanin Simultaneously Using a Single 3D
Magnetization Transfer Sequence: Combining Neuromelanin, Iron and the
Nigrosome-1 Sign as Complementary Imaging Biomarkers in Early Stage
Parkinson’s Disease
Introduction2
Parkinson’s disease (PD) is one of the fastest growing neurodegenerative disorders in the world
and a leading cause of disability. Early PD diagnosis is still challenging and motivates an increasing
need for non-invasive imaging biomarkers. Although Datscan can be used as an absolute exclusion
criterion for diagnosing PD, [204] it is not widely available, it is expensive, and it uses radioisotopes.
PD is characterized by the classical motor features of parkinsonism with early prominent death
of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The SNpc (referring to the
dorsal part of SN) and the SN pars reticulata (SNpr, referring to the ventral part of the SN) are
anatomically and functionally distinct (see Supplementary Section 9.1 for further anatomical
details). The SNpr contains higher levels of iron than the SNpc in normal subjects, while the SNpc is
rich in dopaminergic neurons which are known to accumulate neuromelanin (NM). Consequently, in
most previous neuroimaging studies, [205] the SNpr is usually detected as a T2*W hypointense
region due to high iron content while the SNpc has both hypointense regions with high iron and
hyperintense regions such as the nigrosome-1 NM rich area (due to its high T2* values and lower
iron content) as validated in NM-sensitive MRI (NM-MRI). [9] As a result, while the SNpc is
characterized by NM content, the SNpr is usually responsible for regional high iron content in the

The content from this chapter is now published in the following journal paper: He, N., et al., Imaging iron and
neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining
neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
Neuroimage, 2021. 230: p. 117810.
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SN. Practically, it is very difficult to differentiate SNpr and SNpc with MRI. However, similar to
other major deep gray matter nuclei of the brain, and complicating the issue, is the fact that total iron
content in the SN increases as a function of age with a relatively large spread in values. [12, 198]
Anatomically, the NM-containing dopaminergic neurons are not restricted to the SNpc region.
According to histological studies, [206] the dopaminergic neurons in the midbrain are located in
three different groups referred to as A8, A9 and A10. Apart from the SNpc (group A9), the overall
ventral tegmental area (VTA) region (located in A8 and A10) contain dopaminergic neurons. [205]
The parabrachial pigmented nucleus (PBP) or SN pars dorsalis (SNpd) is located ventromedially to
dorsolaterally between the red nucleus and the SNpc while the VTA nucleus lies ventral to the RN at
the ventromedial limit of the PBP. The PBP together with the midline VTA nucleus constitute the
dorsal tier of the dopaminergic neurons in the midbrain. Due to the variability of anatomical and
neurochemical properties within the overall VTA region, it is difficult to separate the SNpc and the
overall VTA region both histologically in humans and in-vivo on MR images. [207] However, using
multi-contrast MRI, particularly using QSM, it is possible to differentiate the SNpc from the overall
VTA region as a whole. [45] A schematic of the midbrain summarizing these structures is shown in
Figure 5.1.
It is believed that dopaminergic neuronal death in the SNpc is followed by NM depigmentation
leaving behind iron that is then phagocytized and becomes visible in MRI. [43] Therefore, the most
promising clinical MR biomarker candidates are iron content as seen with R2* or quantitative
susceptibility mapping (QSM) [11] and NM as measured with NM-MRI. [17] QSM provides a
quantitative measure of the iron in the total SN, including the SNpc and SNpr, while the
hyperintense signal seen in NM-MRI is spatially associated with the SNpc and the overall VTA
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region inclusive of the SNpd as well as with the NM seen in postmortem histological studies. [27] It
has been shown that the MRI representation of NM matches the dopaminergic territory seen in PET
and that the intensity of the NM signal in MRI correlates with the dopamine release capacity. [24]
The literature generally supports the concept that iron content is expected to increase in the SNpc in
PD subjects while NM is expected to decrease in PD subjects. [21, 22, 184] An alternate approach
that does not measure NM throughout the SN but rather is sensitive to just the NM in the nigrosome1 (N1) territory has also been promoted as a possible means to discriminate between PD subjects and
healthy controls (HC). [16-18] The disappearance of the N1 sign is a surrogate marker to the loss of
NM overall as well as an increase in local iron content, [19] but this approach does not actually
measure NM or iron content quantitatively. However, the sensitivity and specificity of either NM,
iron or the N1 sign in the SN may not be good enough for them to qualify as diagnostic biomarkers
by themselves. [20-22]
Some studies have combined NM and iron measures, but they used two different sequences
which required co-registration and data interpolation [21, 22, 30, 44, 45] and, sometimes, the use of
a NM template mask. [9] Only one group used a single two-echo 2D gradient echo (GRE) sequence
to study NM and susceptibility weighted imaging (SWI). [73] Apart from the volume and intensity
measures of SN or NM usually used in PD neuroimaging studies, a prior study [208] showed that the
overlap between the iron content as determined by R2* mapping and the neuromelanin mask of the
SNpc provided good diagnostic performance to differentiate PD from HC. Also, during the past few
years, the N1 sign which is usually imaged with a 3D SWI scan [18] is gaining attention as a
potential imaging biomarker of pathophysiologic changes in PD subjects. Our hypothesis is that the
combination of these imaging measures will provide a comprehensive understanding about
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pathophysiological changes in the SN underlying PD and outperform each single measure by
themselves.
Therefore, our goal in this chapter is to use a single sequence to evaluate four metrics as imaging
biomarkers to differentiate early stage PD subjects from HCs: the NM complex volume (SNpc plus
PBP), SN volume (SNpc plus SNpr), SN iron content (as measured using susceptibility in QSM) and
N1 sign. This innovative approach uses a 3D multi-echo, GRE, magnetization transfer contrast
(MTC) sequence that can be run in a clinical setting in less than 5 minutes.
Materials and Methods
Subjects
This study was approved by the local ethics committee at Ruijin Hospital and consent forms
were signed by all subjects. Forty subjects with early-stage idiopathic PD and 40 sex- and agematched HCs were recruited consecutively from the Ruijin movement disorder clinic and local
advertisements from May 2018 to January 2019. All subjects were on medication. The diagnosis and
severity of motor symptoms were assessed by two neurologists based on the Movement Disorders
Society (MDS) PD criteria, [204] the Hoehn & Yahr (H&Y) stage and the MDS Unified Parkinson’s
Disease Rating Scale Part-III (UPDRS-III), [209] Symptom laterality was determined by measuring
the difference between the right and left UPDRS-III sub scores, [210] The exclusion criteria of PD
were as follows: (1) H&Y scale more than 2.5; (2) Mini-Mental State Examination (MMSE) score
less than 24; (3) a history of cerebrovascular disease, brain tumor, head trauma or any other type of
psychiatric disorders; (4) a history of medication known to cause parkinsonism or affect clinical
assessment; (5) contraindications to an MRI examination, and (6) younger than 40 years of age. The
inclusion criteria for the HCs were as follows: (1) no family history of movement disorders; (2) no

76

neurological or psychiatric disorders; (3) an MMSE score of at least 24 and (4) older than 40 years
of age. PD subjects were evaluated one year later to confirm the diagnosis using the same MDS-PD
diagnostic criteria as used at the baseline for PD diagnosis.
MRI Data Collection
All data were collected on a 3T Ingenia scanner (Philips Healthcare, Netherlands) using a 15channel head coil. A seven-echo 3D SWI sequence with an MTC pulse was collected using: TE =
7.5 ms and ΔTE = 7.5 ms, TR = 62 ms, flip angle = 30˚, pixel bandwidth = 174 Hz/pixel, matrix size
= 384 × 144, slice thickness = 2 mm, in-plane resolution = 0.67 mm × 1.34 mm and total scanning
time = 4 min 47 s for 64 slices. The MTC pulse was an on-resonance [211] 90o flip angle with 3
block pulses of 1.91ms which is part of the Philips product sequence. [212] To validate that the
phase images from the MTC scan can also provide normative QSM data, a separate multi-echo SWI
sequence was acquired as part of the strategically acquired gradient echo (STAGE) protocol [213215] using: TEs = 7.5 and 17.5 ms, TR = 25 ms, flip angles = 6˚ and 24o, pixel bandwidth = 220
Hz/pixel, imaging matrix size = 384 × 144, slice thickness = 2 mm, an in-plane resolution = 0.67
mm × 1.34 mm and a scanning time of 1 min 53 s for 64 slices per scan. In both cases, the images
were interpolated to an in-plane resolution of 0.67 mm × 0.67 mm. The axial slice orientation was
the anterior commissure posterior commissure (ACPC) line for all scans.
MTC and QSM Data Processing
The NM signal was evaluated from the first echo (TE = 7.5 ms) of the MTC data while the
susceptibility maps (denoted as MTC-QSM) were calculated using the second echo (TE = 15 ms)
data to avoid more severe aliasing at the longer echo times. The MTC-QSM process included the
following steps: a brain extraction tool was applied (threshold = 0.2, erode = 4 and island = 2000)
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[195] using the first echo magnitude data; a 3D phase unwrapping algorithm (3D sorting by
reliability following a non-continuous path or 3DSRNCP) was used to unwrap the original phase
data [196]; sophisticated harmonic artifact reduction (SHARP) was used to remove unwanted
background fields (threshold = 0.05 and deconvolution kernel size = 6) [58]; and a truncated kspace division based inverse filtering technique (threshold = 0.1) [59] was used with an iterative
approach (iteration threshold = 0.1 and number of iterations = 4) to reconstruct the susceptibility
maps. [117] The same QSM processing pipeline was used to reconstruct the second echo (TE = 17.5
ms) data from the STAGE sequences, denoted as STAGE-QSM. Finally, the MTC-QSM and the
magnitude image of the second echo were used to create true SWI (tSWI) data for the detection of
the N1 sign. [121]
Defining the NM and iron boundaries and quantification of volumes and susceptibility
Two sets of regions of interest (ROIs) were outlined separately one for NM on the MTC images
and one for iron on the MTC-QSM images. The images were first zoomed by a factor of four to
more easily and accurately draw the boundaries for NM and iron. The iron-based SN ROIs were
traced starting from one slice below the most cranial slice where the subthalamic nucleus was visible
and continued for four to five consecutive slices to the most caudal slice. The NM boundaries,
however, were traced from the last caudal slice (which corresponds to the most caudal slice showing
iron content in the SN) for four to five slices cranially until the NM was no longer visible as shown
in Figure 5.1. The NM complex used in this study was defined as the region showing NM contrast in
the midbrain but excluding the midline VTA nucleus (as shown in the central dark gray area in
Figure 5.1 fourth column).
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Figure 5.1. Neuromelanin, iron and N1 in the SN as represented by MTC magnitude, MTC-QSM and MTC-tSWI data.
From left to right the first three columns show four consecutive slices from a 63-year-old healthy control followed by the
schematic of different midbrain structures and the same contrasts from a 62-year-old PD subject shown in the last three
columns. The top and bottom rows show the most rostral and most caudal slices, respectively. The red ROIs representing
the NM complex were drawn on the MTC magnitude data and then overlaid on the corresponding MTC-QSM and MTCtSWI datasets. It should be noted that the overlap between the NM complex and the iron containing SN (i.e., the SNpc in
controls) increases towards the caudal slices in the HC subject while this area is substantially smaller in the PD subject
on a slice-by-slice basis (p = .040 for all the slices where both NM and the iron containing SN are present). The yellow
arrows in the second and third columns show the N1 territory located in the ventral-lateral aspect of the NM complex
while the yellow arrows in the right column represent the directionality of the NM loss (and overlap) starting from the
ventral tier and continuing towards the dorsal tier of the SNpc. The regions shown by the NM boundaries but that lie
outside the SN as highlighted in the QSM data represent the PBP (also known as the SNpd). The highlighted regions in
the schematic represent: green: mammillary bodies; pink: superior cerebellar peduncles; red: red nucleus, orange:
Nigrosome-1 territory; yellow: SN pars reticulata (SNpr); blue: SN pars compacta (SNpc); light gray: SN pars dorsalis
(SNpd)/parabrachial pigmented nucleus (PBP); and dark gray: ventral tegmental area (VTA) nucleus.

Finding the final boundaries was done with a two-step process. First, all initial input boundaries
were reviewed by three raters and then an intermediate set of boundaries was chosen by consensus.
These boundaries were initially traced a few pixels outside what would have otherwise been drawn
manually by any of the raters while avoiding the hyperintense structures such as veins outside the
desired final ROI. Second, to remove the human element completely, a dynamic programming
algorithm was used to determine the final boundaries [216] (see Supplementary Section 9.2 and
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Supplementary Figure 9.3 for more details). This semi-automated approach provides a means to
generate a mathematically determined user independent boundary. DICE similarity coefficients
associated with different sets of results from the raters before reaching consensus were calculated as
.89 and .84 for the SNVOL,MTC and .91 and .88 for the SNVOL,QSM in the HC and PD subjects,
respectively. A partial volume correction of the most caudal slice was performed on the NM, QSM
and overlap fraction data. The partial volume effect was calculated based on the contrast of the most
caudal slice and of the second and third most caudal slices via:
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑙𝑖𝑐𝑒 𝑤𝑖𝑡ℎ 𝑝𝑎𝑟𝑡𝑖𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑒𝑓𝑓𝑒𝑐𝑡

(5.1)

= 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑙𝑖𝑐𝑒
×

𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑙𝑖𝑐𝑒
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑡𝑤𝑜 𝑚𝑖𝑑𝑑𝑙𝑒 𝑠𝑙𝑖𝑐𝑒𝑠

A volumetric analysis was performed using the boundaries from all slices covering both the NM
and iron containing SN. The results were then compared between the PD and HC groups as well as
between the two hemispheres for each group for the NM complex and iron containing SN total
volumes. The overlap between the NM complex volume (SNpc plus PBP) and iron containing SN
volume (SNpc plus SNpr) was evaluated by superimposing the two ROIs from the MTC and MTCQSM data, respectively. This overlap was normalized by the iron containing SN volume creating an
overlap fraction measure which basically represents the SNpc fraction with respect to the entire SN
volume (Figure 5.1), as given below:
𝑂𝑣𝑒𝑟𝑎𝑙𝑙 𝑂𝑣𝑒𝑟𝑙𝑎𝑝 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛
=

∑𝑠𝑙𝑖𝑐𝑒𝑠 𝑤ℎ𝑒𝑟𝑒 𝑆𝑁𝑝𝑐 𝑖𝑠 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑖𝑛𝑡𝑒𝑟𝑠𝑒𝑐𝑡𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑁𝑀 𝑎𝑛𝑑 𝑆𝑁
∑𝑠𝑙𝑖𝑐𝑒𝑠 𝑤ℎ𝑒𝑟𝑒 𝑆𝑁𝑝𝑐 𝑖𝑠 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑖𝑟𝑜𝑛 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 𝑆𝑁

(5.2)
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For ease of reference, hereafter we define SNVOL,MTC as the SNpc plus PBP volume measured
from the MTC data in mm3; SNVOL,QSM as the total SN volume (SNpc plus SNpr) measured on
MTC-QSM in mm3; SNΔχ as volumetric mean susceptibility from MTC-QSM in ppb; and SNOVERLAP
as the intersection of the SNVOL,MTC and SNVOL,QSM normalized to SNVOL,QSM in percent.
The mean susceptibility of the SN was measured and compared between the two groups in both
hemispheres. These global values were plotted as a function of age against the corresponding
baselines from a normal population established by Liu et al. [12]. To demonstrate that MTC-QSM
and the normative STAGE-QSM (without the MT pulse) are equivalent to each other, the same SN
boundaries traced on MTC-QSM were superimposed on the STAGE-QSM data for the HCs. The
two datasets acquired with the same resolution and brain coverage were aligned to each other by the
magnitude images using SPM software (V12, Functional Imaging Laboratory, UCL, London, UK),
and the QSM data were then transformed according to the geometric displacement matrix. For each
case, the mean susceptibility was extracted from the whole 3D ROI and averaged over the two
hemispheres. A linear regression model was applied to evaluate the correlation between the averaged
mean susceptibility between these two sequences for all the HCs and PD subjects. (see
Supplementary Section 9.3)
In order to assess the potential dependence of volumetric analyses to brain tissue atrophy and
spread of the data in both cohorts, a normalization of SNVOL,MTC and SNVOL,QSM to the whole
midbrain volume was done by manually tracing 3D boundaries on the first echo magnitude data. (see
Supplementary Section 9.6)
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N1 sign evaluation
The N1 sign evaluation (no loss, unilateral loss or bilateral loss) was performed in a blinded
manner using the MTC-tSWI data (which has been found to be the best modality to show the N1
sign in previous works) [18, 217] and the MTC-QSM data by two reviewers separately. The
consensus results between the two reviewers were then used for the final analyses. To validate the
interpretation of the data, each slice where the N1 sign was found was compared with the boundaries
from the MTC data to ensure that the interpretation of the N1 sign was correct in that it was situated
in the ventral-lateral side of the NM complex. This has not been possible previously when just using
QSM by itself as the N1 sign is usually recognized either by the swallowtail or ovoid sign and a
hyperintense area remaining inside. Using the MTC boundaries assures a correct interpretation of the
data.
Statistical Analysis
Subject characteristics are presented as mean ± standard error of the mean (SEM). Two-sample
and paired t-tests were used for inter-group comparisons between the two groups and intra-group
comparisons between the two hemispheres as well as the comparison between the ipsilateral and
contralateral sides in the PD group, respectively. The area under the curve (AUC) for receiver
operating characteristic (ROC) analysis was calculated to evaluate the overall diagnostic
performance of the SNΔχ, SNVOL,QSM, SNVOL,MTC and SNOVERLAP, as independent predictors. Then,
the diagnostic performances for PD were compared using the DeLong test. Binary logistic regression
was used to integrate information from different combinations of these measures to produce
associated ROC curves. We performed partial correlation analysis to explore relationships between
each image feature and the clinical variables (disease duration and UPDRS-III) using age and sex as
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covariates. All statistical analyses were performed using IBM SPSS Statistics Version 25
(International Business Machines Corporation, Armonk, NY, USA). A p-value < .05 for two-sided
tests was considered significant. The Bonferroni correction was used to correct the partial
correlations when multiple comparisons were used in the correlation analyses (p-value threshold for
significance: .006) and ROC comparisons (p-value threshold for significance: .003).
Results
Demographic and clinical characteristics are shown in Table 5.1. There was no significant
difference in sex or age between the two groups. For any of the imaging measures discussed herein,
there were no significant differences between the ipsilateral and contralateral side for the PD group,
or between the left side and right side for the HC group.
Table 5.1. Comparison of clinical status between two sub-groups of the PD cohort with normal and
abnormal RII iron content in the substantia nigra.
Sex, man:woman
Age, yearsa
Disease duration, years
UPDRS-III
Hoehn and Yahr scale
Symptom laterality, left:right

Parkinson’s disease
20:20
63.10 ± 8.05 [43 - 76]
2.55 ± 2.92 [0.08 - 15]
22.73 ± 14.26 [6 - 64]
1.78 ± 0.52 [1 - 2.5]
14:26

Healthy controls
20:20
65.50 ± 8.19 [44-81]

p-value
.19

Values represent mean ± standard deviation [range]. The UPDRS-III was administered while subjects were in the ON medicated
state. aSignificant differences were tested using independent t-test.

NM complex and iron containing SN volume comparison between early stage PD subjects and
healthy controls
An example set of the slices evaluated is shown pictorially in Figure 5.1. These boundaries were
used to calculate SNVOL,MTC and SNVOL,QSM. The SNVOL,MTC were (322.85 ± 4.72) mm3 and (234.58 ±
6.22) mm3 averaged between the right and left hemispheres of the HC and PD groups, respectively.
This example also highlights the fact that the N1 sign shown in the caudal slices lies within the
ventral-lateral tier of the NM boundary. The PD group had significantly lower NM complex volumes
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than those of the HC group (p < .001). There was no significant correlation of SNVOL,MTC with age
for either group. (see Supplementary Section 9.4 and Supplementary Figure 9.6) The SNVOL,QSM
were (477.53 ± 12.63) mm3 and (395.38 ± 9.61) mm3 averaged over the right and left hemispheres of
the HC and PD groups, respectively, with the PD group showing lower volumes (p < .001). There
was a decreasing trend in SNVOL,QSM as a function of age (Supplementary Figure 9.6) which reached
significance for PD (p = .001) but not for HCs (p = .070). The mean SNOVERLAP values were (39.96 ±
1.05)% and (36.49 ± 1.29)% averaged over the right and left hemispheres of the HC and PD groups,
respectively, with the PD group showing lower overlap percentages (p = .040) (Supplementary Table
9.1). There were no significant differences between male and female results in any of the measures
(p > .050 in all cases).
The scatter plots for SNVOL,MTC versus SNOVERLAP, SNVOL,QSM and SNΔχ are presented in Figure
5.2A-C, respectively. Figure 5.2A shows the SNVOL,MTC as a function of SNOVERLAP in all 4 to 5
slices where both NM and SN are present. However, there is a larger overlap of PD and HC cases
between SNVOL,MTC and either SNOVERLAP or SNVOL,QSM

(Figure 5.2A-B) compared to that of

SNVOL,MTC and SNΔχ (Figure 5.2C). The sensitivity, specificity and accuracy associated with the
relationship between SNVOL,MTC and SNΔχ (Figure 5.2C) provided slightly better, although
statistically insignificant, performance in separating the two cohorts compared to the other two
metrics. (p = .292 comparing SNVOL,MTC/SNΔχ to SNVOL,MTC/SNOVERLAP and p = .470 comparing
SNVOL,MTC to SNVOL,MTC/SNVOL,QSM).
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Figure 5.2. Distinguishing between the two groups using NM complex volume and three other measures. SN VOL,MTC
volume as a function of (A) SNOVERLAP, (B) SNVOL,QSM, and (C) SNΔχ. The data indicate the loss of N1 for both groups.
Sensitivity (SENS), specificity (SPEC) and accuracy (ACC) values are also shown for each plot.

Using MTC-QSM to quantify iron in PD
The relationship for the HCs between the two QSM approaches is shown in Supplementary
Figure 9.4 and Supplementary Figure 9.5 in Supplementary Section 9.3. The results confirm a strong
positive relationship (R2 = .751, p < .001, slope = 1.11, p < .001) between them indicating that MTCQSM provides similar susceptibility values compared to the normative STAGE-QSM and, therefore,
MTC-QSM is suitable to estimate regional brain iron levels.
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SN iron deposition in PD
Using MTC-QSM, there was a higher iron content for early stage PD subjects compared to HCs
in both hemispheres (p < .001). The data for the SN susceptibility analyses superimposed on the
corresponding susceptibility-age baselines [12] are shown in Figure 5.3. The SNΔχ values were
(132.12 ± 4.01) ppb and (155.30 ± 4.09) ppb averaged over the right and left hemispheres of the HC
and PD groups, respectively, with the PD group showing higher SNΔχ (p < .001). Not only did the
PD group show higher iron content, within the PD group, the presence of bilateral loss of N1 sign
was most evident in those cases with the highest iron content. Specifically, a total of 21 out of 25 PD
cases on the right and 14 out of 15 cases on the left that lay above the 95% prediction interval for the
iron distribution had bilateral loss of the N1 sign (Figure 5.3). We also note that the more caudal the
slice the more the NM overlaps with the iron (representing the SNpc) until at the last slice where it is
almost a complete overlap showing that caudally the SN is predominantly the SNpc (see Figure 5.1).
The added information from the N1 sign
The results from the N1 analysis reveal that 36 out of 40 HC cases showed bilateral presence of
N1 while N1 loss, either unilaterally or bilaterally, was detected in 34 out of 40 PD cases. The N1
sign information included in Figure 5.2 shows that some PD cases that appear in the HC region are
in fact bilateral loss of the N1 sign, making it possible to remove them from the HC region and
further improve the sensitivity of the NM and SN volume. The N1 sign performed reasonably well
by itself (AUC = .891) but was significantly improved when merged with SNVOL,MTC (AUC= .979; p
< .001) and SNΔχ (AUC =.953; p = .056). However when the N1 sign was merged with SNVOL,MTC
and SNVOL,QSM, , the highest AUC of .983 (p = .003) was obtained.
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Figure 5.3. Mean susceptibility as a function of age for a large normal population as well as HC and Parkinson’s cases in
this study. SN global iron content of the HC and Parkinson’s disease groups associated with the (A) right and (B) left
hemisphere. The bilateral, unilateral, and no loss of Nigrosome-1 for each group are also shown. The data are
superimposed on the corresponding normal baselines established by Liu et al. illustrated by open circles. [12] The solid
line and dashed lines show the linear regression model associated with the normal baseline and its corresponding 95%
prediction intervals, respectively.

Diagnostic performance for early stage PD
The AUC values associated with the average of the right and left hemispheres were .960 for the
SNVOL,MTC; .788 for the SNVOL,QSM; .740 for the SNΔχ and .629 for the SNOVERLAP. However,
combining the two QSM related measures, SNVOL,QSM and SNΔχ, yielded AUC values of .859 and
adding SNOVERLAP brought these values to .911. Normalizing the SNVOL,MTC and SNVOL,QSM volumes
to the whole midbrain volume did not improve the classification performance associated with any of
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the measured values. To support this claim, the p-values associated with the un-normalized versus
normalized ROC curves corresponding to the combination of SNVOL,MTC with each of SNVOL,QSM,
SNΔχ and SNOVERLAP were found to be .38, .36 and .49, respectively, indicating that the normalized
data showed no significant improvement over the un-normalized data (see Supplementary Section
9.6 and Supplementary Figure 9.9).
The ROC curves associated with the SNVOL,MTC, SNVOL,QSM, SNΔχ and SNOVERLAP are illustrated
in Figure 5.4A. As suggested in these plots and with respect to the above-mentioned AUC values,
the SNVOL,MTC had a significantly higher AUC compared to those of the SNVOL,QSM, SNΔχ or
SNOVERLAP for the average of the right and left hemispheres in differentiating early stage PD subjects
from HCs (p < .001 for all), respectively (Figure 5.4A). The ROC curves associated with the
combination of SNVOL,MTC and the three other measures are shown in Figure 5.4B. The
corresponding AUC values were .969 for the combination of SNVOL,MTC and SNVOL,QSM, .965 for
SNVOL,MTC and SNOVERLAP, and .976 for SNVOL,MTC and SNΔχ for the average of the right and left
hemispheres, respectively. The AUCs associated with all of the measure combinations are shown in
Supplementary Table 9.2. Although we obtained a higher AUC value for the combination of all four
measures than any individual measure, the difference was not significant (p = .222) compared to
SNVOL,MTC alone, but was significant when compared to the rest of the individual measures (p <
.001). Also, the AUC from the combination of SNΔχ and SNVOL,QSM measures showed a low p value
of .020 compared to SNVOL,MTC alone but not low enough to be significant at the .003 level
(Supplementary Table 9.3).
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Figure 5.4. ROC analyses of diagnostic performance using different neuroimaging measurements. (A) ROC analyses of
the different combinations of NM complex volume (SNVOL,MTC), SN volume (SNVOL,QSM), global mean iron
content (SNΔχ,) and overlap fraction (SNOVERLAP) for the individual measures. (B) The combination of NM complex
volume with the three other measures was calculated via a binary logistic regression analysis. The data are averaged over
both hemispheres.

Correlation analysis between imaging features and clinical scales
There was a significant loss of SNVOL,QSM with increasing UPDRS-III score (R2 = .22, p = .002)
(Figure 5.5A). The correlation was not significant between the SNΔχ and disease duration for the
whole group (R2 = .12, p = .027) (Figure 5.5B), but there was a positive correlation between SNΔχ
and disease duration (R2 = .32, p < .001) in the subgroup of PD patients with disease duration less
than or equal to 5 years which is considered as early PD. [204] There were no other significant
correlations with any of the other quantitative MRI measures or clinical scales.
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Figure 5.5. The correlations of SN volume and iron content with clinical characteristics of Parkinson's disease. (A)
SNVOL,QSM (averaged over both hemispheres) versus UPDRS-III. There is a significant reduction in the SNVOL,QSM as
UPDRS-III increases (p = .002). (B) The correlation between SNΔχ (averaged over both hemispheres) and disease
duration in PD subjects (p = .027) is not significant after Bonferroni correction (p-value threshold for significance:
.0125). There appears to be a rapid rise in the iron content in the first 5 years (with y = 11.8x + 133.4, R 2 = .32, and p <
.001) and then it levels off for the early stage PD group.

Discussion and Conclusions
To our knowledge, the integration of NM, iron, iron-NM overlap and the N1 sign derived from a
single sequence to differentiate early stage PD from healthy controls has not been presented in the
literature. In this study, the SNVOL,MTC provided the highest single measure diagnostic accuracy
while the N1 sign provided the second highest diagnostic performance. Merging the SNVOL,MTC and
SNVOL,QSM with the N1 sign yielded the highest AUC among all singular predictors and all
combinations of predictors. We also found SNVOL,QSM negatively correlated with UPDRS-III and the
SNΔχ increased with disease duration in PD subjects during the first 5 years after showing clinical
symptoms.
Previous studies have shown that diagnostic AUC for individual measures (NM contrast,
SNVOL,MTC, SNΔχ and the width of SNpc) can vary from .65 to .92 [8, 10, 21, 22, 29-31, 34, 218-220]
whereas our results for the combination of SNVOL,MTC, SNVOL,QSM, SNΔχ and the N1 sign generated
an AUC of up to .98. The main advantages of this single MTC sequence approach include:
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simultaneous NM and iron content information; rapid acquisition time (less than 5 minutes); no need
for co-registration or the creation of templates; and high contrast data which is critical for boundary
detection. [212] Further, the semi-automated DP boundary detection approach we used in this study
brought the boundaries traced by the raters in line with each other. This rapid approach to obtain
both the iron and NM information simultaneously opens the door to its potential practical use in a
clinical setting.
The results of this study showed an AUC for SNΔχ and SNVOL,QSM measures together (which are
both derived from QSM data) of .859 in differentiating early stage PD subjects from HCs. A similar
approach comparing the NM and QSM data (but derived from two sequences) was used by
Takahashi et al. using QSM and SNVOL,MTC derived from the SNpc component (VTA volumes
removed); they found an AUC of .86 in both studies. [21, 22] The SNOVERLAP by itself performed
poorly, likely due to the fact that the SNVOL,MTC and SNVOL,QSM can both be reduced leaving the
overlap fraction invariant. On the other hand, it should be noted that even though under normal
circumstances there is an almost complete overlap between SNVOL,MTC and SNVOL,QSM in the most
caudal slice delineating the SNpc, the NM loss in PD patients appears to be happening mostly in the
posterolateral aspect of the SNpc where the N1 territory is anatomically located.
Prior studies have shown that the N1 sign could be used to differentiate PD from HCs with
reasonably good accuracy. [16, 17] Although this method is attractive because of its visual nature in
the images, it is not trivial as there is still overlap of the N1 appearance between PD subjects and
HCs and none of the approaches introduced to date take the volume of the N1 sign into account. [18]
Our study for the first time incorporated the N1 sign along with other quantitative measures such as
the SNVOL,MTC, SNVOL,QSM, SNOVERLAP and SNΔχ resulting in a comprehensive analysis of the
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pathological changes in PD. Although the N1 sign performs well by itself (AUC = .891), similar to
the findings in Cheng et al, [18] it can be improved by combining this data with either SNVOL,MTC,
SNVOL,QSM, or SNΔχ. This is not surprising since the N1 sign detection is not infallible. Further, the
N1 sign does not quantitatively represent either iron or NM despite the fact that the absence of iron
helps define the N1 sign appearance. We note that those PD cases with very high iron content turned
out to show bilateral loss of the N1 sign. This is not surprising either as the loss of the N1 sign is
generally assumed to mean that there is higher iron content in that area. [18] Based on the
aforementioned discussion, it is imperative to understand the role of each of these potential
biomarkers by themselves. Ideally, in future studies, one may use all of this complementary
information to have a more comprehensive picture of the pathology behind what is actually
happening in the midbrain of PD patients in terms of volumetric changes, N1 loss and iron
deposition.
We found a significant correlation between the SNVOL,QSM and UPDRS-III total score. A number
of studies have also shown a negative association between clinical measures such as UPDRS-III and
SNVOL,MTC, [30] area [34] and width. [36] It should be noted that, from a pathological perspective,
the loss of pigmented neurons in the SNpc is associated with disease duration and severity in PD
[221] and that detecting atrophy of the contralateral SNpc side may allow earlier diagnosis as
suggested by longitudinal PET studies. [222] Therefore, it is reasonable to expect such clinical
correlations with the SNVOL,QSM. The correlation was not significant between the global iron content
and disease duration in the whole PD group but only significant in the sub-group during the first 5
years of disease duration. The increase in iron content is most likely due to the loss of at least the N1
and the increase in iron in that territory. [18]
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However, no correlation was found between SNVOL,MTC and clinical scales even though it
provided the highest AUC to differentiate early stage PD subjects from controls. The question of
clinical correlation with imaging biomarkers is complicated since PD is a heterogeneous
neurodegenerative condition with different genetics, pathology, clinical phenotypes and disease
duration. In this work, only early stage PD subjects were recruited which means that a correlation
with clinical data may not necessarily exist for these subjects. Ideally, we should be able to see
correlations as subjects progress towards later stages of the disease. Furthermore, there is
contradictory evidence in the literature regarding the correlation between NM measures and
UPDRS-III scores. Some previous neuroimaging studies have shown significant correlations of NM
volume with either UDPRS-III and/or disease duration [30, 36, 37, 42, 223] while a few other papers
were unable to find any clinical correlations with NM volume. [10, 42, 192] Several pathological
studies showed a loss of NM with the severity of the disease or disease duration in PD subjects.
[221, 224-226] These findings are consistent with a loss of NM as a representation of pathological
changes in the SN of PD patients. On the other hand, while other studies have shown weak or
moderate correlations between UPDRS-III scores and the NM signal area [227] or NM volume, [40]
another paper shows no association between the NM content and any of the above-mentioned
clinical scores. [41] Therefore, given that we have a relatively small sample size of PD subjects
going through their early stages and the fact that these clinical manifestations may vary across
different populations, it is not surprising that we do not see such correlations. (see Supplementary
Section 9.4) We found no correlation of QSM values with UPDRS-III in this study, although such
correlation has been seen before in the literature. [228] However, in general, inconsistent results
have been reported across studies with some papers reporting no correlation of QSM values with
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UPDRS-III. [169, 170] Since UPDRS-III measures motor performance at the time of the
examination, [229] this discrepancy of the correlation between QSM values and UPDRS-III scores
among different studies can be partly caused by residual treatment effects at the time of motor
examination.
The semi-automatic DP approach used in this study provides a means to obtain consistent final
boundaries using different initial ROIs for the NM complex and SN. However, it should be noted
that any automated or semi-automated method still has certain constraints associated with them that
can potentially lead to changes in volumetric results. Specifically, one study by Ogisu et al. found
that by using a region-growing semi-automated technique the NM volumes can substantially
decrease as a function of increasing thresholds leading to poor separation between PD and HC at
lower threshold values. [29] Given the CNR associated with the MTC and QSM images as well as
the nature of the DP algorithm used here, this technique tends to produce boundaries and volumes
close to those from the full width half maximum and, hence, will have an intermediate volume
compared to methods using low or high thresholds. We also reviewed the DP boundaries to ensure
that no artifacts or errors in the boundaries occurred. This was unlikely given that the initial
boundaries were manually drawn. See the supplementary material (Supplementary Section 9.7 in
particular) for a more in-depth discussion of volume measurements compared across different
methods and different papers.
There are a few limitations in this work. First, the lack of definite diagnostic confirmation by
neuropathologic assessment is a potential limitation. Nevertheless, all the PD subjects were followed
up clinically for at least 12 months and the clinical diagnoses were confirmed. Second, the sample
size was relatively small and for clinical adoption of this methodology; a much larger number of
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subjects will be required. Third, in order to accurately define the initial boundaries outside the final
ROIs, the DP algorithm proposed in this study requires a priori knowledge of the anatomy of the
structures in the midbrain. Fourth, one could use higher in-plane resolution to better define the
boundaries of the ROIs, but it would come at the expense of increased scan time and less signal-tonoise as well as increased potential for patient motion. Fifth, this study only focused on
differentiating early stage PD subjects from HCs but not differential diagnosis among parkinsonian
disorders which is more challenging clinically. In the future, it will be interesting to investigate the
differential diagnosis performance using this approach between PD and atypical parkinsonian
syndromes.
In summary, we have introduced a rapid 3D imaging approach to depict NM degeneration and
iron deposition simultaneously using a semi-automated boundary detection algorithm. Although the
SNVOL,MTC had the highest AUC of the individual measures followed by the N1 sign with the second
highest AUC, each measure plays a complementary role in evaluating PD with the SNVOL,QSM
specifically correlating with UPDRS-III. This approach provides a practical MR imaging method to
differentiate early stage subjects with PD from HCs with an AUC as high as .98. With minor
changes in the sequence design, this multi-contrast GRE-based single MRI sequence has the
potential to be implemented across all major manufacturers’ equipment with a total acquisition time
on the order of 5 minutes.
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Chapter Six: Assessing brain iron and volume of subcortical nuclei in idiopathic rapid
eye movement sleep behavior disorder
Introduction3
Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by vocalizations,
jerks and abnormal motor behavior during REM sleep, often associated with REM-related dream
content. [230] Idiopathic RBD (iRBD) is recognized as the prodromal stage of α-synucleinopathies
including Parkinson’s disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB), and
multiple system atrophy (MSA). Therefore, iRBD represents a unique opportunity for potential
disease-modifying interventions. [46-48] Previous studies have shown cognitive dysfunction [49, 50]
and subtle motor impairment in iRBD patients [51, 52] which might be useful in predicting early
conversion and the specific type of α-synucleinopathy.
Iron metabolism has been a research focus in studying movement disorders such as idiopathic
PD (IPD). [11] Local changes in iron content have been measured in different structures for different
disorders. [198] More specifically, increased iron deposition has been found in the substantia nigra
(SN) of IPD subjects. [148, 184, 231, 232] Given the iron deposition that takes place in the SN of
IPD subjects and the loss of the nigrosome-1 (N1) sign, one can postulate that abnormal iron
deposition may also occur in iRBD subjects. To date, only two studies have explored brain iron
deposition in iRBD patients. A study by Lee et al. has reported that no differences were found in
iron-related R2* values between 15 iRBD patients and 20 healthy controls (HCs). [233] However,
R2* mapping is not as sensitive to iron content as quantitative susceptibility mapping (QSM) and it

The content from this chapter is now published in the following journal paper: Zhang, X., et al., Assessing brain iron and
volume of subcortical nuclei in idiopathic rapid eye movement sleep behavior disorder. Sleep, 2021.
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can be affected by some confounding factors such as water and calcium content. [134] QSM can be
used to overcome these limitations and provide better signal-to-noise in mapping iron content. [11,
98, 156, 234-237] Using QSM, a second study found significantly increased iron deposition in the
SN of iRBD patients compared to HCs. [238] They explored iron deposition in the SN, globus
pallidus (GP), red nucleus (RN), head of the caudate nucleus (CN), and putamen (PUT), but did not
include the dentate nucleus (DN). [238] It has been reported that iron deposition in the DN is a
potential biomarker for tremor-dominant PD [183] and it is considered appropriate to evaluate iron
deposition in the DN for iRBD patients as well. Neither of these two studies evaluated the regional
high iron content (RII iron) which may also be useful in differentiating iRBD from HCs. [239]
Recently, loss of the N1 sign has been reported as a potential imaging biomarker of
pathophysiological changes in PD patients. [18] The N1 sign, also known as the swallowtail sign,
has been described as a hyperintense signal in the middle of the posterior SN with two hypointense
lateral and medial tails on susceptibility weighted imaging (SWI) or T2* weighted imaging (T2*WI)
and the opposite contrast on QSM and R2* data. [240] A loss of the N1 sign has been associated with
an increase in iron deposition. [197] Using QSM, SWI and true-SWI (tSWI, where instead of using
filtered phase data the QSM maps are used as masks to generate susceptibility-weighted images
[102, 121]) it is possible to monitor the presence of the N1 sign, [18, 121] although this has not been
done yet for iRBD patients. The loss of the N1 sign is believed to be caused by the depigmentation
of the neuromelanin content in that region resulting in an increase in MR visible iron as seen by
susceptibility-dependent contrast imaging methods. [43] Of interest is the association between iron
deposition and cognitive or motor impairment in PD, [157, 241] PDD, [234] Alzheimer’s
disease[242] and subcortical vascular mild cognitive impairment. [243] With that said, we
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hypothesized that abnormal iron deposition could also be correlated with cognitive dysfunction and
subtle motor impairment reported in iRBD patients. However, whether global or RII iron
accumulation in the cerebral nuclei correlates with cognitive and motor impairment in iRBD patients
remains uninvestigated.
Therefore, the aims of this chapter are: 1) to investigate the difference in the incidence of the N1
sign between iRBD patients and HCs using QSM, SWI and tSWI; 2) to measure global and RII iron
deposition and volume changes of cerebral nuclei in iRBD patients using QSM; and 3) to investigate
the correlations between global and RII iron in the cerebral nuclei with cognitive and motor function.
Materials and Methods
Participants
This prospective study was approved by the Tianjin Medical University General Hospital
Review Board and Ethics Committee. All participants signed the informed consent. Twenty-nine
iRBD patients were enrolled from Tianjin Medical University General Hospital from October 2016
to January 2020. The iRBD patients were diagnosed according to the standards described in the
International Classification of Sleep Disorders criteria. [244] Patients with the following features
were excluded: 1) age less than 18 years; 2) not right-handed; 3) history of psychiatric disorders,
stroke, head trauma, unstable hypertension or diabetes, chronic obstructive pulmonary disease, or
electroencephalographic abnormalities suggesting epilepsy, encephalitis, or any other neurologic
disorders. All patients were observed with overnight video polysomnography (v-PSG) using a digital
sleep laboratory system (Nicolet v32) and were instructed to go to sleep at their usual bedtimes.
Twenty-eight age-, gender- and education-matched HCs were enrolled from Tianjin Medical
University General Hospital staff or community members by advertisement. All HCs were right-
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handed and eighteen years or older. The main demographic and clinical characteristics including
age, sex, and disease duration were recorded for each subject. In order to evaluate the disease
severity, iRBD patients were evaluated using the Rapid Eye Movement Sleep Behavior Disorder
Questionnaire–Hong Kong (RBDQ-HK).
Neuropsychological and Motor Function Evaluation
Neuropsychological and motor function evaluations were performed by a trained neurologist in
an evaluator-blinded fashion (X.Z. with 5 years of experience) in a quiet environment on the same
day prior to MRI scanning. The neuropsychological evaluations included the following: 1)
visuospatial function using the Rey Complex Figure Test (RCFT) [245] for score and time; 2)
memory function using the Auditory Verbal Learning Test (AVLT), [246] including the total score,
short delay recall, long delay recall, recognition, and RCFT delayed recall test; 3) attentionexecutive function with the Trail Making Test (TMT) A, TMT B, Stroop Color-Word Test (modiﬁed
version) (Stroop A, Stroop B, Stroop C and Stroop interference effect which equals the time of
Stroop C minus the time of Stroop B), and verbal fluency test, [247] and 4) language function using
the Boston Naming Test. [247] The neuropsychological tests are listed in Table 6.1. In our study, all
29 patients and 28 HCs underwent the same battery of neuropsychological tests. For each of the
domains, the raw neuropsychological test scores were converted into z-scores according to the mean
and standard deviations of the scores in the HC cohort. Subsequently, an average cognition z-score
was calculated by averaging the z-scores of all separate cognitive domains.
The motor function tests included: 1) part III of the Movement Disorder Society revised Unified
Parkinson’s Disease Rating Scale (MDS UPDRS-III), 2) the alternate tap test, [248] 3) the 3-meter
Timed Up and Go test [249] to evaluate the speed and flexibility of movement, and 4) the Flamingo

99

test [250] to assess the ability of the patient to balance on one leg for 1 minute. In our study, a subset
of 21 iRBD patients and 16 HCs underwent the motor function tests while the others refused to take
these tests due to the relatively long testing time.

Table 6.1. Comprehensive battery of neuropsychological tests used to evaluate cognitive status.
Cognitive function
Visuospatial function

Tests
Rey Complex Figure Test for score and time

Memory function

Auditory Verbal Learning Test (AVLT) for total learning score short-delay
and long-delay free recall and recognition
Rey Complex Figure Test (RCFT) delayed recall test

Attention-executive function

Trial making test
Stroop color-word test
Verbal fluency test

Language function

Boston naming test

MRI Data Acquisition
All Twenty-nine iRBD patients and 28 HCs underwent MRI examinations. The MRI data were
acquired using a 3.0T MRI scanner (MAGNETOM Prisma, Siemens Healthcare, Erlangen,
Germany) equipped with a 20-channel phased-array head coil. Foam pads were used to keep the
head motionless, and earplugs were used to reduce noise during scanning. All axial images were
acquired parallel to the anterior–posterior commissural line from the middle sagittal plane of the
MRI positioning image. The sequences run included: conventional axial T1-weighted images (T1WI)
and T2WI to exclude subjects with congenital cerebral structural abnormalities, cerebrovascular
diseases, and space-occupying lesions followed by a high-resolution, 3D flow-compensated
gradient-echo (GRE) as a part of the MR angiography and venography (MRAV) sequence [251] to
acquire both original magnitude and phase images. The imaging parameters of the sequences were:
1) T1WI: repetition time/echo time (TR/TE) = 250/2.43 ms, matrix size = 384 × 312; flip angle =
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85o, number of slices = 22, slice thickness = 5 mm, in-plane spatial resolution = 0.6 × 0.6 mm2; FOV
= 240 × 195; receiver bandwidth/pixel = 350 Hz/pixel and a total acquisition time = 1 minute and 4
seconds; 2) T2WI: TR/TE = 3500/89 ms, matrix size = 384 × 312; flip angle = 150o, number of slices
= 22, slice thickness = 5 mm, in-plane spatial resolution = 0.6 × 0.6 mm2; FOV = 240 × 195 mm2;
receiver bandwidth/pixel = 221 Hz/pixel and a total acquisition time = 1 minute and 1 second; 3)
high-resolution 3D flow-compensated MRAV sequence: TR/TE = 20/12.5 ms, matrix size = 384 ×
288; flip angle = 12o, number of slices = 64, slice thickness = 2 mm, in-plane spatial resolution =
0.67 × 0.67 mm2; FOV = 256 × 192; receiver bandwidth/pixel = 240 Hz/pixel and a total acquisition
time = 6 minutes and 8 seconds.
Postprocessing of QSM and Measurement of Susceptibility
The post-processing of QSM from magnitude and phase images was performed with SMART
(Susceptibility Mapping and Phase Artifacts Removal Toolbox, Detroit, MI) software. The following
are the post-processing steps of the QSM reconstruction: First, the Brain Extraction Tool (BET) in
the FMRIB Software Library (FSL) was employed to eliminate the skull and other regions with low
signals. [195] Second, a 3D best-path algorithm was employed to exclude the phase wraps in the
original phase images. [196] Third, the sophisticated harmonic artifact reduction for the phase data
(SHARP) algorithm was employed to remove the background phase information. [58] Finally, the
QSM images were reconstructed using the truncated k-space division algorithm using a k-space
threshold of 0.1. [59]
The mean susceptibility values for the global iron (calculated from the whole structure) and RII
regional high iron (calculated by using structure-specific thresholds to extract pixel values above the
upper 95% prediction intervals of the corresponding global susceptibility-age normal baselines
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established by Liu et al. [12]) were measured from the QSM data using SPIN (Signal Processing in
Nuclear Magnetic Resonance, SpinTech MRI, Inc., Bingham Farms, MI, US) software. Two of the
authors (CC with 9 years of experience in neuroradiology; KG with 6 years of experience in MR
imaging, respectively) were responsible for these measurements; both were blinded to the clinical
and epidemiological information. The cerebral nuclei in our study included: bilateral substantia nigra
(SN), red nucleus (RN), dentate nucleus (DN), head of the caudate nucleus (CN), putamen (PUT),
globus pallidus (GP), thalamus (THA) and pulvinar thalamus (PT). Considering that the size and
shape of the cerebral nuclei are slightly different in different people and to ensure that the
susceptibility was measured as accurately as possible, 3D regions of interests (ROIs) were outlined
manually on the continuous slices of cerebral nuclei to include the entire volume of each structure
visible on the QSM maps (Figure 6.1). The large identifiable cerebral vessels in the cerebral nuclei
were excluded when drawing the ROIs. The mean and standard deviation of the susceptibility values
were measured for both left and right hemispheres from each structure. Finally, when analyzing the
global and regional susceptibility measurements from each cohort, the effect of age-related iron
changes of both hemispheres in all deep gray matter nuclei was corrected for by subtracting the
measured susceptibilities from the corresponding values derived from the linear regression models
established by Liu et al. [12]
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Figure 6.1. Regions of interest traced on quantitative susceptibility maps on three representative slices showing deep
gray matter nuclei. A) the basal ganglia; blue: caudate nucleus, orange: putamen, cyan: globus pallidus, green: thalamus,
red: pulvinar thalamus. B) midbrain; purple: red nucleus, yellow: substantia nigra. C) cerebellum; orange: dentate
nucleus.

Postprocessing of tSWI and Evaluation of the N1 Sign
To review the N1 sign throughout the SN, four types of images were visually evaluated: the
original T2*WI magnitude images, SWI, QSM and tSWI data. The tSWI data were created using a
mask generated from QSM to augment susceptibility-dependent contrast in the original magnitude
data. [121] The application of tSWI is not affected by the orientation dependence inherent in the
phase images, which negatively affects the SWI data. The data were reviewed from the most caudal
SN slice to the most cranial slice abutting the sub-thalamic nucleus. This usually included 4 to 5
slices covering the SN with a 2mm slice thickness. The loss of the N1 sign was defined as either
bilateral or unilateral. To be called bilateral loss, there had to be no evidence of the sign in any of the
slices, while to be defined as unilateral loss, it had to be seen in at least one caudal slice of either
hemisphere. [18] In our study, the presence or absence of the N1 sign was reviewed based on
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consensus by two experienced raters (one with 6 and one with 35 years of experience in MR
imaging).
Statistical Analysis
The statistical analyses were performed using SPSS 16.0 (SPSS Inc. Chicago, Ill., USA). The
normal distribution of data was explored with the Shapiro-Wilk test. The reproducibility and
reliability between the two raters for the N1 sign and global susceptibility were explored using the
intraclass correlation (ICC) analysis. The diagnostic test for the N1 sign loss between iRBD patients
and HCs was investigated with Fisher’s exact test. The differences in the distribution of age,
education and gender between the iRBD patients and HCs were explored using two independent
sample t-tests and the Chi-square test, respectively. The differences in the cognitive scores,
Alternate-tap test, 3-meter Timed Up and Go test and the global and RII susceptibility of the cerebral
nuclei were investigated using two independent sample t-tests. The difference in the Flamingo test
was investigated using the rank sum test. The relationships between the global and RII susceptibility
of the cerebral nuclei and the neuropsychological and motor function measures in the iRBD patients
were investigated using Pearson’s correlation analysis. Furthermore, stepwise multiple linear
regression analysis was used to explore the predictive risk factor of global and RII susceptibility for
the neuropsychological and motor function. In the stepwise regression analysis, F-to-enter 0.05 and
F-to-Remove 0.1 were applied.
It is commonly known that iRBD patients are inherently unaware of RBD-related behavior since
they occur during sleep and only in the case of awakening due to dream-enactment-related impact or
injury is this behavior usually noticed. [46] If these events are not serious, they are easily ignored,
making patient recruitment clinically challenging. For this reason, the sample size in our study was
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relatively small. Nevertheless, it was still of interest to perform an exploratory analysis without
adjusting for multiple comparisons at first, especially when testing for iron effects in the SN and DN
where there is ample evidence of changes in PD. [252] To err on the safe side, when evaluating the
significance of all tested variables, the false discovery rate (FDR) correction to P < 0.05 was
considered to be statistically significant.
Results
Demographic and Clinical Characteristics of iRBD Patients and Healthy Controls
The demographic and clinical characteristics of the iRBD patients and HCs are presented in
Table 6.2 and Table 6.3.
Table 6.2. Demographic, clinical characteristics and cognitive tests of all the participants.
iRBD patients (n = 29)

HCs (n = 28)

P value

PFDR value

Age, yr

64.6 ± 7.6

62.7 ± 4.2

0.255

0.255

Gender, F/M

9/20

9/19

0.928

0.928

Education, yr

11.0 ± 4.5

11.5 ± 3.1

0.653

0.653

iRBD duration, yr

6.1 ± 4.9

--

--

RBDQ-HK

42.2 ± 14.8

--

--

-0.60 ± 1.21

0.04 ± 0.12

0.009#
#

0.085

Cognitive tests, z scores
visuospatial function

0.045*

memory function

-0.41 ± 0.88

0.00 ± 0.80

0.034

attention-executive function

-0.19 ± 0.96

0.00 ± 0.60

0.304

0.380

language function

0.18 ± 0.81

0.00 ± 0.98

0.419

0.419

Average cognition

-0.27 ± 0.67

0.01 ± 0.64

0.080

0.133

Plus-minus values are means ± SD. iRBD = idiopathic rapid eye movement sleep behavior disorder, HCs = healthy controls, F =
female, M = male, RBDQ-HK = RBD Questionnaire–Hong Kong,
#, P value <0.05 without FDR correction
*, PFDR value <0.05 with FDR correction

The average disease duration of the iRBD patients was 6.1 ± 4.9 years. The average RBDQ-HK
score of the iRBD patients was 42.2±14.8 and they also performed worse in visuospatial function (P
=0.009) and memory function (P =0.034) compared with the HCs before FDR correction (Table
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6.2). After FDR correction, the only significant difference was in the visuospatial function (P
=0.045). For the motor function tests, the iRBD patients performed worse in the Alternate-tap test
(left: P =0.010; right: P =0.013; Average: P =0.010) and the 3-meter Timed Up and Go test (P
=0.007) compared with the HCs before FDR correction. After FDR correction, all the differences in
the Alternate-tap test (left: P =0.016; right: P =0.016; Average: P =0.016) and the 3-meter Timed Up
and Go test (P =0.016) remained significant (Table 6.3).
Table 6.3. Demographic, clinical characteristics and motor function tests.
iRBD patients (n = 21)

HCs (n = 16)

P value

PFDR value

Age, yr

65.3 ± 7.0

62.9 ± 5.1

0.253

0.253

Gender, F/M

6/15

7/9

0.338

0.338

Education, yr

11.7 ± 4.5

11.2 ± 3.1

0.719

0.719

iRBD duration, yr

5.7 ± 5.0

--

--

RBDQ-HK

44.0 ± 13.1

--

--

UPDRS III

4.40 ± 4.3

--

--

Left

180.2 ± 35.8

216.5 ± 44.7

0.010#

0.016*

Right

190.9 ± 45.3

228.6 ± 41.4

0.013#

0.016*

Average

185.6 ± 39.6

222.5 ± 41.3

0.010#

0.016*

3-meter Timed Up and Go (s)

7.3 ± 1.7

6.0 ± 0.8

0.007#

0.016*

Flamingo test, median (P25, P75)

2.8 (0, 5.5)

1.5 (0.5, 3)

0.403

0.403

Alternate-tap test (Taps/min)

Plus-minus values are means ± SD. iRBD = idiopathic rapid eye movement sleep behavior disorder, HCs = healthy controls, F =
female, M = male, RBDQ-HK = RBD Questionnaire–Hong Kong,
#, P value <0.05 without FDR correction
*, PFDR value <0.05 with FDR correction

Reproducibility and Reliability of N1 Sign Evaluation and Iron Deposition
The ICC values between the two raters for N1 sign evaluation was calculated to be 0.87 for the
combined HC and iRBD groups. The final choice of which cases showed the N1 sign was reached
based on consensus between the two raters. The ICC values between the two raters for the global and
regional susceptibility measurements of cerebral nuclei were calculated to be 0.87 and 0.98,
respectively, derived from both HC and iRBD groups combined.
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Loss of the N1 Sign in iRBD Patients and Healthy Controls
Based on the consensus results between the two raters, out of 29 iRBD patients, 8 patients had
bilateral loss and 4 patients had unilateral loss (3 on the left and 1 on the right) of the N1 sign. Out of
28 HCs, only two had unilateral loss of the N1 sign while the rest showed the N1 sign on both sides
(Figure 6.2). As a result, the number of iRBD patients with N1 loss was significantly higher than that
of HCs (P=0.005).

Figure 6.2. Nigrosome-1 sign in the substantia nigra. The top row shows bilateral presence of N1 in A) tSWI, B) QSM,
C) SWI and D) T2*WI of a healthy control. E, F) tSWI and QSM images of an iRBD patient with unilateral loss of N1 in
the left hemisphere. G, H) tSWI and QSM images of an iRBD patient with bilateral loss of N1.

Susceptibility and Volumes of the Cerebral Nuclei in iRBD Patients and Healthy Controls
In order to explore the relationship between N1 loss and elevated iron deposition in the SN, we
compared the global and RII susceptibility of the SN among the iRBD patients with bilateral N1 sign
loss (n=8), iRBD with no N1 loss (n=17) and HCs with no N1 loss (n=26). There were no significant
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differences in the global and RII susceptibility of the SN among these three groups (Supplementary
Table 10.1 and Figure 6.3).

Figure 6.3. Distribution of global and regional mean susceptibility values of the SN in HCs and iRBD groups based on
the appearance of N1 sign. Red squares: iRBD patients with bilateral presence of N1; green triangles: iRBD patients with
bilateral loss of N1; yellow triangles: iRBD patients with unilateral loss of N1; blue x's: healthy controls. Hollow circles,
solid lines and dashed lines are associated with the normal population data, the linear regression model and 95%
prediction intervals, respectively. [12]

The comparison of global and RII susceptibility of the cerebral nuclei between the HC and
patient groups before and after correcting for age are summarized in Table 6.4 and Table 6.5,
respectively.
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Table 6.4. Comparison of the global and RII susceptibility of cerebral nuclei between the iRBD
patients and HCs.
Iron Analysis
Hemisphere
CN
HCs
iRBD
p-value
PFDR-value
GP
HCs
iRBD
p-value
PFDR-value
PUT
HCs
iRBD
p-value
PFDR-value
THA
HCs
iRBD
p-value
PFDR-value
PT
HCs
iRBD
p-value
PFDR-value
SN
HCs
iRBD
p-value
PFDR-value
RN
HCs
iRBD
p-value
PFDR-value
DN
HCs
iRBD
p-value
PFDR-value

Global analysis (ppb)
Right
Left
43.8 ± 16.7
47.1± 17.3
49.0 ± 13.6
46.9± 12.3
0.200
0.953
0.626
0.984
133.0 ± 23.2
125.8 ± 25.2
134.9 ± 26.7
128.7 ± 27.0
0.780
0.676
0.960
0.901
56.5 ± 19.3
61.3 ± 20.8
62.0 ± 26.2
68.5 ± 27.6
0.365
0.274
0.649
0.626
-7.1 ± 10.3
-6.9 ± 9.3
-9.3 ± 9.7
-9.3 ± 9.1
0.421
0.320
0.674
0.640
38.9 ± 17.0
36.2 ± 17.7
38.8 ± 26.9
36.0 ± 25.0
0.984
0.978
0.984
0.984
141.9 ± 25.8
140.3 ± 23.3
149.1 ± 21.7
150.7 ± 27.9
0.259
0.133
0.626
0.532
132.8 ± 34.2
130.8 ± 37.2
148.2 ± 30.1
137.0 ± 27.6
0.077
0.479
0.512
0.697
99.0 ± 23.8
109.1 ± 26.4
114.4 ± 27.1
121.9 ± 30.1
#
0.027
0.096
0.432
0.512

RII analysis (ppb)
Right
Left
106.6 ± 12.9
103.1 ± 12.0
107.5 ± 11.5
102.8 ± 11.2
0.783
0.912
0.912
0.912
240.0 ± 36.4
232.2 ± 34.4
246.5 ± 38.1
240.7 ± 38.5
0.515
0.379
0.749
0.726
138.8 ± 12.8
134.4 ± 12.1
147.1 ± 19.7
139.8 ± 19.7
0.062
0.221
0.384
0.589
28.0 ± 7.7
32.2 ± 7.7
28.3 ± 9.6
32.8 ± 8.8
0.912
0.777
0.912
0.912
87.5 ± 8.8
84.7 ± 8.7
87.1 ± 13.4
86.7 ± 11.7
0.905
0.454
0.912
0.726
212.5 ± 16.4
217.5 ± 15.6
216.8 ± 18.7
223.7 ± 19.8
0.355
0.190
0.726
0.589
185.7 ± 17.4
189.2 ± 16.8
192.8 ± 21.3
192.6 ± 15.6
0.171
0.420
0.589
0.726
151.8 ± 13.1
162.8 ± 15.7
162.5 ± 17.2
171.5 ± 19.8
#
0.011
0.072
0.176
0.384

Plus-minus values are means ± SD. CN = caudate nucleus, GP = globus pallidus, PUT = putamen, THA = thalamus, PT = pulvinar
thalamus, SN = substantia nigra, RN = red nucleus, DN = dentate nucleus. #, P value <0.05 without FDR correction

The results of volumetric measurements from each nucleus are also summarized in Table 6.6.
The global and RII susceptibility values in the right DN of the iRBD patients were both significantly
higher than those in the HCs (global: P = 0.027 and RII: P = 0.011, without FDR correction) but
these differences were not significant after the FDR correction was applied.
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Table 6.5. Comparison of the age-corrected global and RII susceptibility of cerebral nuclei between
the iRBD patients and HCs
Iron Analysis
Hemisphere
CN
HCs
iRBD
p-value
PFDR-value
GP
HCs
iRBD
p-value
PFDR-value
PUT
HCs
iRBD
p-value
PFDR-value
THA
HCs
iRBD
p-value
PFDR-value
PT
HCs
iRBD
p-value
PFDR-value
SN
HCs
iRBD
p-value
PFDR-value
RN
HCs
iRBD
p-value
PFDR-value
DN
HCs
iRBD
p-value
PFDR-value

Global analysis (ppb)
Right
Left
-5.9 ± 16.7
1.5 ± 17.3
-1.8 ± 11.8
-0.3 ± 11.5
0.294
0.751
0.866
0.910
5.8± 23.1
-1.5 ± 25.2
7.2 ± 26.5
1.1 ± 26.9
0.829
0.702
0.910
0.910
-28.3 ± 18.6
-18.9 ± 20.5
-26.0 ± 23.8
-14.7 ± 24.5
0.682
0.479
0.910
0.894
-6.0 ± 10.3
-10.2 ± 9.3
-7.7 ± 9.3
-12.3 ± 8.6
0.503
0.382
0.894
0.873
-6.1 ± 16.8
-10.6 ± 17.7
-6.8 ± 27.2
-11.3 ± 25.4
0.906
0.910
0.910
0.910
4.2 ± 24.8
2.6 ± 22.7
4.8 ± 21.4
3.5 ± 27.8
0.325
0.190
0.867
0.760
32.7 ± 33.8
24.2 ± 37.8
45.0 ± 30.0
27.0 ± 28.5
0.152
0.758
0.760
0.910
13.6 ± 23.9
15.8 ± 26.5
27.5 ± 26.9
26.6 ± 29.7
0.046#
0.156
0.736
0.760

RII analysis (ppb)
Right
Left
2.8 ± 12.4
3.6 ± 11.1
1.5 ± 8.3
1.3 ± 8.4
0.634
0.371
0.920
0.920
12.5 ± 36.0
8.8 ± 34.3
17.6 ± 36.6
16.5 ± 37.4
0.601
0.425
0.920
0.920
-17.0 ± 11.9
-10.6 ± 10.2
-13.7 ± 16.3
-9.6 ± 16.1
0.384
0.783
0.920
0.920
-3.2 ± 7.7
-8.0 ± 7.7
-3.1 ± 9.7
-7.4 ± 8.9
0.946
0.805
0.965
0.920
4.7 ± 8.4
1.2 ± 8.4
3.5 ± 13.4
2.5 ± 11.7
0.698
0.644
0.920
0.920
18.6 ± 15.3
13.6 ± 14.8
21.5 ± 18.2
18.3 ± 19.2
0.512
0.303
0.920
0.920
6.2 ± 16.9
7.3 ± 16.5
9.8 ± 21.0
7.2 ± 15.5
0.489
0.965
0.920
0.965
-8.5 ± 13.3
-6.6 ± 15.9
0.5 ± 17.0
-0.1 ± 18.6
0.032#
0.165
0.512
0.920

Plus-minus values are means ± SD. CN = caudate nucleus, GP = globus pallidus, PUT = putamen, THA = thalamus, PT = pulvinar
thalamus, SN = substantia nigra, RN = red nucleus, DN = dentate nucleus. #, P value <0.05 without FDR correction

Additionally, the volumes of the bilateral CN were significantly lower than those of the HCs
(right: P = 0.003, left: P = 0.021, without FDR correction). After FDR correction, only the right CN
showed a significant difference between iRBD patients and HCs (P = 0.048, with FDR correction).
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Table 6.6. Comparison of the volume of cerebral nuclei between iRBD patients and HCs.
Structure
CN

GP

PUT

THA

PT

SN

RN

DN

Hemisphere
HCs
iRBD
p-value
PFDR-value
HCs
iRBD
p-value
PFDR-value
HCs
iRBD
p-value
PFDR-value
HCs
iRBD
p-value
PFDR-value
HCs
iRBD
p-value
PFDR-value
HCs
iRBD
p-value
PFDR-value
HCs
iRBD
p-value
PFDR-value
HCs
iRBD
p-value
PFDR-value

Right
2080.0 ± 266.0
1788.5 ± 345.6
0.003#
0.048*
2103.1 ± 271.1
1929.8 ± 276.0
0.052
0.153
3150.7 ± 368.0
2947.2 ± 497.8
0.224
0.326
4010.6 ± 619.0
3876.4 ± 478.5
0.067
0.153
673.6 ± 116.4
610.2 ± 123.4
0.067
0.153
618.3 ± 79.9
570.0 ± 107.0
0.089
0.171
208.2 ± 27.3
212.1 ± 40.7
0.680
0.725
679.0 ± 154.3
658.2 ± 125.4
0.660
0.725

Left
2101.2 ± 306.5
1839.4 ± 390.6
0.021#
0.153
2130.3 ± 261.4
1966.0 ± 280.9
0.057
0.153
2988.5 ± 369.1
2782.2 ± 474.6
0.197
0.315
3808.3 ± 566.5
3668.9 ± 419.1
0.372
0.496
619.1 ± 110.7
550.5 ± 125.9
0.063
0.153
590.8 ± 82.8
548.3 ± 92.1
0.096
0.171
208.9 ± 35.6
212.7 ± 36.5
0.593
0.725
680.6 ± 152.9
678.7 ± 132.1
0.944
0.944

Plus-minus values are means ± SD. CN = caudate nucleus, GP = globus pallidus, PUT = putamen, THA = thalamus, PT = pulvinar
thalamus, SN = substantia nigra, RN = red nucleus, DN = dentate nucleus. #, P value <0.05 without FDR correction

Correlation between Magnetic Susceptibility and Clinical Features in iRBD Patients
In order to evaluate the correlation between susceptibility and clinical measures and since it is
well known that the susceptibility of deep gray matter structures changes as a function of age, [12,
94] we corrected the mean susceptibility values in both analyses for age in all the structures by using
the projected age-matched values taken from the corresponding linear regression models. [12]
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Before FDR correction, the global susceptibilities of the bilateral DN were positively correlated with
the time in the Stroop C test (left: r = 0.411, P = 0.030; right: r = 0.520, P = 0.005); the global
susceptibility of the right DN was negatively correlated with the AVLT short-delay free recall (r = 0.466, P = 0.012); the global susceptibility of the left PUT (r = -0.406, P = 0.032) and left CN (r = 0.376, P = 0.049) were negatively correlated with the memory score of the RCFT test.
The RII susceptibility of the bilateral DN were positively correlated with the time in the Stroop C
test (left: r = 0.525, P = 0.004; right: r = 0.614, P = 0.001); the RII susceptibility of the right DN was
negatively correlated with the AVLT short-delay free recall (r = -0.392, P = 0.035); the RII
susceptibility of the left GP was negatively correlated with the AVLT short-delay free recall (r = 0.381, P = 0.041); and the RII susceptibilities of the bilateral PUT (left: r = -0.404, P = 0.033, right: r
= -0.426, P = 0.024) were negatively correlated with the memory score of the RCFT test. After FDR
correction, only RII susceptibility of the right DN was found to be positively correlated with the time
in the Stroop C test (r = 0.614, P = 0.032). These results are summarized in Figure 6.4. The
corresponding correlations between the susceptibility values from ROI results and cognitive function
scores in the HCs are given in Supplementary Figure 10.1.
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Figure 6.4. Correlations between age-corrected iron deposition and cognitive scores in the iRBD patients. The global
iron deposition of the bilateral DN were positively correlated with the time in the Stroop C test (A). The RII iron
deposition of the bilateral DN were positively correlated with the time in the Stroop C test (B). The global (C) and RII
(D) iron deposition of the right DN were negatively correlated with the AVLT short-delay free recall. The RII iron of the
left GP was negatively correlated with the AVLT short-delay free recall (E). The global iron of the left PUT (F), the
global iron of the left CN (G), the RII iron of the bilateral PUT (H) were negatively correlated with the memory score of
the RCFT test. AVLT = Auditory Verbal Learning Test; RCFT = Rey Complex Figure Test; LDN = left dentate nucleus;
RDN = right dentate nucleus; LGP = left globus pallidus; RGP = right globus pallidus; LPUT = left putamen; RPUT =
right putamen; LCN = left caudate nucleus; RCN = right caudate nucleus.
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Before FDR correction, the global susceptibility of the bilateral CN and DN were negatively
correlated with the average taps from the Alternate-Tap test (for CN: left: r = -0.569, P = 0.001;
right: r = -0.502, P = 0.020 and for DN: left: r = -0.507, P = 0.019; right: r = -0.537, P = 0.012); the
global susceptibility of the bilateral GP and right SN were positively correlated with the time of the
3-meter Timed Up and Go test (for GP: left: r = 0.622, P = 0.003; right: r = 0.437, P = 0.048 and for
right SN: r = 0.454, P = 0.039); the global susceptibility of the right CN was positively correlated
with the time of the 3-meter Timed Up and Go test (r = 0.472, P = 0.031). The RII susceptibility of
the bilateral DN and CN were negatively correlated with the average taps from the Alternate-Tap
test (for DN: left: r = -0.554, P = 0.009; right: r = -0.523, P = 0.015 and for CN: left: r = -0.494, P =
0.023; right: r = -0.502, P = 0.020); the RII susceptibility of the left GP was positively correlated
with the time of the 3-meter Timed Up and Go test (r = 0.499, P = 0.021); and the RII susceptibility
of the bilateral SN were positively correlated with the time of the 3-meter Timed Up and Go test
(left: r = 0.488, P = 0.025; right: r = 0.493, P = 0.023). After FDR correction, the global
susceptibility of the left CN remained significantly negatively correlated with the average taps from
the Alternate-Tap test (r = -0.569, P = 0.032). These results are summarized in Figure 6.5. The
corresponding correlations between the susceptibility values from the ROIs and motor function
scores in the HCs are shown in Supplementary Figure 10.2.
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Figure 6.5. Correlations between age-corrected iron deposition and motor scores in the iRBD patients. The global
susceptibility of the bilateral CN (A) and DN (B) were negatively correlated with the average taps from the AlternateTap test. The global susceptibility of the bilateral GP (C), right SN (D) and CN (E) were positively correlated with the
time of the 3-meter Timed Up and Go test. The RII susceptibility of the bilateral DN (F) and CN (G) were negatively
correlated with the average taps from the Alternate-Tap test. The RII susceptibility of the left GP (H) and bilateral SN (I)
were positively correlated with the time of the 3-meter Timed Up and Go test. LCN = left caudate nucleus; RCN = right
caudate nucleus; LDN = left dentate nucleus; RDN = right dentate nucleus; LGP = left globus pallidus; RGP = right
globus pallidus; LSN = left substantia nigra; RSN = right substantia nigra.

Finally, the global susceptibility of the right SN was positively correlated with disease duration
(r = 0.420, P = 0.029); the global and RII susceptibility of the right GP was positively correlated
with the RBDQ-HK score (r = 0.428, P = 0.021; r = 0.424, P = 0.022). However, these two
correlations did not remain significant after FDR correction. These results are summarized in Figure
6.6. The correlations between the susceptibility values from the other ROIs and cognitive, motor,
disease duration and RBDQ-HK scores are shown in Supplementary Figure 10.3-9.

115

Figure 6.6. Correlations between age-corrected iron deposition and clinical features in the iRBD patients. The global
iron of the right SN was positively correlated with disease duration of iRBD (A). The global and RII iron deposition of
the right GP were positively correlated with the RBDQ-HK score (B and C). iRBD = idiopathic rapid eye movement
sleep behavior disorder; RBDQ-HK = RBD Questionnaire-Hong Kong; LSN = left substantia nigra; RSN = right
substantia nigra; LGP = left globus pallidus; RGP = right globus pallidus.

We explored the predictive risk factor of global and RII iron of subcortical nuclei for
cognitive/motor performance tests using stepwise multiple linear regression analysis. Regarding the
cognitive performance, we found that the RII iron of the right CN was the predictive factor for the
visuospatial function and the global iron of the right DN was the predictive factor for the memory
function (all P<0.05, FDR correction) (Table 6.7).
Table 6.7. The relationship between RII iron of the cerebral nuclei and cognitive scores in iRBD
patients using stepwise multiple regression analysis
Cognitive
function

Iron of cerebral
nuclei (global/RII)

95% Confidence
interval

Partial
correlation

Collinearity
statistics
VIF

P
value

PFDR
value

Visuospatial
function

RII iron of RCN

(-0.716, -0.152)

-0.535

1.002

0.004#

0.004*

Memory
function

Global iron of RDN

(-0.848, -0.194)

-0.549

1.232

0.003#

0.004*

#, P value <0.05 without FDR correction
*, PFDR value <0.05 with FDR correction

Regarding the motor performance, we found that the RII iron of the left DN and global iron of
the left CN were predictive factors for the Alternate-Tap test (left, average), the global iron of the
left DN was the predictive factor for the Alternate-Tap test (right), and the global iron of the left GP
was the predictive factor for the 3-meter Timed Up and Go test (all P<0.05, FDR correction) (Table
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6.8). The variance inflation factor (VIF) ranged from 1.002 to 1.927, indicating that there was no
multicollinearity among the global and RII iron of subcortical nuclei in the multiple stepwise
regression analysis.
Table 6.8. The relationship between global/RII iron of cerebral nuclei and motor scores in iRBD
patients using stepwise multiple regression analysis
Motor function

Iron of cerebral
nuclei
(global/RII)

95% Confidence
interval

Partial
correlatio
n

Collinearit
y statistics
VIF

P
value

PFDR
value

Alternate-Tap
test (Left)

RII iron of LDN

(-2.003, -0.866)

-0.791

1.691

<0.001#

0.002*

Global iron of LCN

(-1.973, -0.449)

-0.430

1.125

0.004

0.004*

Global iron of LDN

(-3.324, -0.767)

-0.609

1.000

0.003#

0.004*

RII iron of LDN

(-2.258, -1.098)

-0.838

1.927

<0.001#

0.002*

Global iron of LCN

(-2.788, -1.209)

-0.802

1.322

<0.001#

0.002*

Global iron of LGP

(0.014, 0.055)

0.628

1.000

0.002#

0.003*

Alternate-Tap
test (Right)
Alternate-Tap
test (Average)

3-meter Timed
Up and Go test

#, P value <0.05 without FDR correction
*, PFDR value <0.05 with FDR correction

Discussion and Conclusions
This study compares the N1 sign, global and RII iron deposition and the correlations between
iron deposition with cognitive and motor impairment in iRBD patients. The most important findings
in this study are: 1) the number of iRBD patients with the N1 sign loss was significantly higher than
that of HCs; 2) the global and RII susceptibility values of the right DN were significantly higher than
those of the HCs before FDR correction while losing their significance after FDR correction.
Although not significant after FDR correction, increases in iron deposition in the DN should be
further investigated with a larger sample size in the future; 3) the volume of the right CN was
significantly lower than that of the HCs before and after FDR correction; and 4) linear correlation
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analysis showed that the RII susceptibility of the right DN was correlated with poor attentionexecutive function and the global susceptibility of the left CN was significantly correlated with poor
motor performance (after FDR correction). Furthermore, multiple regression analysis revealed the
following for cognitive and motor performances: for the cognitive performance, the RII iron of the
right CN was the predictive factor for the visuospatial function and the global iron of the right DN
was the predictive factor for memory function (after FDR correction). For the motor performance,
the RII iron of the left DN and global iron of the left CN were predictive factors for the AlternateTap test (left, average), the global iron of the left DN was the predictive factor for the Alternate-Tap
test (right), and the global iron of the left GP was the predictive factor for the 3-meter Timed Up and
Go test (after FDR correction). Taken together, these results suggest that global and regional high
iron deposition may be potential imaging biomarkers for early evaluation of cognitive and motor
impairment in iRBD patients. It should be noted that before FDR correction, there were more
significant results while after FDR correction, most of these results lost their statistical significance.
The reason for this may be due to the small sample size and the number of variables included. A
bigger sample size and fewer statistical variables would warrant a more meaningful analysis of
potential correlations between iron measures and clinical scores.
It should also be noted that similar relationships have been investigated in more advanced stages
of neurodegeneration in the literature. In addition to motor impairment being a common
characteristic of Parkinsonism, [253, 254] it is of great interest that correlations between iron content
and cognitive impairment in some brain structures have also been studied. [234, 241, 255, 256]
Specifically, Uchida et al. reported a negative correlation between magnetic susceptibility (i.e.,
global iron content) and Montreal cognitive assessment (MoCA) scores in the CN of PD patients.
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[256] In a separate study by the same group and through a voxel-based QSM technique, the same
negative relationship between global susceptibility and MoCA scores was replicated in PD patients
with mild cognitive impairment. [241] Additionally, Li et al. have also reported negative correlations
between QSM values in bilateral hippocampus and Mini-Mental State Examination (MMSE) scores.
[234] Hence, one may argue that the correlations seen between motor and cognitive impairment and
global and regional analyses in the brain structures of iRBD patients may then be reflected into such
abnormalities seen in different forms of Parkinsonism.
Global and RII iron changes in iRBD patients
Our exploratory analysis also found that iRBD patients had significantly increased global and
RII mean susceptibility values of the right DN compared with those in the HC group before
correction, indicating that increased iron deposition in the DN of iRBD patients may be a potential
biomarker for early identification of α-synucleinopathies before clinical extrapyramidal and
cerebellar symptoms begin. The findings of our study were different from those of Sun et al.’s study,
[238] in which they found significantly increased iron deposition in bilateral SN in iRBD patients.
This could be due to smaller errors in measuring the iron content which then would lead to a
decreased and possibly significant p-value. Furthermore, in Sun et al.’s study, the global iron content
in the DN and regional iron content for any of the deep gray matter structures were not investigated.
With that said, one may also argue that the reason for different findings between Sun et al.’s and our
study could be due to different subtypes of α-synucleinopathies (such as PD, MSA and DLB)
exhibiting different patterns of brain iron accumulation in this early stage. Previous studies found
that MSA and PD patients had a wider range of excessive iron deposition; MSA patients tend to
have increased iron content in the PUT and SN compared to HCs while PD patients show increased
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iron deposition in the SN, GP and RN compared to HCs. [231, 238] Iron deposition of the DN in the
PD patients, however, remains controversial. [11] That is, in a study by Guan et al. it has been
reported that even though elevated nigral iron content is present regardless of disease type, abnormal
iron deposition in the RN and DN appears to be only seen in tremor-dominant patients. [182]
Similarly, He et al. reported abnormally high iron deposition of the bilateral DN to be the only
biomarker separating tremor-dominant PD from other disease types as well as the HCs, [183] wheras
Acosta-Cabronero et al. claimed to have found a decrease of magnetic susceptibility in the DN of
idiopathic PD patients compared to that of HCs. [187] Nevertheless, based on the literature and with
respect to the fact that Acosta-Cabronero did not include tremor-dominant PD patients in their study,
there seems to be some evidence that the high iron deposition in the DN may be a potential
biomarker specific to tremor-dominant PD. It should also be noted that in our study these differences
in iron deposition between iRBD patients and HCs lost their statistical significance after FDR
correction, possibly due to the small sample size and number of comparisons included. Nonetheless,
the above mentioned studies along with the results from this work suggest that there might be
abnormal iron deposition in the DN of iRBD patients which requires further investigation.
Volume changes of cerebral nuclei in iRBD patients
In this work, iRBD patients had significantly decreased volumes of the right CN compared to
those of the HC cohort. Previous voxel-based morphometry results showed lower gray matter
volume in the CN of iRBD patients, [257, 258] which is consistent with our study. Furthermore,
decreased volume of the CN was also found in patients with PD [259-262] and MSA [260, 263]
compared to the HCs. This suggests that degeneration of the CN in patients with iRBD may be an
early biomarker for α-synucleinopathies. Abnormal iron homoeostasis can induce cellular damage,
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[264] which may then lead to a decrease of volume in the deep gray matter nuclei. Additionally,
greater atrophy of the caudate nucleus in patients with PD has been associated with poor cognitive
function, [262, 265] although no correlation between the CN volume and cognitive/motor function
was found in iRBD patients in our study. Further studies are needed to understand the significance of
decreased volumes of the CN in early stage iRBD subjects.
N1 sign loss in the SN of iRBD patients
We found the incidence of the N1 sign loss in the SN of iRBD patients was significantly higher
than that of the HCs, indicating that the iRBD patients may be showing signs of neuromelanin loss in
the N1 territory of the SN. It has been reported that the N1 sign loss is correlated with increased iron
deposition over time [197] and that it is a potential imaging biomarker of pathophysiological
changes in PD patients. [18] In a recent study, Cheng et al. created a robust high quality and rapid
imaging protocol for clinical detection of the N1 sign in 80 parkinsonism and related disorders and
found that about 79% of the IPD patients had loss of the N1 sign. [18] In our study, about 41.4%
(12/29) of iRBD patients showed loss of the N1 sign. This increased number of subjects showing N1
loss relative to HCs seems reasonable given that the iRBD subjects are in a much earlier stage
compared to PD. However, we did not find any significant differences in the global and RII
susceptibility of the SN among the iRBD patients with bilateral N1 sign loss (n=8), iRBD patients
with no N1 loss (n=17) and HCs with no N1 loss (n=26). The volume of the N1 territory is small
relative to the entire SN and the standard error in measuring the iron was quite large making it
difficult to detect subtle changes in iron content.
Correlation between iron deposition and clinical features in iRBD patients
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Our study found that increased iron deposition in the right DN not only correlated with motor
function, but also correlated with poor attention-executive and memory function in both linear and
multiple regression analysis. The cerebellum has been shown to influence nonmotor function such as
working memory. [266] In the cerebrocerebellar circuitry, the cerebellum is interconnected with the
cerebral cortex, including prefrontal and posterior parietal cortex, as well as the cortical motor areas.
[267, 268] Thus, the disruption in these circuits could lead not only to motor deficits but also to
cognitive, attentional, and affective impairments. [269] Our study also found that the iron deposition
of the CN was correlated with poor visuospatial function in iRBD patients. The CN is an important
part of the striatum and plays an important role in cognitive functions. [270] Dopamine loss in the
CN and ventral striatum is closely associated with attention/working memory, frontal/executive,
and visuospatial dysfuction in early-stage PD. [271] Corticostriatal, pallidal, thalamic and cortical
re-entrant neural circuits are thought to promote certain domains of cognition, emotion and behavior.
[272] Therefore, abnormal iron accumulation in the right CN and right DN may be associated with
the disruption of the corticostriatal networks in iRBD patients, and may be a valuable marker
representing the severity of cognitive dysfunction.
Compared with HCs, iRBD patients showed significantly decreased movement speed and lack of
flexibility in motor function tests, indicating subclinical changes in their motor systems. Subtle
motor impairment has been reported to be frequent in iRBD patients. [51, 52] However, we did not
find a significant difference in the ability of balance on one leg measured by the Flamingo test,
which is inconsistent with Barber et al.’s study. [273] Studies with imaging modalities such as
transcranial sonography, [274, 275] neuromelanin-sensitive MRI, [276] and SWI [193, 277] have
identified changes in the SN neuromelanin and iron content in iRBD patients. Our study
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demonstrated that the RII iron deposition of the left DN and the global iron deposition of the left
CN, left DN and left GP were negatively correlated with poor motor performance in the iRBD
patients. In accordance with our findings, Guan et al. have also reported significant correlations
between magnetic susceptibility (i.e., global analysis) in the DN and tremor severity as well as
between magnetic susceptibility in the CN and akinetic/rigid severity. [182, 256] The GP has also
been reported to play an important role in monitoring of motor function in PD. The GP externa can
affect the processing of motor information by virtue of its widespread projections to all basal ganglia
nuclei. [278] The GP interna is also a target for deep brain stimulation to treat motor complications
in PD.[279] Such dependence could serve as a potential biomarker to monitor the severity of motor
function abnormalities in iRBD patients which may then be reflected in more advanced
manifestations of neurodegeneration.
Excessive iron likely contributes to the dysfunction of the nigrostriatal pathway, [66] which may
underlie the subtle motor impairments in iRBD patients. Some PD studies have shown that the
susceptibility in the SN and GP were significantly correlated with motor impairment measured by
UPDRS. [157, 169, 179] On the other hand, as part of the motor system, the cerebellum controls the
body's movements and balance. However, iron content of the DN has not been studied previously in
iRBD patients. Our study shows that the iron content in the DN was associated with poor movement
flexibility in iRBD patients. We also found increased iron deposition in the GP was positively
correlated with RBDQ-HK score before correction, which was consistent with Sun et al.’s study,
suggesting that increased iron deposition of the GP correlated with the severity of iRBD.
There are a number of limitations in our study. First, this was a cross-sectional design; a
longitudinal study with a larger sample size is warranted to validate the current findings and
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investigate the relationship between iron deposition with cognitive and motor impairment in iRBD
patients over time. Second, not all patients and HCs had motor function evaluations due to their
unwillingness or objective reasons, such as the relatively long testing times. This limited the power
of the statistical analysis for all the variables. Third, due to the small sample size and too many
variables included in our study, many of the significant differences were lost after FDR correction,
with the remaining significant differences being the volume of the right CN between iRBD patients
and HCs and some correlations between iron deposition and clinical features in iRBD patients.
Fourth, we did not collect neuromelanin-sensitive imaging data which could have helped with
evaluating potential neuromelanin loss in the iRBD patients against N1 sign localization.
The exploratory analysis in this study shows that iRBD patients had a higher incidence of N1
sign loss and reduced right CN volume relative to HCs after FDR correction. Cognitive and motor
impairment in iRBD patients were also associated with iron deposition of several cerebral nuclei
after FDR correction. Future studies with a larger sample size may help reveal further relationships
that lost their significance here due to multiple comparison corrections.
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Chapter Seven: Conclusions and Future Directions
In this thesis, multiple qualitative and quantitative MRI techniques have been used to evaluate
abnormal levels of iron and neuromelanin in the brains of PD and RBD patients compared against
age-matched healthy populations. In Chapter Four, global and regional susceptibility measurements
were performed in eight major deep gray matter nuclei of PD patients and age-matched HCs. These
evaluations revealed an increase in iron deposition in the SN of PD patients over and above the
increasing trend due to normal aging, with the regional analysis being more sensitive in picking up
such abnormalities. The regional analysis was also seen to separate the PD population into two subgroups from which the cohort with abnormal RII iron showed significantly higher UPDRS-III scores
than those from the other sub-group with RII iron levels within the normal ranges. Finally, and in
agreement with previous literature, even though the higher global R2* in the SN of PD patients were
found to be statistically significant from those of HCs, they all fell within normal ranges in the
literature making QSM a more reliable choice for iron quantification purposes. [239] However, it
should be noted that the sample size for the patient group was relatively small (25 PD patients) in
which most recruited subjects were going through intermediate stages of the disease. In order to
have a more meaningful and comprehensive evaluation of iron behavior, especially RII iron, a much
larger patient population is required.
Taking it one step further and by focusing only on the midbrain area in Chapter Five, we utilized
a single multi-echo MT-augmented 3D GRE sequence to simultaneously visualize the NM content
and N1 sign in the SN as well as quantifying iron deposition in this structure. Based on the results
from this study, combining NM volume from MTC, SN volume from QSM and N1 data from tSWI
yields an AUC as high as 0.98 when separating PD patients from age-matched HCs. It should be
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emphasized, however, that unlike the PD cohort used in Chapter Four, in this study almost all of the
recruited subjects in the patient group were going through early stages of the disease with a mean
disease duration of only 2.55 years since clinical diagnosis. [280] With that said, and with respect to
what has been discussed previously in the chapter, only the global iron analysis seems to have
played a role in separating PD patients from the HC cohort (AUC = 0.74); one may argue that this
may be due to the SN not having developed enough abnormal iron to survive the RII thresholds in
earlier stages of the disease. Therefore, a potential future study could use the same analyses as what
used in this chapter, but on PD patients specifically going through intermediate and later stages of
the disease. The hypothesis here is that by the time these patients get to those stages, more NM
depigmentation and higher iron deposition will occur, paving the way for RII analysis to distinguish
between the two cohorts with an even higher accuracy.
Another step towards understanding pathogenesis of PD was taken in Chapter Six where iron and
volumetric measurements along with the N1 sign were assessed in RBD patients and an age-matched
HC cohort. In addition to volume shrinkage in the CN and abnormal iron in the DN (as well as other
correlations between these MRI measurements and cognitive and motor functions) being consistent
with what has been reported in the literature for both RBD and PD, the most interesting and novel
finding in this study was the significantly higher number of RBD patients showing N1 loss
compared to that of HCs. [281] Since the N1 territory is included in the NM complex in the SN, one
may postulate that NM loss may start during pre-symptomatic stages of PD, especially RBD.
Unfortunately, NM-MRI data were not collected in this study. However, the promising results
reported in this study warrants further investigation of changes in iron, NM, volume and N1 of RBD
patients, ideally using the same MT-enhanced 3D GRE sequence discussed in Chapter Five.
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Another very interesting area as a potential future direction is the correlations between in vivo
MR measures and SPECT/PET DAT scans highlighting localized dopamine loss. As mentioned in
the previous chapters, DAT scan is currently the gold standard for clinical diagnosis of PD. In fact,
in separate individual studies a reduction in striatal dopamine levels have been seen to be correlated
with NM loss in the SNpc [25, 40] as well as iron overload in SNpc [30] with no evidence of such
relationships between DAT and N1 to date. It is of great interest to simultaneously evaluate the
potential correlations between striatal DAT and all the MR biomarkers discussed in this thesis. It is
anticipated that by combining DAT and MRI, not only will a higher diagnosis accuracy be achieved
differentiating PD from HC, but it is also expected to see a substantial improvement in picking up
subtle changes in RBD (as a prodromal stage of PD) leading to a better understanding of the
nigrostriatal pathology and degeneration of dopaminergic pathway.
Furthermore, another somewhat undiscovered research realm appears to be the spatial growth of
iron content as a function of age. Over the lifespan, in addition to being temporally variable, iron
deposition in the human brain is believed to be spatially changing as a function of age as well [97,
282]. Given the promising results seen in iron behavior in the SNpc and its relationship with the NM
complex in PD, there is a great potential for the newly developed RII high iron analysis to be
spatially assessed in the midbrain. The spatial RII iron trajectory in patients both longitudinally from
a given subject over a certain period of time and cross-sectionally between patients at different
stages of the disease could provide insight for a better interpretation of disease monitoring and
progression.
In addition to dopaminergic neuronal death in the SN of PD patients, the loss of noradrenergic
neurons in the LC has also been found to be associated with the disease with limited evidence stating
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that LC neurodegeneration might occur prior to SNpc NM loss. [283] Being able to detect the NM
signal in the LC could be a powerful imaging tool to help with PD diagnosis especially in early
stages of the disease and ideally when the patients are still at the pre-symptomatic phase. [284]
However, the LC is a very small structure (with a diameter and length of roughly 2.5 mm and 8 mm,
respectively) and hard to image at clinical level spatial resolution. To be fair, it should also be noted
that collecting MR data at higher resolution may come at a cost of longer acquisition time which
could become a hurdle with the data covering the NM content in both SN and LC, particularly for
PD patients showing sever symptoms and potential motion artifacts. To address this, Liu et al. have
introduced a variant of STAGE technology known as MTC-STAGE from which synthetic MTC data
at virtually any flip angle is achievable at a reasonable scan time of under 15 minutes. [212] Taking
advantage of imaging the NM content in both SN and LC, coupled with other in vivo biomarkers
(global and regional iron, N1, DAT etc.), could pave the way for a much more comprehensive
interpretation of underlying PD pathophysiology.
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Chapter Eight: Supplementary Material I (Multi-Center QSM Validation)
As previously pointed out QSM has been proven many times to have a higher reliability over
other iron quantification techniques, especially R2* and phase. However, a multi-center approach to
validate the consistency of susceptibility mapping could be of great interest to researchers. In this
chapter, we will discuss the consistency of QSM measurements in the SN across all the studies
included in this thesis. We will be seeking to answer two major questions in this regard: 1) under
normal circumstances, how do QSM measurements from each of these studies compare to one
another as well as to the gold standard normal population? and 2) how does iron behave in the SN
upon neurodegeneration in PD and RBD in subjects with bilateral loss of N1 compared to those with
no bilateral loss?
We put together all QSM measurements from three studies in Chapters 4-6 and superimposed the
results from HC, PD and RBD subjects onto the global and regional susceptibility-age normal
baselines established by Liu et al. [12] In order to strengthen the analyses, we have added a fourth
group that only includes 22 PD patients (17 males and 5 females) whose data were collected at a
different center. These 22 patients were scanned on a 3.0 T Skyra MR system (Siemens, Germany)
with a twenty-channel head/neck coil. The 3D SWI imaging parameters were: TE/TR = 20/30 ms,
flip angle = 15°, slice thickness = 2mm, pixel bandwidth = 121 Hz/pixel and an in-plane resolution
of 0.2 × 0.2 mm2. The average ± standard deviation for disease duration, H&Y and UPDRS-III
scores for these patients are 7.1 ± 5 years, 2.0 ± 0.3 and 28.5 ± 2, respectively. ROI tracings, iron
quantification and N1 analysis were performed on these data using the same algorithm discussed in
Chapter Five. The following summarizes the MR scanners and subject groups from the five studies
including: 174 HCs on a 1.5T GE Signa (normal baselines), 24 HCs and 25 PD patients on a 3T GE
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Signa (Chapter Four), 40 HCs and 40 PD patients on a 3T Philips Ingenia (Chapter Five), 28 HCs
and 29 RBD patients on a 3T Siemens Prisma (Chapter Six) and finally 22 PD patients on a 3T
Siemens Skyra. Therefore, excluding the HCs in the healthy baseline population, a total of 92 HC,
87 PD and 29 RBD patients are included whose data were collected on five separate scanners from
three manufacturers and two field strengths. The datapoints associated with all these studies are
shown in Supplementary Figure 8.1.

Supplementary Figure 8.1 Overlay of HC, PD and RBD data on the global and regional baselines from Liu et al. [12]
in the SN. Colored solid circles: HC data from each corresponding study, colored solid triangles: PD and RBD data from
each corresponding study, red triangles: PD and RBD data with bilateral N1 loss from all studies combined.

There are two important takeaways from this figure. First, by looking at the solid circles
representing the normal subjects from each study, it is clearly seen that the majority of both global
and regional QSM results associated with the HC data fall within the normal range restricted by the
lower and upper bands of the corresponding baselines. Out of a 92 HCs across all four studies, 80
(87%) and 86 (93%) subjects from the global analysis and 81 (88%) and 82 (89%) subjects from the
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regional analysis fell between the lower and higher 95% intervals in the right and left hemisphere,
respectively. This essentially validates the fact that both global and regional susceptibility values
derived from all HCs are consistently within the normal ranges regardless of the manufacturer.
Furthermore, in addition to higher sensitivity and reliability, these results confirm QSM superior
performance over R2* in terms of being dependent upon field strength.
Second, it appears that the majority of PD and RBD cases with bilateral loss of the N1 sign (red
triangles) are located above the linear regression model associated with global and regional
susceptibility-age trends. Out of 72 PD/RBD cases with bilateral N1 loss across all four studies, 70
(97%) and 69 (96%) subjects from the global analysis and 68 (94%) and 66 (92%) subjects from the
regional analysis had susceptibility values higher than the corresponding linear regression models
from the healthy population in the right and left hemisphere, respectively. Additionally, the majority
of subjects with abnormally high iron content in both analyses (i.e. susceptibility values above the
upper 95% interval) also appear to be PD and RBD subjects with bilateral N1 loss. Out of 46 and 30
patients with abnormally high global iron, 39 (85%) and 23 (77%) subjects and out of 36 and 30
patients with abnormally high regional iron, 27 (75%) and 24 (80%) subjects had bilateral loss of N1
in the right and left hemisphere, respectively. The fact that patients with bilateral N1 loss seem to do
worse in terms of abnormal iron deposition in their SN is another novel finding in this thesis which
could potentially lead to a better understanding of underlying pathogenesis in Parkinsonism at its
earlier stages. Nevertheless, these observations warrant further investigation evaluating the
relationships between elevated levels of iron these patients with NM signal and volume as well as
clinical scores.
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Chapter Nine: Supplementary Material II (Chapter Five)
Visualizing the midbrain structures
Imaging neuromelanin and iron as biomarkers in Parkinson’s disease depends not only on
imaging these two components with MRI but also on identifying them in the midbrain.
Understanding the anatomy and its associated nomenclature is a major part of this process. However,
there seems to be some confusion in the field in terms of the anatomy of the SN and what the iron
and neuromelanin provide in terms of the SN sub-structures (SNpc and SNpr). In fact, a recent paper
was published solely to discuss the nomenclature and understanding of the ventral tegmental area
(VTA) in the midbrain. [207]
The first consideration in mapping iron and neuromelanin is their relationship to the SN. From an
anatomical perspective, as one goes from superior towards inferior slices, the SN is located in the
midbrain and starts where the nigrostriatal pathway ends in the subthalamic nuclei. It appears from
about the middle of the RN to directly below the RN usually for 4 to 5 slices with a 2 mm thickness
(roughly 8 mm) depending on the partial volume effect in the caudal slices. Rostrally, from the
middle of the RN, the subthalamic nucleus (STN) branches off and can be seen in the two upper
slices covering about 4mm. Both the STN and SN make an angle to the x-axis and z-axis making it
difficult to choose any particular optimal imaging plane. However, with isotropic or near isotropic
resolution, the size of the SN can be reasonably accurately measured. The SN consists of two parts,
the SNpc and SNpr. The SNpr is predominantly ventral and rostral while the SNpc is predominantly
dorsal and caudal. Visualizing that difference is difficult on one single sequence at 3 T although
some progress differentiating them has been made at 7 T. [285] They show the usual N1 region as an
oval loop surrounded by iron. In the gradient echo data of the cadaver brain shown in their Figure 2,

132

centrally the signal is bright highlighting the N1 sign. These N1 findings are found more caudally in
the SNpc. Since the neuromelanin content present in the N1 region does not show paramagnetic
characteristics like iron, the N1 sign can be seen with an opposite intensity on susceptibilitysensitive contrast methods. For example, the contrast between iron and neuromelanin can be seen on
SWI/QSM where the lateral and medial portions of the SN show hypointense/hyperintense signal in
most cases while the NM in N1 shows hyperintense/hypointense signal for healthy controls because
it has less MR visible iron content.
Supplementary Table 9.1. The p-values for the various imaging variables for HCs and PD subjects.
In these measures, a p-value less than .05 is considered significant and shown in bold.
Mean ± Standard error
Measures
SNVOL,MTC (mm3)
SNVOL,QSM (mm3)
SNΔχ (ppb)
SNOVERLAP (%)

HC

PD

P Value

322.85 ± 4.72
477.53 ± 12.63
132.12 ± 4.01
39.96 ± 1.05

234.58 ± 6.22
395.38 ± 9.61
155.30 ± 4.09
36.49 ± 1.29

< .001
< .001
< .001
.040

Naming the different parts of the SN has been somewhat confusing since people use the usual x,
y and z coordinates as lateral/medial, anterior/posterior and cranial/caudal, respectively, as well as
rostral/caudal, ventral/lateral and superior/inferior. These various terminologies in themselves can be
confusing. Further, a careful naming of the different parts of the midbrain in the transverse plane is
quite complicated because of the many small unclear structures. VTA visualization is complicated in
that there are no clear anatomical borders to delineate the structure because the VTA consists of a
heterogeneity of nuclei which exhibit gradual transitions, and until the recent paper by Trutti et al,
there has been no consensus about the anatomical nomenclature to define the VTA territory as a
whole in the literature. [207] In this work, for the clarity of terminology, the term NM complex is
used to refer to the entire NM hyperintensity region in the midbrain. Given there is still considerable
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inconsistency in the terminology of the VTA as a nucleus [286] versus VTA as a region, [287] we
refer to the VTA as the midline VTA nucleus and SNpd (also referred to as the parabrachial
pigmented (PBP) nucleus) to the area located ventromedially to dorsolaterally between the red
nucleus and the SNpc as used in previous histological studies. [286] To help clarify these concerns
we presented a cartoon at the end of Figure 5.1 in the main text which we reproduce here as
Supplementary Figure 9.1.
Supplementary Table 9.2. Statistics for the various combinations of imaging variables. Sensitivity
(SENS), specificity (SPEC), area under the curve (AUC) and accuracy (ACC) for the individual
features as well as different combinations of the studied measures SNVOL,MTC, SNOVERLAP,
SNVOL,QSM, SNΔχ and Nigrosome 1 (N1). Accuracy here is defined as (true positive + true negative) /
(healthy controls + Parkinson’s patients).
Individual/Combinations of Features

SENS

SPEC

AUC

ACC

SNVOL,MTC

.863

.913

.960

.888

SNVOL,QSM

.738

.825

.788

.781

SNΔχ

.581

.888

.740

.734

SNOVERLAP
N1
SNVOL,MTC / SNVOL,QSM

.613
.913
.900

.775
.838
.975

.629
.891
.969

.694
.875
.938

SNVOL,MTC / SNOVERLAP

.900

.975

.965

.938

SNVOL,MTC / SNΔχ

.925

.975

.976

.950

SNVOL,MTC / SNVOL,QSM / SNΔχ

.913

.950

.981

.931

SNVOL,MTC / SNVOL,QSM/ N1

.969

.950

.983

.959

SNVOL,MTC / SNOVERLAP / SNΔχ

.856

.950

.976

.903

SNVOL,MTC / SNVOL,QSM/ SNOVERLAP

.888

.938

.969

.913

SNVOL,QSM/ SNOVERLAP / SNΔχ

.825

.913

.911

.869

SNVOL,MTC / SNVOL,QSM/ SNOVERLAP / SNΔχ

.913

.950

.981

.931

SNVOL,MTC / SNVOL,QSM/ SNΔχ / N1

.969

.950

.980

.959
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Supplementary Figure 9.1. Schematic representation of the midbrain. Here we show a cartoon of the four
representative transverse levels (a, b, c, d) based on iron-NM contrasts and landmarks from previous human post-mortem
works. SNpr = substantia nigra pars reticulata, SNpc = substantia nigra pars compacta, PBP= parabrachial pigmented
nucleus, SNpd=substantia nigra pars dorsalis, VTA=ventral tegmental area, N1 = nigrosome-1, RN=red nucleus,
SCP=superior cerebellar peduncles and MB=mammillary body. For the direction labels, L=lateral, M=medial,
V=ventral, D=dorsal, A=anterior and P=posterior.

Four separate examples showing the N1 sign are shown in Supplementary Figure 9.2. The N1
sign appears in the ventral lateral part of the NM boundary and is usually evident in HCs.

Supplementary Figure 9.2. Demonstration of the location of the N1 sign. NM-MRI and tSWI for 4 different healthy
controls showing the overlay of the NM boundary (traced using DP semi-automated technique) onto the tSWI. The
yellow arrows show the hyperintense region in tSWI data presumably highlighting the N1 territory which is also located
in the ventrolateral aspect of the NM boundaries (as drawn on the NM-MRI data).
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Supplementary Table 9.3. The p-values for the various combinations of imaging variables. The
Bonferroni correction yields a significance threshold of 0.003 for the p-values. The significant pvalues are shown in bold.
Measures
SNVOL,MTC
SNVOL,QSM
SNΔχ
SNOVERLAP
SNVOL,QSM / SNΔχ
SNVOL,MTC / SNVOL,QSM / SNOVERLAP /
SNΔχ

SNVOL,MTC
< .001
< .001
< .001
.020
.222

Comparison Between the ROC Curves
(reported numbers are p-values)
SNVOL,QSM
SNΔχ
SNOVERLAP
.001
< .001
< .001
.570
.070
.570
.157
.070
.157
< .001

< .001

< .001

Dynamic programming to determine the boundaries of the SN and NM
The initial regions-of-interest (ROIs) associated with neuromelanin and substantia nigra were
drawn outside the objects on the MTC and QSM images, respectively, which were then used as input
to the dynamic programing algorithm (DPA) to determine the final boundaries. To keep the shape of
the object, the centerline associated with the initial boundary was detected first. [288] The edge
detection occurs using a cost function which is evaluated along the centerline. The rays originate
from each selected point on the sorted centerline points, towards the drawn boundary point, which
move clockwise. The cost function consists of a derivative term as well as a radius of curvature term
which avoids the leakage of the structure of interest into the adjacent objects although we usually
limit the search radius outside the boundary as well. [216] The cost function is given by:

𝐶(𝑟, 𝑚) =

𝐺(𝑟, 𝑚) + 𝐺𝑝𝑟𝑒
|𝑅(𝑟, 𝑚) − 𝑅𝑎𝑣𝑔 |
−𝛼∗
𝐺𝑚𝑎𝑥
𝑅𝑎𝑣𝑔

𝑚−1

𝐺𝑝𝑟𝑒 = ∑ 𝐺(𝑡)𝑚𝑎𝑥
𝑡=𝑚−3
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where the gradient and the radius along the mth ray at the rth point are denoted by 𝐺(𝑟, 𝑚) and
𝑅(𝑟, 𝑚), respectively. The term 𝐺𝑚𝑎𝑥 represents the maximum derivative inside the image and 𝑅𝑎𝑣𝑔
is the average radius over the previous three radii.
For each ray, the calculations are done based on the average radius of curvature associated with
the previous three rays, except for the first three which are chosen to start at the center of the
centerline. The search process then encircles the entire boundary and iterates five times around the
boundary. The candidate points for the new boundary are selected by maximizing the abovementioned cost function for each ray. Besides the derivative and radius of curvature, the cost
function is also dependent on parameters such as the maximum derivative along each ray, and α was
set to 0.4. In this work, since the raters drew the initial boundaries a few pixels outside the objects,
the algorithm was set to search inside only. An example of the proposed DPA used by two
independent raters on both MTC magnitude and MTC-QSM is shown in Supplementary Figure 9.3.

Supplementary Figure 9.3. Dynamic programming boundary detection on MTC and QSM images. An example of two
different manually drawn boundaries (A, D) on MTC, and (E, H) QSM images. The final boundaries, which were found
by dynamic programming (B,C) and (F,G), are almost identical with the number of pixels being (B) 1339 and (C) 1349
for MTC, and (F) 1960 and (G) 1975 for QSM. The average signal intensity changed from 20,730 (B) versus 20,717 (C)
for MTC. For QSM, the average susceptibility for these boundaries were (F) 143 ppb and (G) 140 ppb, respectively.
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MTC-QSM can be used to quantify iron in PD
Our approach uses a single sequence to obtain iron and neuromelanin measures. One of the
advantages of phase and QSM is that, apart from SNR in both cases, the former is independent of
flip angle and the latter is independent of echo time. We compared the usual STAGE gradient echo
sequence without an MTC pulse and with an MTC pulse and found that the susceptibility
measurements were similar (Supplementary Figure 9.4). Paired-sample t-tests revealed no significant
difference between the mean susceptibility values measured using these two sequences (p = .452).
An example comparison of the QSM results for the two methods (along with the R2* maps and SWI
results from the MTC data) is shown in Supplementary Figure 9.4.

Supplementary Figure 9.4. Comparison of the susceptibility maps from the non-MT STAGE data and the MTCSTAGE data. (A) QSM data using TE = 15ms from the MTC-GRE data. (B) QSM data using TE = 17.5 ms from
STAGE non-MT GRE scans. (C) R2* map from the 5 echoes of the MTC data (ΔTE = 30 ms). It can be seen that both
echo times provide QSM measures that are very similar in their overall contrast as the plots in the paper also show in
their equivalent quantification of iron content. The R2* maps show similar results for the high iron content regions for the
5-echo MTC data. It should also be borne in mind that R2* will show high iron regions larger than they really are because
of the dipole effects in the image leading to edge signal loss. (D) SWI from the MTC 22.5 ms echo time data. Here the
N1 sign is seen clearly in the last two caudal slices for the left SN.
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The boundaries from the QSM data from the MTC sequence were copied over to the STAGE
QSM data after co-registration of the two data sets and then the DPA was run again. A plot of the
measured susceptibility values between these two methods is shown in Supplementary Figure 9.5
where there is a good linear relationship (slope = 1.11, R2=0.751, p < .001) between the
susceptibility values measured from MTC-QSM and STAGE-QSM in both HC and PD cohorts
combined.

Supplementary Figure 9.5. Plot of susceptibility from MTC-QSM and STAGE-QSM for all 80 cases (40 HCs and 40
PDs). This plot shows a good correlation between these two methods using a linear regression model (p < .001). The data
points show the average mean susceptibility values between the two hemispheres. The intercept of the linear regression
model was set to the origin leading to a slope of 1.11 and an R2 of .751.

The relationship between iron volume, NM volume and NM contrast in the SN with age
As discussed in this study, some papers have shown a change in signal intensity for NM as a
function of disease and age. We saw no significant correlation of SNVOL,MTC with age for either
group but a significant correlation with age was seen for the contrast of the NM with respect to the
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background for the HC group (p = .048) and for SNVOL,QSM, for the PD group (p = .001).
(Supplementary Figure 9.6).

Supplementary Figure 9.6. The change in NM volume, NM contrast and SN volume with age. (A) SN VOL,MTC (averaged
over both sides) showed no correlation with age for both HCs and early stage PD patients (p = .746 and p = .382,
respectively). (B) SNVOL,MTC contrast (averaged over both sides) relative to the background (the crus cerebri) as a
function of age. There is a trend downward in contrast for the HCs (p = .048) but not the PD patients (p = .415) as a
function of age. (C) SNVOL,QSM (averaged over both sides) as a function of age. There is a significant trend seen in the
change of SNVOL,QSM as a function of age for the PD patients (p = .001) but not for the HC group (p = .069). PD =
Parkinson’s disease, HC=healthy control.
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PBP volume
It is interesting to note that the PBP (or SNpd) volume can be found by subtracting the overlap
volume from the SNVOL,MTC. There appears to be a linear downward trend of PBP volume with
overlap volume increase (Supplementary Figure 9.7A) and SNVOL,QSM (Supplementary Figure 9.7B).

Supplementary Figure 9.7. PBP volume as a function of overlap volume and SNVOL,QSM volume for both groups.
(A) HC showed a correlation of PBP with overlap volume (p < .001) while PD did not (p = .306). (B) HC showed a
correlation of PBP with SNVOL,QSM (p < .001) while PD did not (p = .078). PD = Parkinson’s disease and HC =
healthy controls.

Also of interest is the fact that the average PBP volume can be estimated in the limit that the
overlap volume vanishes for the Parkinson’s disease cases (the intercept shown in Supplementary
Figure 9.8A) and is found to be 110.81 ± 18.10 mm3. Finally, the reduction in SNVOL,QSM is mirrored
by the SNVOL,MTC (Supplementary Figure 9.8B).
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Supplementary Figure 9.8. The correlation between SNVOL,MTC and SNVOL,QSM and overlap volume for both groups. (A)
SNVOL,MTC as a function of overlap volume to determine average SNpd volume for early stage PD patients (p < .001). (B)
SNVOL,QSM as a function of overlap volume (p = .032). The trend line in (B) is fitted on all the data points of both groups
except the two PD outliers showing very low overlap volume. Assuming the loss of volume occurs in the SNpc, when
the overlap is zero, the SNVOL,QSM would be 184.3 mm3, which one could interpret as the average SNpr. PD = Parkinson’s
disease. SNpc = SN pars compacta. SNpr = SN pars reticulata.

Normalization by the midbrain volume
One could argue that the volumes of the NM complex and iron containing SN could be more
spread out in terms of their absolute values because of different brain sizes or at least different
midbrain sizes. Therefore, we also normalized the NM and iron containing SN volumes for all cases
by the midbrain volume and replotted Figure 5.2 from the main body of the paper (see
Supplementary Figure 9.9).
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Supplementary Figure 9.9. Distinguishing between the two groups using normalized SNVOL,MTC and three other
measures. Normalized SNVOL,MTC by midbrain volume as a function of (A) SNOVERLAP, (B) normalized SNVOL,QSM, and
(C) SNΔχ. Sensitivity (SENS), specificity (SPEC) and accuracy (ACC) values are shown for each plot. PD = Parkinson’s
disease. HC = healthy control.

For the healthy controls, the ratio of the mean over standard deviation for un-normalized and
normalized SNVOL,QSM was 5.98 and 5.53, respectively. For the Parkinson’s disease patients, the ratio
of the mean over standard deviation for un-normalized and normalized SNVOL,QSM was 6.50 and
4.56, respectively. For the HCs, the ratio of the mean over standard deviation for un-normalized and
normalized SNVOL,MTC was 10.82 and 7.95, respectively. For the Parkinson’s disease patients, the
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ratio of the mean over standard deviation for un-normalized and normalized SNVOL,MTC was 5.96 and
4.80, respectively. The higher values seen in the un-normalized data indicate that there was less
spread of the data without normalization. This could be due to the fact that the normalization process
itself can introduce error into the volume measurements. According to these findings, we did not see
any significant improvement in the results associated with the normalized SNVOL,QSM or SNVOL,MTC
compared to the un-normalized scenario. The results for sensitivity, specificity, and accuracy
confirm that normalization of the SNVOL,MTC does not make a significant improvement in separation
of the two groups (the p-values associated with the un-normalized versus normalized ROC curves
corresponding to the combination of SNVOL,MTC with each of SNVOL,QSM, SNΔχ and SNOVERLAP were
calculated as .381, .363 and .492, respectively, which do not show any significant improvement in
the normalized data).

Discussion on the behavior of NM complex volume between PD subjects and HCs
In this study, the SNVOL,MTC dropped roughly 25% for PD subjects relative to HCs. This
reduction in volume is lower than the pathological changes of NM depigmentation in PD seen with
postmortem studies which is thought to be on the order of 50-60% [10, 42, 189, 221]. However, the
SNpd volume was estimated to be almost 111 mm3 and if we subtract this from SNVOL,MTC for PD
(238 mm3 for right and 232 mm3 for left hemispheres) and HCs (323 mm3 for left and right
hemispheres) yields a net SNpc volume for PD of 127 mm3 (121 mm3) for the right (left) side and
for HCs of 212 mm3 (left and right). This assumes the PBP (or SNpd) volume is the same for both
PD and HCs which is not an unreasonable assumption. Now the apparent NM loss increases from
25% to 40% because the PBP contribution has been removed and this is more representative of the
SNpc NM volume loss.
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There is a broad range of NM volumes quoted in the literature. The most common values range
from 112 to 370 mm3 for HC and 52 to 215 mm3 for PD subjects, the larger of these being consistent
with our results [10, 29, 30, 38-42, 289]. The larger volumes were from a 3D Turbo Field Echo
(TFE) sequence [29] using a semi-automated determination of the SNpc volumes (using a threshold
of 2.0) which found NM volume results similar to ours using a higher resolution of 0.67 mm×1 mm×
1 mm. Two other studies quote volumes of more than 1000 mm3 and 900 mm3 for HC and PD
subjects, respectively [21, 22]. These discrepancies most likely result from one or all of the
following: the different resolutions that were used; the different contrast-to-noise ratios available for
visualizing these structures; whether manual versus automated drawing methods were used; the
threshold and the type of imaging sequence used as 2D methods usually have thick slices and slice
gaps while 3D methods have contiguous thinner slices; and finally whether the upper levels of NM
showing only VTA were included [10, 21, 22, 30, 38-42, 289]. These results should be compared to
SNVOL,QSM determined from histological studies. A postmortem study shows that the SN consists of
approximately 68% pigmented neurons and they find the SN volumes to be (512 ± 117) mm 3 and
(390 ± 136) mm3 for HCs and PD subjects, respectively. [290] Therefore, one can estimate
SNVOL,MTC to be (348 ± 80) mm3 and (265 ± 92) mm3 for HCs and PD subjects, respectively, again
in line with what we measured.
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Chapter Ten: Supplementary Material III (Chapter Six)
The correlations between age-corrected susceptibility values from ROI results with cognitive and
motor function scores in the HCs are given in Supplementary Figure 10.1 and Supplementary Figure
10.2, respectively. Additionally, as shown in Supplementary Table 10.1, there were no significant
differences in the global and RII susceptibility of the SN between the RBD group with N1 loss and
those of the RBD group without N1 loss and HCs.

Supplementary Figure 10.1. Correlations between age-corrected iron deposition and cognitive functions in the HCs.
Solid lines: linear regression model, dashed lines: 95% confidence intervals, DN: dentate nucleus, GP: globus pallidus,
PUT: putamen, CN: caudate nucleus.
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Supplementary Figure 10.2. Correlations between age-corrected iron deposition and motor functions in the HCs. Solid
lines: linear regression model, dashed lines: 95% confidence intervals, CN: caudate nucleus, DN: dentate nucleus, GP:
globus pallidus, SN: substantia nigra.

Supplementary Table 10.1. The global and RII susceptibility (ppb) of substantia nigra among
groups of iRBD with bilateral N1 loss, iRBD with no N1 loss and HCs with no N1 loss.
iRBD with bilateral
N1 loss (N = 8) (A)

iRBD with no N1
Loss
(N = 17) (B)

HCs with no N1
Loss
(N = 26) (C)

A vs. B

B vs. C

A vs. C

Right SN

45.3 ± 19.0

49.5 ± 20.1

40.6 ± 24.9

0.665

0.215

0.614

Left SN

31.8 ± 14.6

36.2 ± 29.7

25.1 ± 22.3

0.674

0.146

0.494

average

38.5 ± 14.4

42.8 ± 24.2

32.8 ± 21.7

0.645

0.146

0.520

Right SN

13.3 ± 8.8

25.1 ± 18.4

18.4 ± 15.8

0.091

0.185

0.434

Left SN

9.7 ± 10.7

21.7 ± 20.3

13.3 ± 15.0

0.095

0.108

0.591

average

11.5 ± 9.6

23.4 ±19.0

15.8 ± 14.8

0.084

0.131

0.498

Structure

P value

Global

RII

Plus-minus values are means ± SD. RII = high-iron thresholded region; SN = substantia nigra; iRBD = idiopathic rapid eye movement
behavior disorder; HCs = healthy controls, ppb = part per billion.
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Finally, the correlations between the susceptibility values from the rest of the ROIs and
cognitive, motor, disease duration and RBDQ-HK scores are shown in Supplementary Figure 10.3-9.

Supplementary Figure 10.3. Correlations between age-corrected iron deposition and attention-executive function in the
iRBD patients. Solid lines: linear regression model, dashed lines: 95% confidence intervals, DN: dentate nucleus, GP:
globus pallidus, PUT: putamen, CN: caudate nucleus, SN: substantia nigra, RN: red nucleus, THA: thalamus, PT:
pulvinar thalamus.
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Supplementary Figure 10.4. Correlations between age-corrected iron deposition and verbal memory function in the
iRBD patients. Solid lines: linear regression model, dashed lines: 95% confidence intervals, GP: globus pallidus, PUT:
putamen, CN: caudate nucleus, SN: substantia nigra, RN: red nucleus, THA: thalamus, PT: pulvinar thalamus.
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Supplementary Figure 10.5. Correlations between age-corrected iron deposition and visuospatial memory function in
the iRBD patients. Solid lines: linear regression model, dashed lines: 95% confidence intervals, DN: dentate nucleus,
GP: globus pallidus, CN: caudate nucleus, SN: substantia nigra, RN: red nucleus, THA: thalamus, PT: pulvinar
thalamus.
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Supplementary Figure 10.6. Correlations between age-corrected iron deposition and scores of the alternate-tap test in
the iRBD patients. Solid lines: linear regression model, dashed lines: 95% confidence intervals, GP: globus pallidus,
PUT: putamen, SN: substantia nigra, RN: red nucleus, THA: thalamus, PT: pulvinar thalamus.
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Supplementary Figure 10.7. Correlations between age-corrected iron deposition and scores of the 3-meter Timed Up
and Go test in the iRBD patients. Solid lines: linear regression model, dashed lines: 95% confidence intervals, DN:
dentate nucleus, GP: globus pallidus, PUT: putamen, CN: caudate nucleus, RN: red nucleus, THA: thalamus, PT:
pulvinar thalamus.
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Supplementary Figure 10.8. Correlations between age-corrected iron deposition and disease duration of iRBD. Solid
lines: linear regression model, dashed lines: 95% confidence intervals, CN: caudate nucleus, DN: dentate nucleus, GP:
globus pallidus, PUT: putamen, SN: substantia nigra, RN: red nucleus, THA: thalamus, PT: pulvinar thalamus.
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Supplementary Figure 10.9. Correlations between age-corrected iron deposition and scores of RBDQ-HK in the iRBD
patients. Solid lines: linear regression model, dashed lines: 95% confidence intervals, CN: caudate nucleus, DN: dentate
nucleus, PUT: putamen, SN: substantia nigra, RN: red nucleus, THA: thalamus, PT: pulvinar thalamus.
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ABSTRACT
ASSESSING MIDBRAIN ABNORMALITIES IN PARKINSON’S DISEASE USING
MAGNETIC RESONANCE IMAGING
by
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August 2021
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Major: Biomedical Engineering
Degree: Doctor of Philosophy
Diagnosing early-stage Parkinson’s disease (PD) and its manifestations is still a clinical
challenge. Previous imaging studies using iron, neuromelanin (NM) and the Nigrosome-1 (N1)
measures in the substantia nigra (SN) by themselves have been unable to provide sufficiently high
diagnostic performance for these methods to be adopted clinically. In this dissertation, we start by
studying idiopathic PD patients at their intermediate stages of the disease to evaluate the role of
global and regional iron in the major deep gray matter nuclei. Then, we only focus on the NM
complex in the midbrain and how neuronal loss interact with iron overload as well as their
relationship with clinical scores strictly on early PD patients. Finally, by taking one more step back
in the disease progression process, we investigate the impact of iron deposition and N1 appearance
in idiopathic rapid eye movement sleep behavior disorder (RBD) as the prodromal stage of PD.
The results of this work are summarized as the following: 1) the increase in iron in the SN in
some PD patients is higher than the normal range in healthy controls (HC) as found in both regional
and global analyses and that regional high iron content may provide a means to separate two
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populations of PD patients; one with and one without iron increases in the SN; 2) we have
introduced a rapid five-minute 3D approach to depict NM degeneration and iron deposition
simultaneously which provides a practical MR imaging method to differentiate early stage subjects
with PD from HCs with an approximately 98% accuracy; and finally 3) iRBD patients were found to
have a higher incidence of N1 loss, reduced volume and elevated iron levels in a few brain structures
as well as cognitive and motor impairment scores being correlated with iron deposition of several
cerebral nuclei. All these in vivo biomarkers put together can significantly contribute to a better
understanding of the underlying pathophysiology in PD onset and progression with the ultimate goal
being a more confident clinical diagnosis prior to symptomatic dysfunction.
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